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Abstract 
 
Mechanical ventilation is life saving as a respiratory support for preterm 
infants with respiratory distress syndrome. There is good evidence now 
that any form of volume-targeted modality of mechanical ventilation is 
superior over pressure-targeted modality to reduce chronic lung disease 
and death. It is perceived by minimising the duration of mechanical 
ventilation would reduce the exposure to positive pressure breaths and 
thereby could reduce long term morbidities such as chronic lung 
disease. 
An area of lacunae is defining what is weaning on mechanical 
ventilation. Whilst most clinicians will agree when to commence 
mechanical ventilation there is paucity of consensus on when to 
commence weaning on mechanical ventilation and the best way for 
weaning to prevent extubation failure. 
Pressure support ventilation (PSV) is pressure-targeted modality of 
ventilation designed to support spontaneous breathing. It was designed 
as a weaning mode to facilitate extubation. Pure PSV has no back up 
rate. Currently, PSV is used in combination with other modes such as 
SIMV to provide some back up respiratory rate for the unreliable 
respiratory drive due to apnoea in preterm infants. However, there is 
inadequate understanding of the appropriate PSV level for weaning 
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preterm infants on mechanical ventilation.  Clinicians routinely use 
50%-70% of peak inflation pressures used prior to commencing the 
weaning mode. 
Use of Pressure support ventilation (PSV) could be variable- with one 
extreme utilising minimal pressure to just overcome the tube resistance 
(PSmin) with the aim to prevent fatigue and avoid extubation failure.  
The other extreme is augmenting spontaneous breathing effort to 
provide a full tidal volume breath (PSmax). Features of flow triggering 
and flow cycling aid synchrony at inspiration and expiration and this 
allows greater autonomy to the infant to control all aspects of its 
breathing cycle. Addition of some PSV to aid spontaneous breaths has 
shown to reduce the duration of weaning.    
A randomised controlled study was designed to compare duration of 
weaning using PSmax and SIMV. Infants less than 32 weeks gestation at 
birth with respiratory distress syndrome from surfactant deficiency were 
eligible to participate.  
93 infants stratified in three groups based on their gestation at birth 
were randomised over 30-month period. Weaning was commenced in 
the randomised mode when infants reached a set priori of MAP<10 cm 
H2O, FiO2 <40% and had a reliable respiratory drive for at least 2 
consecutive hours.  
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In the control arm (SIMV with PSmin)– clinicians reduced the back up 
rate to wean. In the intervention arm (PSmax with ten SIMV breaths)- 
clinicians reduced the PSVmax to PSVmin for weaning. A minute 
ventilation test was performed to assess readiness to extubation when 
both arms reached PSmin with ten back up SIMV breaths.  
 Primary outcome for the study was duration of weaning on mechanical 
ventilation. 
Our study suggests there is no difference between the two groups but 
there is a trend towards faster extubation in the PSV arm (the median 
time to extubate in the SIMV arm was 42 (95%CI, 28.23 to 55.76) 
hours and the median time to achieve the primary outcome in the PSV 
arm was 31 (95% CI, 12.59 to 49.40) hours). The survival distribution 
between the interventions was statistically not significant, Chi-square 
0.768, p 0.381. This effect was more evident in bigger infants weighing 
at least 1500 grams. 
There was no difference in the secondary outcomes between the two 
groups and common preterm morbidities were equally balanced. There 
were no adverse events during the study period to report.  
Contrary to the general belief, infants are not disadvantaged by 
weaning on PSVmax.  Clinical outcomes were comparable with the 
traditional SIMV method of weaning on mechanical ventilation.  
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1 Introduction to Newborn Respiratory 
Physiology 
Oxygenation in the newborn lungs is driven by the oxygen pressure 
gradient. Thus the lungs must be well expanded and perfused. 
Deficiencies in either, lead to imbalance in perfusion to ventilation 
efficiency and impair gas exchange. The expansion of lungs depends 
upon the stage of lung development and thus the limiting factor in 
premature infants.  
1.1 Lung development  
Phases of lung development (Agrons et al., 2005) 
• Embryonic phase (3-6 weeks) 
• Pseduoglandular phase (6-16 weeks) 
• Acinar or Canalicular phase (16-26 weeks)  
• Terminal sac phase (26-36 weeks) 
• Alveolar phase (36 weeks- up to 5 years) 
It is during the canalicular phase that type II cells capable of producing 
surfactant appear first. Towards the end of this stage primitive distal 
saccules (primitive alveoli) begin to form through a process known as 
primary septation. It is the primitive alveoli that help in maintaining gas 
exchange. With the development of pulmonary capillaries effective gas 
exchange is dependent upon the degree of acinus capillary coupling.  
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1.2 Mechanics of respiratory physiology  
Inspiration- is an active energy-expending act.  The diaphragm and the 
intercostal muscles expand the lungs through its insertion on the chest 
wall. Diaphragmatic contraction leads to an increase in the chest 
volume. This causes drop in the intra-pleural pressures and causes gas 
flow into the chest.  
Expiration- is a passive state. The elastic recoil of the muscles and the 
high surface tension due to lack of surfactant in premature infant aid 
expiration. During tidal exhalation, abdominal muscles play little role in 
expiration.  
Compliant chest wall leading to easy deformation, atelectasis at end 
expiration resulting into lower functional residual capacity provide little 
structural support for ventilation. The shape of the chest wall (more 
cylindrical) and the ribs insertion (more horizontal) lead to mechanical 
disadvantage of the inspiratory muscles not getting enough fulcrum to 
lift the chest when compared to the adults.  
1.2.1 Compliance  
Compliance is a measure of the change in the volume resulting from 
unit change in the pressure.  
Compliance = Change in volume (∆V)/ change in pressure (∆P) 
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Compliance measured during active expiration is called as dynamic 
compliance. This reflects the elastic recoil of the lungs. This 
underestimates the static compliance especially in infants who are 
breathing rapidly.  
The pressure volume loop (compliance curve) is sigmoidal. Hence at 
both the ends of the loops, the compliance is low, i.e. for the unit 
change in the pressure there is very limited change in the volume. The 
compliance curve also help in identifying the necessary residual 
distending pressure to establish an appropriate functional residual 
capacity (residual lung volume). Without this distending pressure, there 
is progressive atelectasis of the alveoli and cause atelectotrauma. The 
level of PEEP at which the static lung compliance is maximised is called 
the optimum PEEP.  
1.2.2 Resistance  
Resistance (R) could be differentiated into  
a. Viscous resistance- by the tissues surrounding them 
b. Airway resistance – by the moving molecules in the gas stream 
and between the respiratory system 
c.  Imposed resistance – from the ventilator circuit when the infant 
needs respiratory support 
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Resistance is defined as pressure gradient between two points to move 
the gas at a constant flow rate.  
R= Pressure/ flow 
 
1.2.3 Time constant  
Time constant is the measure of how quickly the lungs inflate or 
deflate. This is directly related to the compliance of the respiratory 
system and the resistance of the airways system. Thus in a 
mathematical formula this is represented as  
Kt=Compliance (CL) X Resistance (Raw) 
where Kt represents expiratory time constant 
CL =Lung compliance  
Raw = Airway Resistance  
One time constant is defined as the time it takes the alveoli to 
discharge 63% of the tidal volume. This is important when commencing 
mechanical ventilation to appropriately set expiratory time. Five time 
constants are required to exhale 99% of tidal volume in normal lung. 
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1.2.4 Work of breathing  
Breathing requires expenditure of energy. This energy is required to 
overcome the elastic and the resistive forces. Thus work of breathing in 
a mathematical model is represented as  
Pressure (force) X Volume (displacement) 
The work of breathing can closely correlate to oxygen consumption. 
Mechanical ventilation reduces oxygen consumption by decreasing the 
pressure generated by the inspiratory muscles. Kanak & Roze have 
nicely elucidated this point in adults and in neonates respectively 
(Kanak et al., 1985), (Roze et al., 1997).  
1.3 Treatment options  
In the acute phase, the treatment option in a neonate with surfactant 
deficiency is surfactant replacement and supporting spontaneous 
breathing. Spontaneous breathing could be supported by:  
a. Non invasive respiratory support  
b. Mechanical ventilation 
1.3.1 Non invasive respiratory support 
Non invasive respiratory support could be provided by using a nasal 
interface (i.e. a nasal prong or mask) and keeping the mouth free to 
provide respiratory support for spontaenously breathing newborn. More 
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recently use of laryngeal masks that bypasses the need to intubate has 
also come into practice but the evidence so far is limited.  
High surface tension from surfactant deficiency and a tendency to 
develop atelectasis from alveolar collapse increases risk of respiratory 
failure. It is well known, use of constant distending pressure from CPAP 
mitigated this problem and subsequent effort at breathing. CPAP also 
improved oxygenation and achieved better gas exchange by improved 
alveolar recruitment also known as ‘open lung approach’.  The clinical 
application being to mimick the normal physiologic reflex of grunting as 
seen in infants with respiratory distress. Grunting is expiratory braking 
against closed glottis and diaphragmatic contraction which limits the 
airflow during exhalation to help maintain end expiratory volume i.e. 
avaoid alveolar collapse.  
Continuous distending pressure is applied throughout the breathing 
cycle. Since its successful application in infants with respiratory distress 
by gregory (Gregory GA, 1971) in 1970s CPAP delivery systems have 
undergone rapid transformation in its ability to deliver the set positive 
pressure, minimise work of breathing. Tremendous interest in the early 
years has also enhanced our understanding of pulmonary mechanics 
and fine tuned the CPAP delivery based on well designed research.  
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CPAP systems could be classified by the technique used to control gas 
flow. 
1. Constant flow device such as Bubble CPAP and the older 
generation of ventilator CPAP. 
Ventilator CPAP- This traditionally has been a constant flow device 
with flow rate set by the clinician. Advances in technology has added 
features of demand flow. Bubble CPAP is another example of 
constant flow and variable pressure device.  
  
2. Variable Flow device are so called because they use fludic control 
to maintain CPAP. Fluidic Control mechanisms provides adequate 
inspiratory flow and maintain stable pressue (Bernoulli effect). 
The other adavantage of providing CPAP with this flow driver is 
satisfying patient demand by Coanda effect should patient 
demand more flow than that provided by the constant 
background flow. Expiration is easiier compared to constant flow 
system from ‘fluidic flip’ principle which reverses gas flow to the 
expiratory limb.  
CPAP as a respiratory support could be provided early in the respiratory 
distress- termed as ‘Prophylactic’ or subsequently for post extubation 
care. The earlier approach of supplemental oxygen and ‘rescue’ CPAP 
for signs of respiratory distress is no longer favoured with good 
evidence suggesting reduced need for mechanical ventilation and 
surfactant with decreased incidence of BPD and death(Subramaniam, 
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2016). Post extubation, CPAP has shown to reduce the incidence of 
extubation failure and needing further mechanical ventilation (Davis, 
2003).  
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1.3.2 Mechanical ventilation  
Mechanical ventilation could be provided by either pressure-controlled 
modality or volume controlled modality. There is good evidence to 
suggest volume targeted ventilation in any form is superior to pressure 
targeted ventilation (Wheeler et al., 2010). Although there is emerging 
consensus to practice volume targeted ventilation, there is lack of 
agreement amongst clinicians of the best practice for weaning on 
mechanical ventilation. These issues and modes of mechanical 
ventilation would be highlighted in the subsequent chapters.  
Along with mechanical ventilation come associated problems of 
ventilation- Ventilator induced lung injury (VILI). The etiology is 
multifactorial. Surfactant deficiency, premature antioxidant systems, 
premature lung structures and compliant chest wall are the qualities of 
premature lung that lead to VILI (Donn and Sinha, 2006).  
Lung injury from mechanical ventilation could be attributed to: 
a. Volutrauma – damage caused by overdistention  
b. Barotrauma- caused by excessive pressure  
c. Atelectotrauma- shearing forces that lead to continual opening 
and closing of the alveoli 
d. Biotrauma- injury from infection and inflammation 
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e. Rheotrauma- injury from inappropriate airflow leading to 
turbulence, inefficient gas exchange and inadvertent positive end 
expiratory pressure leading to lung overdistention. 
Lung protective strategies aims to mitigate these issues and minimise 
the damaging effects of these components. This could be use of patient 
triggered ventilation modes, volume targeted ventilation and use of 
pulmonary graphics to optimise ventilation.  
Preventing VILI starts with use of antenatal steroids along with 
surfactant therapy.  
Other contributing factors include preventing hypocapnia. Anecdotal 
report of use of CPAP and preventing hypocarbia led to lower incidence 
of chronic lung disease (Avery ME, 1987) was further supported in a 
retrospective multicentre cohort analysis of 235 infants of birth weight 
less than 1000 grams (Kraybill EN). They concluded hypocapnia in the 
first 48 hours was a predictor for developing chronic lung disease. 
Further evidence of hypocarbia and adverse neurodevelopmental 
outcome (Graziani LJ, 1992) led to permissive hypercarbia as a strategy 
for preventing chronic lung disease. However in a controlled study 
(Mariani G, 1999) suggested there is no evidence to support this 
approach. 
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2 Introduction to respiratory support in 
neonates 
2.1 Non invasive respiratory support  
Non-invasive respiratory support is a positive pressure delivery through 
a nasal interface. This could be CPAP or bi-level CPAP delivered either in 
synchronised or non-synchronised form. Most studies have investigated 
the use and benefits in post extubation state. The primary use of CPAP 
versus Bi-level CPAP in respiratory distress syndrome as primary mode 
of respiratory support is very limited. In a recent study of 120 infants 
born between 28-32 weeks gestation, choice of CPAP or SiPAP for 
respiratory distress from surfactant deficiency at birth did not show any 
significant difference in need for intubation and ventilation in the first 
72 hours of life. There was no significant difference in the rates of 
pneumothorax or chronic lung disease (Wood FE, 2013).  
 In another study (Lista et al., 2010) comparing Bi-level CPAP to CPAP, 
40 newborn infants born between 28-34 weeks gestation were 
randomised to receive either form of respiratory form within 1 hour of 
life. A quarter of infants received surfactant in delivery suite. They 
investigated the clinical course, respiratory outcomes and markers of 
inflammation in the two groups. They concluded infants cared for in the 
bi level CPAP group required shorter duration of respiratory support and 
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shorter duration of oxygen requirement. There were no significant 
differences in other outcomes. The only limitation of this study was this 
included more mature infants (mean gestation 30 weeks in both the 
groups) and small cohort.  
The other forms of non-invasive respiratory support include Humidified 
High Flow Nasal Cannula Oxygen (HHFNC). In a more recent Cochrane 
review, HHFNC when compared to CPAP either as first line support after 
birth (total of 439 infants) showed no difference in the rates of chronic 
lung disease or death. However infants in the HHFNC treatment group 
needed longer duration of respiratory support. When HHFNC therapy 
was used after a period of mechanical ventilation (total of 934 infants), 
there was no difference in the rates of treatment failure, chronic lung 
disease or death (Wilkinson et al., 2016).  
The only form of non-invasive respiratory support extensively studied is 
CPAP. Ever since Gregory et al. established the use of CPAP for RDS 
(Gregory GA, 1971), this has been the most well studied for its safety 
and efficacy as a mode of respiratory support for use in newborn and 
preterm neonates.  
But despite considered as a gentle and perceived to prevent lung 
damage seen in mechanical ventilation, three large trials COIN (Morley 
et al., 2008),  SUPPORT(2010) and Vermont Oxford Network(Dunn et 
al., 2011) concluded there was no difference in the clinical outcomes 
such as death or bronchopulmonary dysplasia. Although the incidence 
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of pneumothorax was reported higher in the CPAP group in COIN trial, 
this has not been reported in the other two large trials. Although the 
trials show that preterm infants could be supported by non-invasive 
support, at least 50% infants in the CPAP group required mechanical 
ventilation in COIN trial and the same noted in the SUPPORT trial and 
VON trial. Study by Sandri et al(Sandri et al., 2010) also showed there 
was no difference in the need for mechanical ventilation in infants 
managed with surfactant followed by CPAP versus rescue treatment 
with surfactant. Thus whatever the approach mechanical ventilation is 
the default mode of supporting such infants who fail non-invasive 
respiratory support or are not suitable to receive non-invasive 
respiratory support.  
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2.2 Invasive respiratory support 
Mechanical ventilation of the neonate could be defined as movement of 
gas into and out of the lung by an external source connected directly to 
the patient via an endotracheal tube or tracheostomy. 
The origins to the modern day ventilation can be traced to the Old 
Testament(Goldsmith JP, 2011) with description of the mouth to mouth 
resuscitation technique. Description of endotracheal intubation by 
Hippocrates in 400BC is one of the earliest evidence to support artificial 
breathing support. This was followed by report from Paracelsus after 
2000 years using bellows and oral tube. 
In 1879, a simple rubber bulb connected to a tube inserted into the 
upper airway ‘aerophore pulmonaire’, was the first device specifically 
designed for suction and short-term ventilation of newborn infants. 
Alternate compression and suction provided fresh air and ventilation 
achieved by passive exhalation.  
Later foot compression of the bellows to provide longer term positive 
pressure ventilation was published by O’Dwyer in 1887 (O'Dwyer, 
1885). 
Bloxsom (Bloxsom, 1950) in 1950, suggested it was the oxygen uptake 
in the respiratory tract which was the most important mechanism to 
initiate respiration. However, he felt that change of pressures aided this 
mechanism. He believed that positive pressure is the only mechanism 
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to overcome the respiratory resistance. He argued that tracheal 
intubation was fraught with danger of lung perforation and suggested 
use of positive pressure air lock. This machine produced alternate 
positive and negative pressure in a tightly sealed cylindrical steel 
chamber. 
The earliest use of servo controlled ventilator is reported by Donald & 
Lord (Donald and Lord, 1953). Their case series reported a device that 
actively assisted lung expansion and rapid oxygenation. They reported 
success by means of achieving lung expansion. This was an apt 
inference and not merely limiting to success to survival or death. In an 
era when there was high infant mortality in the first month of life, 
largely due to prematurity, atelectasis and intracranial haemorrhage 
and health care largely ‘laisser-faire or let them be’, good nursing, 
airway clearance and oxygen supplementation was a breakthrough. 
They used clinical spirometry to assess respiratory efficiency in babies 
with atelectasis, a photoelectric pick up mechanism to trigger the 
respirator and synchronise to the infant’s spontaneous breathing to 
‘amplify’ spontaneous breathing efforts. The infant thus controlled the 
machine with feeble respiratory efforts. Solenoid operated valves 
reduced the inertia of the cranks, bellows and pistons.  
The Kennedy tragedy in 1963 boosted research and development in the 
field of premature care and respiratory support. Atelectasis of the 
alveoli was a recognised problem. Hence in an attempt to keep them 
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open, CPAP was delivered via endotracheal tube with remarkable 
improvement. Until then most of the respiratory support was provided 
by adult machines, modified for use in babies, and utilised intermittent 
gas flow delivered by the ventilator.  
In 1971, using continuous gas flow Kirby and co-workers developed a 
new generation neonatal ventilator. This device not only helped in 
spontaneous breathing between the mandatory breaths, but also helped 
prevent dead space breathing noted in the intermittent gas flow types. 
Spontaneous breathing also overcame the need for paralysis and the 
problem of babies ‘fighting the ventilator’. This combination of 
spontaneous breathing under constant flow and intermittent mechanical 
breaths was termed Intermittent Mandatory Ventilation (IMV) and 
became the standard method of neonatal ventilation(KIRBY et al., 
1972) 
Over the decades the technology to support newborn breathing has 
seen an exponential progression. Current generation of neonatal 
ventilators have undergone series of modifications and refinements. 
This includes improving response times and delivering accurate tidal 
volume consistently, a problem with the old generation ventilators. Now 
the microprocessor technology with complex computer algorithms has 
replaced the use of solenoid activated switch for delivery of gas and 
accurate mixing and stopwatch to control inspiratory time. The new 
generation ventilators utilise computer based safety mechanisms and 
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have replaced spring-loaded manometer for monitoring peak inspiratory 
pressure used in the first generation ventilators.  
With increasing survival of premature babies and technological 
advances, the survival of premature babies has increased. This has 
resulted into a new complication of prematurity, bronchopulmonary 
dysplasia (BPD). BPD was first described by Northway et.al (Northway 
WH, 1967), seen in moderate premature babies and related to the 
iatrogenic reason of ventilation induced lung injury from the ventilation 
practices. Designs to minimise this led to alternate forms of respiratory 
support- High Frequency Ventilation and patient triggered ventilation 
modalities. The current generations of ventilators allow synchronising 
infant’s breath with ventilator and allow infant to control the ventilation. 
The use of pulmonary graphics and judicious use of lung distension 
through breath to breath monitoring allow minimising iatrogenic lung 
injury through artificial ventilation(Donn and Sinha, 2006).  
For respiratory management of premature babies the discovery of 
exogenous surfactant complemented the advances in ventilation 
strategies. The pioneering work of Avery and Mead (Avery, 1959) 
reported surfactant deficiency was critical for development of lung 
atelectasis. This breakthrough has clearly shown to have a significant 
impact on newborn survival along with antenatal steroid treatment to 
prevent surfactant deficiency.  
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Although improved technology and their availability has led to newer 
ventilation techniques, this has not led to a significant change in the 
neonatal outcomes (Costeloe et al., 2012). Mechanical ventilation 
though is the mainstay in treatment of preterm infants with surfactant 
deficiency; it still remains a major contributor to adverse neonatal 
outcomes related to iatrogenic lung injury. 
Thus, it is not only important to recognise who to ventilate and how to 
ventilate, but an important part of jigsaw is to recognise when to 
commence weaning and the best mode of weaning infants from 
mechanical ventilation. Early weaning could facilitate earlier extubation 
and perhaps reduce the extent of ventilation induced lung injury. At 
present clinicians continue to have differences in practices and our 
study attempts to explore if pressure support ventilation can assist in 
faster weaning of preterm infants from mechanical ventilation. 
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2.3 Conventional Ventilation  
Neonatal mechanical ventilation for respiratory distress due to 
surfactant deficiency was first described in their works in 1953 & 1958 
(Donald and Lord, 1953, Donald et al., 1958). The aim of mechanical 
ventilation was to normalise acid base balance for preventing death. 
Mechanical ventilation methods have improved over the years with the 
introduction of microprocessor technology and servo control methods 
for better patient ventilator interaction and to prevent Ventilator 
Induced Lung Injury (VILI). 
With clinicians advice technological advances have enabled biomedical 
engineering to introduce newer modes of ventilation in babies. But this 
has introduced new terminology specific to parent companies and has 
caused much confusion. The confusion in the literature limits 
understanding and generalisability of ventilation functions.  
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To simply this confusion, neonatal ventilators could be classified as 
below (Donn, 2009) Table 1: 
Conventional (Tidal Ventilation) 
Modes:  
Intermittent mandatory ventilation (IMV) 
Synchronised Intermittent Mandatory ventilation (SIMV) 
Assist/Control (A/C) 
Pressure support ventilation (PSV) 
Modalities:  
Pressure targeted  
Pressure limited 
Pressure control  
Volume targeted  
Hybrid  
High Frequency ventilation  
High frequency jet ventilation (HFJV) 
High frequency oscillatory ventilation (HFOV) 
Hybrids 
Table 1 Classification of neonatal ventilators 
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2.3.1 What is conventional ventilation?  
Conventional ventilation is based on tidal ventilation. It aims to deliver 
air or air and oxygen mixture for gas exchange. The clinicians usually 
target a physiological range of 4-8 ml/kg/breath.  
2.3.2 Classification of conventional ventilation 
Description of mechanical ventilator has historically been devised 
according to the patient physiology rather than the machine function. 
This has led to many commercial manufacturers to devise individual 
nomenclature leading to much confusion. Conventional mechanical 
ventilators can be classified (Donn, 2009) using target or limit modality 
(pressure or volume) and by the cycling mechanism or mode Table 1. 
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Modes of ventilation:  
 
Figure 1: Comparison of IMV, SIMV and A/C modes 
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Intermittent Mandatory Ventilation (IMV)- all mechanical breaths are 
delivered at regular intervals chosen by the clinician. This result in 
significant asynchrony in an infant with active respiratory drive sees 
Figure 1.   
Synchronised Intermittent Mandatory Ventilation (SIMV)-  
In this form of triggered mode of ventilation, the ventilator algorithm 
uses fixed time windows to achieve synchrony in a spontaneously 
breathing infant. When the infant breathes over the set back up rate 
then the set PEEP supports spontaneous breathing. 
In Assist-Control (A/C) mode – 
All spontaneous breaths are supported provided the infants’ 
spontaneous breath exceeds the set trigger sensitivity. The set back up 
breath (control mode) only comes to play if the infant has inadequate 
respiratory drive. Hence this is fail-safe mode of ventilation which 
clinician most often chooses to commence in acute illness. The key 
difference between SIMV and A/C mode is that the timing mechanism is 
reset after every mechanical breath in A/C mode and therefore the back 
up rate is not truly mandatory.  
Modalities of Ventilation:  
Modality refers to the target or the limit variable of the mechanical 
breath.  
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Generally this refers to Pressure Modality or Volume Modality. Until 
recently, clinicians could only regulate or target one form of the 
modality. In pressure-targeted modality, clinician set pressure variables 
and volume variable was dependent on lung mechanics. If, on the other 
hand, clinician targeted volumes, pressure was variable and with 
improved lung compliance, for the same volume there was ‘auto 
weaning’ of pressures see Figure 2. On the same corollary, note change 
of pressure delivery ‘auto weaning’ in volume ventilation.  
 
Figure 2 Change of volume achieved in pressure-targeted ventilation as compliance 
improves.  
  
 25 
 
 
In newer generation of ventilators, although breath form will target one 
of the two modalities, it can however switch from one variable type to 
other during single inspiration using “dual control”. This form is utilised 
in newer hybrid form of ventilation such as  
Volume Assured Pressure Support (VAPS) 
Pressure Regulated Volume Control (PRVC) 
  
 26 
 
A mechanical breath can therefore be classified according to the three 
features:  
a. Trigger variable- mechanism used to initiate the breath and also 
to terminate the breath. This could be:  
a. Time i.e. when the ventilator cycles into inspiration and 
expiration based on pre set time limit for each component. 
This is the oldest mechanism to achieve mechanical 
ventilation.  
b. Pressure: Pressure changes near to the patients’ wye piece 
could also be used to trigger a mechanical breath. Negative 
intra thoracic pressure generated ‘patient pull’ could be 
used a trigger for towards the patient  
c. Flow: Similar to pressure flow of gases near to the patient 
wye piece could also be utilised to achieve synchrony for 
inspiration and expiration. This is also called as flow cycling. 
In flow cycling, the decelerating inspiratory flow is the 
trigger for the ventilator to cycle into expiration. The 
advantage is that the infant is in complete control of 
achieving synchrony for inspiration and expiration. 
b. Limit Variable: refers to the targeted modality, volume or 
pressure 
c. Cycle: The trigger mechanism as described above also allows 
cycling mechanism to enable ventilator to flip between inspiration 
and expiration.  
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Although, the clinical evidence (Greenough et al., 2008) suggests there 
is no clear benefit of synchronised versus non synchronised mode of 
ventilation to prevent death and other long term adverse outcomes, 
current neonatal mechanical ventilation strategies have evolved using 
synchronised form of ventilation and current ventilator manufacturers 
continue to produce newer triggered modes of ventilation. Synchronised 
form of ventilation is preferred perhaps from comparison of A/C mode 
to SIMV with a trend towards shorted duration of weaning (Chan and 
Greenough, 1994, Dimitriou et al., 1995).  
Many variables in triggered modes of ventilation such as optimising 
trigger function, optimising flow rates and individual ventilator 
mechanics preclude generalisability of the trial results for declaring 
superiority of triggered mode of ventilation. More importantly, lack of 
data from adequately powered randomised controlled studies on long-
term outcomes limits applicability of the newer modes of patient 
triggered ventilation despite advances on servo control technology.  
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3 Pressure Support Ventilation  
Although ventilators in the 80s used assisted mode of ventilation, 
randomised trials conducted failed to show any benefit over 
conventional ventilation methods for short term outcomes such as 
duration of weaning and other common neonatal outcomes (Baumer, 
2000). However clinicians caring for preterm infants were aware of the 
problems to achieve ideal synchrony. This was mainly: need for 
complete synchrony: both at inspiration and expiration thus preventing 
‘fighting the ventilator’ scenario and need for sedation and paralysis. 
For a period of time, various trials tried establishing superiority of 
various trigger types (Hird and Greenough, 1991a), (De Luca et al., 
2009). However to date there is no conclusive evidence that any one 
form is better over the other. It is perceived that flow cycled mode of 
ventilation offers the infant better control over its breathing cycle by 
allowing greater synchrony for the full breathing cycle over the 
traditional time cycled ventilators (De Luca et al., 2009),   
A form of partial ventilation support that could bypass the problems of 
patient ventilator asynchrony, using flow cycling as a means to prevent 
‘fighting the ventilator’ scenario and matching the patient demand with 
demand flow features is available with Pressure Support Ventilation 
(PSV). 
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Pressure support ventilation is a pressure controlled spontaneous 
breathing mode of ventilation, where all breaths are triggered by the 
infant and synchronised during inspiration and expiration.  
By definition, PSV is  
• Patient triggered 
• Pressure limited 
• Flow cycled mode of assisted mechanical ventilation 
Hence, for every patient effort that is above the set trigger threshold, 
the patient is rewarded with a predetermined level of pressure support 
(set point decided by the clinician). Flow cycling gives the infant the 
ability to determine the duration of the inspiratory and the expiratory 
portion of the breathing cycle and thereby manage the frequency. This 
ability to control the depth of the breathing cycle allows sigh breaths. 
This feature is available from variable flow feature that allows meeting 
the patient demand. Ability to develop sigh breaths has shown to be 
beneficial for lung recruitment and for oxygenation (Poets et al., 1997) 
Thus, the equation of motion for PSV would be  
Paw+Pmus= VT/C+V/R  
Where Paw is ventilator airway pressure applied, Pmus is pressure 
generated by respiratory muscles. The elastic property of the system is 
determined by the tidal volume (VT) and compliance (C). The resistive 
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property of the lungs is determined by airways resistance (R) and flow 
(V). 
Therefore if the Paw is fixed, tidal volume can be increased by greater 
muscle power by increasing the flow and the volume. An increase in 
PSV will not affect flow and tidal volume if there is a decrease in 
respiratory drive. 
 
Figure 3 shows relation of Paw and Pmus to tidal volume delivery.  
 
Figure 3 (Adapted from Hess RD, Respiratory Care 2005; 50(2) 166-
183) shows airway pressure, oesophageal pressure, flow and tidal 
volume in a patient with 0, 10 and 20 cm H2O of pressure applied to the 
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airway. Note the decrease in oesophageal pressure as airway pressure 
is increased. There is only a small increase in tidal volume with the 
increase in pressure support. In this case the principal effect of 
pressure support is to provide respiratory muscle unloading.  
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Thus PSV has three features (Gupta et al., 2009a): 
1. Identification of the trigger 
2. Pressurisation in the circuit 
3. Breath termination 
 
Figure 4 Schematic diagram-showing features of pressure support ventilation  
 
1- Triggering 
Recognising patients’ inspiratory effort  
2- Pressurisation 
Rapid inspiratory flow to maintain constant inspiratory pressure with 
variable decelerating inspiratory flow 
3- Breath termination or cycling to expiration 
Recognition of the end of spontaneous inspiration 
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With the trigger, PSV increases exponentially and stays at that level 
until the termination of the inspiratory phase. However this delivery is 
affected by ventilator time constant, which in turn is affected by the 
inspiratory rise time. In the old generation PSV mode this was constant 
but advancement in microprocessor technology has enabled to variable 
rise time depending on patient condition. 
3.1 Optimal Patient Ventilator Interactions 
PSV must have following characteristics to match the patient demand:  
a. Inspiratory pressure support to commence with patient effort 
without trigger delay 
b. Provide flow in synchrony with the patient effort  
c. Provide level of pressure support during the inspiratory effort 
sufficient to unload the muscles and prevent fatigue 
d. Terminate with breath in synchrony with the patient effort. 
These characteristics are illustrated in the next page see Figure 5 
Design characteristics of Pressure Support Ventilation breath.  
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Figure 5 Design characteristics of Pressure Support Ventilation breath. 
  
A= Inspiratory pressure triggered by the patient. Responsiveness and demand valve 
sensitivity are characterised by the depth of the negative pressure  
B= The pressure rise is characterised by high initial flow delivery into the airways. 
B1= “ringing” if the initial flow exceeds patient demand, B2= if flow less than the 
patient demand.  
C= Plateau maintained by the servo control to match the patient demand. A smooth 
plateau suggests appropriate responsiveness to patient demand; fluctuation would 
reflect less responsiveness of the servomechanism. 
D= Breath termination should coincide with patient effort. D1= delayed termination 
with patient actively exhaling. D2= premature termination with continued patient 
effort. 
(Adapted from The Nagoya Conference on system design and patient ventilator 
interactions during PSV, Chest 1990; 97: 1990) 
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Since its inception in the adult ITU, system design and delivery of PSV 
has been fine tuned (MacIntyre N, 1990, Kacmarek RM, 1991) in its 
ability to triggering and system design. 
3.1.1 Identification of the trigger (patient effort)  
This can be usually achieved by detecting either a change in the 
pressure (negative pressure drop reflecting active inspiration) or a 
change in the flow or both. Both the methods need an additional 
demand valve to open and close during inspiration and expiration 
potentially increasing the work of breathing and cause an inspiratory 
delay for the machine to support the breath causing asynchrony. In the 
Avea®, a ‘flow-by’ system is introduced. A constant flow (bias flow) is 
available in the circuit. With the spontaneous breathing effort, the 
ventilator detects a difference in the flow between the inspiratory and 
expiratory limb. Flow triggering avoids the need for a demand valve and 
gives the benefit of producing a continuous positive airway pressure. 
The flow trigger is usually set between 0.2L/min to 0.5L/min in neonatal 
ventilation, i.e. for every 0.2L displacement of air or oxygen in the 
circuit the ventilator identifies there is a demand and supports the 
breath. This is an improvement from previous design in that the trigger 
monitoring is closer to the patient at the Wye piece. Despite attempts 
to best achieve synchrony there is no major improvement since the last 
design modification in the 90s. 
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3.1.2 Pressurisation in the circuit  
A high inspiratory flow is provided initially which rapidly decelerates 
throughout inspiration. Servo control provides the infant with an ability 
to interact with the flow delivery and the ventilator adjusts to the infant 
demand. The ventilator works as a pressurised demand flow system at 
the predetermined level. The rate of pressurisation can be altered. In 
the Avea, this can vary from slow rise to sharp rise (0 to 9 respectively) 
with 5 being default position. The modifications to the pressure delivery 
comes from the fact that although high initial flow rate rapidly achieves 
the required pressure this could be too fast and cause overshoot 
“ringing” and in others be too slow and lead to excessive patient effort 
in the initial phase (MacIntyre N, 1990) see Figure 5. 
3.1.3 Breath termination 
Ideally inspiratory pressure assist should cease with patients’ 
inspiratory respiratory effort. Currently this is achieved by flow cycling. 
This can be either an absolute value of flow but more usually a fixed 
percentage of the peak inspiratory flow is reached (5% and 15% of the 
peak flow). As most neonatal endotracheal tubes are uncuffed, a leak in 
the circuit is inadvertent. Therefore an inspiratory time limit is also set 
up for safety backup. This prevents prolonged inspiration and exposure 
to high inspiratory pressures. 
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3.1.4 Flow and tidal volume delivery during PSV 
During PSV, inspiratory flow and volume is determined by interplay of 
the pressure applied to the airway (Paw), the respiratory muscle 
pressure (Pmus), the airways resistance (R) and the time constant 
(resistance×compliance). Mathematically this is represented (Hess, 
2005) by  
Flow= (Paw+Pmus)/R ×log10-t/time constant 
And volume is the integral of flow time curve.  
The above characteristics help in deciding how the PSV is delivered and 
maintained.  
PSV can be utilised for either total unloading of the respiratory muscles 
during spontaneous breaths or partial unloading. Total unloading occurs 
when muscle contraction is just enough to trigger the breath beyond 
which the positive airway pressure and machine flow cause zero 
mechanical work of breathing and virtually no ventilatory muscle 
oxygen consumption (Brochard et al., 1989). This is also called PSmax. 
Partial unloading occurs when levels less than PSmax are used. When 
PSV is just enough to overcome the tube resistance this is called PSmin. 
Here the patient contributes to the volume delivery by active 
contraction of the respiratory muscle whilst being assisted by the PSV. 
The characteristics of PSV delivery such as flow synchrony and servo 
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control of the flow delivery to match the patient demand make it a 
favourable method to wean the patient off mechanical ventilation. 
In many aspects the PSV resembles flow cycled assist control 
ventilation except in PSV there is no backup rate. Therefore this mode 
of ventilation is often coupled with partial modes of ventilation such as 
SIMV. 
Another feature that has been introduced in PSV mode is an adjustable 
inspiratory rise time. An increase in the rise time slows the pressure 
and flow rates and this may be useful in neonates with very short 
inspiratory times that can interfere with adequate tidal volume delivery. 
However this feature has not been studied in infants.  
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3.2 Effect of Pressure support ventilation 
Benefits of PSV include: 
A. Patient comfort (MacIntyre, 1986) – from demand flow feature 
B. Better synchrony- both at inspiration and expiration using flow 
cycling therefore less patient agitation and need for sedation 
C. Decreased patient work of breathing (MacIntyre, 1986, Patel et 
al., 2009)  
D. Muscle reconditioning and possibly lower extubation failure 
(MacIntyre, 1986) 
Disadvantages of PSV  
A. Varying tidal volume depending upon the patient’s condition,  
B. Varying minute ventilation due to unstable/unreliable respiratory 
drive  
C. Atelectasis from smaller tidal volumes  
D. Unstable pressure assist with varying baseline PEEP in presence 
of a leak in the circuit leading to prolonged inspiration exposing 
the infant to inadvertent high airway pressure. 
In a bench study comparing the available commercial ventilators in a 
laboratory based study (Thille et al., 2009) concluded that despite 
advancements in technology there was large variation between different 
ventilators in terms of trigger function and pressurisation quality. This 
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could affect patient ventilator interaction and contribute to increased 
work of breathing. 
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3.3 Clinical studies using PSV in neonates 
In the first ever randomised controlled trial comparing volume 
controlled ventilation to pressure limited ventilation in preterm infants 
with RDS (Sinha et al., 1997), 50 preterm infants (mean gestation 31.2 
in both the groups) weighing 1200g or more were consecutively 
assigned to either volume control or pressure limited ventilation. 
Weaning in SIMV with added PSV of 10-12 cms H2O was commenced in 
the volume-controlled arm when back up rate was ≤40 per minute. 
Weaning in the TCPL was continued in Assist Control mode aiming 
similar tidal volumes. Infants in the volume-controlled mode met the 
success criteria (mean airway pressure less than 8cm H2O and/or 
alveolar –arterial oxygen difference less than 13 kPa for more than 12 
hours) earlier than TCPL mode of ventilation. (mean 65 hours Vs. 125 
hours), and had a shorter duration of ventilation (mean 122 hours Vs. 
161 hours). The authors concluded that the type of flow delivery 
(presence of demand flow system to augment the continuous flow in 
volume ventilation over the continuous flow in the TCPL mode) along 
with better alveolar recruitment from square wave form, consistent tidal 
volume delivery and better ventilation perfusion mismatch helped in 
faster weaning process. However an important attribute that could have 
led to faster weaning process in the volume controlled ventilation could 
be the addition of PSV to augment spontaneous breathing. The authors 
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highlight use of PSV was due to its striking similarity with flow 
synchronised A/C mode.  
Subsequent study investigated the same mode in a randomised 
controlled study (Singh et al., 2006) in smaller and more immature 
infants (less than 32 weeks and less than 1500 grams) with surfactant 
deficient lung disease. The ventilation strategy and the success criteria 
was the same as in the previous study. Infants were stratified into two 
groups based on the birth weight (600-1000g and 1001-1500 grams). 
They were randomly assigned by permutated block algorithm with block 
sizes of 2, 4, and 6. Infants were commenced on SIMV with PSV for 
weaning when PIP <16cm H2O and FiO2  <0.3) PSV (10-12 cms) was 
added to the volume SIMV arm whilst weaning. Infants were extubated 
if they tolerated low SIMV rate (20) and their mean airway pressure 
was less than 8 cm H2O. The study did not show significant difference 
(mean 23 hours Vs. 33 hours) between the two groups to achieve 
success criteria (mean airway pressure less than 8cm H2O and/or 
alveolar –arterial oxygen difference less than 13 kPa for more than 12 
hours). However post hoc analysis showed significant difference in the 
smaller babies weighing less than 1000 g (21 hours Vs. 58 hours). 
Although the results echo the previous study the overall difference 
between the two groups could be related to the steroid up take (95% to 
44%). Addition of PSV in the two studies could also have contributed to 
the study results.  
 43 
 
A pressure support setting of 10-12 cm H2O as a blanket approach 
could deliver a Peak inspiratory pressure of up to 17 cm H2O depending 
on the level of PEEP. This level of pressure support in the smaller 
infants especially <1000g could deliver full tidal delivery and help in 
conditioning of the respiratory muscles thereby benefitting them with 
weaning process.  
There are three randomised controlled studies investigating PSV as a 
weaning mode. Two studies compare fixed PSV level along with variable 
SIMV with other modes (Reyes et al., 2006) (Patel et al., 2012) and a 
more recent study compared two levels of pure PSV (Farhadi Roya, 
2016).  
In the randomised controlled trial comparing SIMV and SIMV +PSV 
(Reyes et al., 2006), preterm infants weighing less than 1000g were 
randomised into two strata (500-699g) and (700- 1000g) using block 
randomisation method in a sequential sealed envelope from a computer 
generated randomisation list. Their mean gestational age was 25.0+/-
1.4 and 25.4 +/- 1.3 weeks. SIMV was also their primary mode of 
ventilation. The level of PSV was determined at 30-50% difference of 
the PIP and PEEP.  
The success criteria were manifold:  
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a. Time to reach minimal ventilator settings defined as PIP≤16cm 
H2O, FiO2 ≤0.30, PEEP ≤5cm H2O and SIMV rate ≤ 15 breaths per 
minute for ≥ 48 hours.  
b. Time to reach extubation (inadvertent or planned by clinician) and 
maintained for ≥48 hours  
c. Age of final discontinuation of mechanical ventilation  
d. Total duration of mechanical ventilation  
e. Ventilator requirement at day 28  
f. Total duration of supplemental oxygen  
g. Oxygen requirement at day 28 and at 36 weeks postmenstrual 
age. 
They reported that addition of PSV to SIMV reduced the duration of 
mechanical ventilation and could lead to decreased oxygen dependency. 
This effect was observed even with lower ventilator rate in the 
SIMV+PSV group. PaCO2 values were same in both the groups. 
This study however has many limitations in the design:  
a. The management of the infants in the SIMV group was left to the 
clinicians and this could bring clinician bias.  
b. The infants in the SIMV+PSV group on commencing the 
randomised mode further had a reduction in the back up rate in 
anticipation of increase in mean airway pressure and possible 
hyperventilation. This could have helped in their faster weaning 
process. 
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c. Infants in the SIMV were disadvantaged by very low SIMV rates 
(rate of 15 or less) maintained for 48 hours possibly by fatigue. 
The second study compared weaning by assist control (A/C) mode of 
ventilation to PSV (Patel et al., 2012). The study recruited 36 infants 
with median gestation of 29 (range 24 to 39) weeks. Infants were 
randomised when FiO2 was <40%, PIP for infants’ ≥29 weeks of ≤20 
cm H2O, ≤17 cm H2O in infants between 26 and 29 weeks, and ≤15cm 
H2O in infants’ ≤26 weeks’ gestation. Block randomisation using opaque 
sealed envelope was used for randomisation. Permissive hypercapnia 
was allowed after 7 days provided pH was ≥7.25. A/C mode was 
delivered by time cycle with inflation time up to 0.4 seconds as 
determined by the clinical team. Flow cycling aided complete synchrony 
in the PSV mode. The researchers changed the termination sensitivity 
depending on the inspiratory time to maintain at least 0.25 seconds. 
Extubation was as per unit policy when the infant needed <16 cm PIP 
and FiO2 <0.3. Failure criteria was defined as infants needing HFOV, PIP 
>26 cm H2O and in the PSV arm if inspiratory time was <0.2 seconds 
despite 5% termination sensitivity. Most infants required a termination 
sensitivity of 5% to maintain an inflation time of at least 0.25 seconds. 
Peak inspiratory pressures were reduced for weaning in both the arms. 
Primary outcome of the study was to determine if the work of 
breathing, respiratory muscle strength, and degree of asynchrony and 
duration of weaning was different in the two modes. The authors 
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concluded that there was no significant difference between the two 
modes and PSV was equally efficacious.  
This study has some limitations. The trial was based on concept of 
sufficient inflation time as perceived appropriate by the clinician. This 
negates the advantage conferred by flow cycling mechanism where the 
infant determines the respiratory rate and the depth of the breathing 
according to its requirement. Instead the authors could have related the 
observed inspiratory time with tidal volume delivery and verified if this 
met the physiological demands. Although the authors measured the 
transdiaphragmatic pressure time product to assess the work of 
breathing we do not know if the oxygen cost of breathing was 
significantly different between the two modes (Roze et al., 1997). 
The most recent study by (Farhadi Roya, 2016) comparing two levels of 
PSV 10 and 14 cms. The study recruited 50 preterm infants between 24 
and 37 weeks gestation (mean gestation- 31 weeks in group weaned on 
10 cms and 32 weeks in group weaned on 14 cms PSV). The two 
groups received flow triggered SIMV for initial respiratory support 
during acute phase. Weaning on PSV commenced when Peak inspiratory 
pressure was <16 cms, PEEP 4 cms, and oxygen supplementation of 
less than 30% with a back up rate less than 20 per minute. During PSV 
mode they received 15 SIMV breaths. After 24 hours they were 
extubated without further weaning if they were deemed clinically stable 
(respiratory rate more than 80/minute were excluded). They concluded 
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PSV of 10 cms favoured extubation and facilitated shorter weaning 
duration. The findings of this study need to be interpreted with caution 
due to methodological limitations. The choice of two levels of PSV (10 
and 14 cms H2O) is purely arbitrary with no physiological data to 
support this.  It is therefore difficult to establish what level of PSV is 
adequate for weaning. They excluded infants with respiratory rate of 
more than 80 indicating non-resolution of lung disease perhaps. But 
this could also be from ‘unsettledness’ from extubation readiness and 
inadequate respiratory support, thereby increasing the duration of 
mechanical ventilation. 
Current literature reviews on PSV confirm safety, practicability and 
feasibility in neonatal medicine.  
In a small quasi experimental crossover study (Gupta et al., 2009a) 
breath to breath analysis of the pulmonary mechanics data was 
analysed in 10 preterm infants (<32 weeks gestation) during the 
weaning stages of ventilation (when MAP was <10 cm H2O  and FiO2  
<0.4). At the time entry into the trial they were on low rate SIMV (20 
breaths/min) with some PSV. PIP in SIMV was between 12 and 16 cm 
H2O. The three modes of ventilation: SIMV alone, SIMV with partial PSV 
(PSmin) (delivering 2.5-4ml/kg tidal volume) and SIMV with full PSV 
(PSmax delivering 4-8 ml/kg). The study showed that respiratory rate 
settled (72 Vs. 65 Vs. 59 p<0.05 by ANOVA) with increasing PSV and 
tidal volume improved with increasing PSV (3.9 vs. 5.2 vs. 6.7 p<0.05 
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by ANOVA) with no significant change in the CO2   levels between the 
three groups before and after the study. There were no major episodes 
of desaturation during the study period in any of the cohorts. These 
results are in agreement with studies by Tokioka (Tokioka et al., 1997). 
They studied three levels of PSV (0, 5, and 10cm H2O) in neonates with 
congenital heart disease post operatively. They also investigated 
thoracoabdominal synchrony through use of respiratory inductance 
plethysmography and measured phase angle differences between rib 
cage and abdomen to measure asynchrony. They concluded with 
increasing PSV level led to more synchronous breathing effort.  
This study highlighted that preterm infants could maintain adequate gas 
exchange without risk of hypo/hypercarbia with varying PSV level. The 
likely explanation is self-regulation of the spontaneous breaths. In 
addition the study also showed appropriate tidal volume delivery by 
regulating the PSV level and efficient respiratory mechanics.  
Similar results were observed in another cross over randomised study 
(Osorio et al., 2005). This study recruited 15 infants mean gestational 
age 26+/-1.5 weeks. The study objective was to evaluate the effect of 
two levels of PSV (3 cm and 6 cm H2O over PEEP) when added to low 
rate SIMV breath with acute reduction of the ventilator rate (by 10 
breaths per minute lower than the clinical setting). All aspects of 
ventilator including PIP, PEEP and inspiratory time of the SIMV breaths 
remained same Incidentally, all infants were intubated by 2.5mm 
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endotracheal tube thus results between the two groups varied from the 
level of the PSV. The authors reported that spontaneous breaths were 
ably supported by addition of PSV. Gas exchange was maintained with 
both levels of PSV over SIMV. The study also suggested with 6 cm PSV 
(93% elastic unloading) stabilised breathing with reduced respiratory 
effort. There was no change in oxygen requirement whilst maintaining 
minute ventilation. The study reported no adverse events during the 
study.  
The above studies investigated feasibility of PSV as a weaning mode 
and reported no adverse outcomes whilst maintaining gas exchange 
perhaps with improved respiratory mechanics. 
However the above studies reported an increased mean airway 
pressure over conventional SIMV mode. This is expected as flow and 
subsequent pressure delivery is dependent on the infant effort rather 
than iatrogenic.  
In a RCT comparing PSV to A/C (Patel et al., 2012) the MAP observed in 
the two groups was identical. This is likely from flow cycling technique 
used in both the groups suggesting similar gas flow. The drawback of 
this study being PSV was provided with fixed flow (instead of the 
variable flow) as determined by the manufacturer. So in a true sense 
there was no difference between the two arms of the study.  
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In a randomised controlled pilot study comparing PSV+VG and SIMV 
(Nafday et al., 2005) during the acute phase of RDS, use of PSV+VG 
did not decrease duration of weaning nor reduced incidence of chronic 
lung disease. The VG was limited to deliver 5ml/kg/breath. The mean 
gestation in both the group was 27 weeks. The authors argued that 
despite volume guarantee delivering a stable tidal volume and 
synchrony achieved by the PSV did not translate into reduction of time 
to weaning compared to SIMV in the first 24 hours during the study 
period. The observed higher MAP in PSV group is related to the flow 
delivery. PSV is a pressure triggered continuous spontaneous breathing 
mode with decelerating inspiratory peak flow early. It is likely that its 
use early in the disease with surfactant deficiency in an infant with 
inadequate respiratory drive would lead to converting a decelerating 
flow to continuous flow type to achieve the desired tidal volume 
(volume guarantee). This phenomenon has been reported in the volume 
controlled ventilation trial (Sinha et al., 1997). Whilst this may be a 
cause for anxiety, the observed effect has now proven not to be 
counterproductive in the long-term outcomes. The trial was 
underpowered to report any strong conclusions, which the authors also 
acknowledge. 
In another randomised cross over trial (Olsen SL, 2002)recruited 14 
preterm infants (32 to 37 weeks) all diagnosed with RDS and received 
surfactant. The mode allocation was random using sealed opaque 
envelopes to determine the sequence. The study commenced after 6 
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hours of the last dose of surfactant administration. Both modes 
targeted about 5ml/kg breath delivery. At the end of each mode helium 
dilution technique was used to assess the end expiratory volume. The 
primary outcome measure was minute ventilation. Secondary outcome 
measures were arterial alveolar oxygen tension (a/A) ratio, end 
expiratory volume and specific dynamic compliance (dynamic 
compliance/EEV). The authors concluded no advantage in pulmonary 
oxygen exchange with PSV+VG based on the lower end expiratory 
volume and higher minute ventilation in the PSV+VG group.  
Despite volume guarantee set at 5ml/kg in this more mature group of 
infants, there was tachypnoea noted (respiratory rate 60±20 vs. 31±10 
in the SIMV group). There was no difference in the PaCO2. One 
explanation could be the level of PSV offered was inadequate leading to 
“pulling the ventilator” to satisfy the need thereby causing increase in 
spontaneous contribution to the tidal volume. This explanation could 
explain the decrease in the EEV due to progressive atelectasis. Another 
explanation could be the difference in the PEEP level setting in the 
ventilator. The methodology of this study has been critiqued (Keszler et 
al., 2003). 
Another short term crossover study of 23 infants of gestational age 
31±6 weeks during the recovery phase of the RDS, reported a 
reduction in PIP and mean airway pressure(Abubakar and Keszler, 
2001) with PSV and PSV+VG. The observed difference was greater 
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when compared with SIMV than with A/C. This was attributed due to 
shorter inspiratory time from flow cycling. Although there was no 
difference in the tidal volume delivery this was less variable with VG 
mode (set to deliver 5ml/kg).  
A cross over study comparing Mandatory Minute Ventilation (MMV) to 
SIMV (Guthrie et al., 2005) showed feasibility of using PSV in infants 
>33 weeks receiving mechanical ventilation for medical or surgical 
procedures. A preset minute volume (150- 240mls/kg/min) was used. 
Continuous online CO2 monitoring was in place. Minute ventilation is 
essentially PSV but ventilator algorithm monitors the minute volume 
over a specified times (usually 7- 10 seconds) and determines the 
mandatory breath rate to meet the targeted minute volume. In the best 
case scenario the ventilator will trigger none and in case of apnoea the 
ventilator will do most part of the breathing. The machine delivered 
breaths are time cycled pressure limited breaths. The authors 
concluded whilst PSV maintained gas exchange effectively, an issue of 
hypoventilation from fast shallow breathing as seen very preterm 
infants could pose a risk for hypoventilation period. This would need 
further investigation. 
In another cross over trial (Migliori et al., 2003) compared SIMV and 
PSV on the effects on respiratory function in preterm infants (<37 
weeks). They used continuous flow ventilator for this study and volume 
limitation to restrict tidal volume delivery to 6 ml/kg in both study 
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modality to restrict higher than usual peak inspiratory pressure. They 
recruited 20 infants (mean gestation 29 weeks, mean weight 1354g). 
Each infant was studied in four study epochs of four-hour duration. 
They concluded a significant reduction in respiratory rate and an 
increase in tidal volume and minute ventilation during the PSV study 
period as compared to SIMV mode of ventilation. This reflects pressure 
support ventilation improves respiratory function and given a good 
respiratory drive the infant can control its respiration. However this 
study has some limitation. Volume limitation could have detrimental 
effect on the complex patient ventilator interaction.  The advantage of 
PSV is to achieve higher tidal volume for similar effort and this is 
dependent on the flow delivery that is controlled by the patient.  Thus 
limiting tidal volumes, it could significantly affect patient comfort and 
cause air hunger. Although the study concluded the advantage of PSV 
and improved respiratory function the results could have been different 
in smaller infants with volume limitation. 
. 
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4 Weaning on Mechanical ventilation 
Mechanical ventilation is one of the major advances in neonatal 
medicine. Despite newer non-invasive respiratory support strategies 
being developed to provide ‘gentler’ alternative approach, intubation 
and mechanical ventilation still remains the mainstay of supporting 
preterm respiratory system. Despite best attempts, extubation success 
is approximately 70% (Gupta et al., 2009b) with one third requiring 
mechanical ventilation. The significant high number in need for re 
intubation and commencing mechanical ventilation reflects limited 
understanding of appropriate weaning strategies from mechanical 
ventilation.  
A dynamic process of reducing support on ventilator after achieving the 
desired gas exchange progressing to extubation is called ‘weaning on 
mechanical ventilation’. This process can also be interpreted as 
transferring the work of breathing from the ventilator to the patient in a 
gradual phased manner ensuring at all times the infant is able to cope 
with the imposed work of breathing. This is generally monitored by 
infant condition at the bedside by either an increase in respiratory rate, 
oxygen requirement and increase in breathing effort. These observed 
parameters are often supported by blood gas biochemistry i.e. increase 
in CO2 retention, fall in pH and decreased alveolar arterial oxygen 
tension. These changes can also be seen in the ventilator graphics such 
as decrease in tidal volume and minute ventilation. 
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Early weaning on mechanical ventilation is important to decrease the 
complications of mechanical ventilation. Whilst most clinicians agree on 
this and agree on how to approach and initiate mechanical ventilation, 
there is very little data to confirm best method of weaning on 
mechanical ventilation. 
Weaning commences when the clinician reduces the ventilation in 
response to infant’s ‘clinically stable’ condition and blood gas supporting 
adequate gas exchange. It is therefore important to acknowledge, that 
weaning on mechanical ventilation is commenced the moment the 
clinician reduces any degree of ventilatory support.  
This ability to cope with the changes depends on a delicate balance 
between ‘loads’ imposed on the respiratory system and its ‘capacity’ see 
Table 2 Causes of weaning and extubation failure  (Sinha and Donn, 
2002).  
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↑ Respiratory Load  ↓Respiratory Capacity 
Increased elastic load  
• Unresolved lung disease 
• Secondary pneumonia  
• Left to right shunting (e.g. PDA) 
• Abdominal distension 
• Hyperinflated lungs  
Decreased respiratory drive 
• Sedation 
• CNS infection  
• PVH /PVL 
• Hypocapnia/alkalosis  
Increased resistive load  
• Think copious airway secretions  
• Narrow/ occluded ET tube  
• Upper airway obstruction  
 
Muscular dysfunction  
• Malnutrition 
• Electrolyte imbalance  
• Chronic pulmonary 
hyperinflation 
Increased minute ventilation  
• Pain and irritability 
• Sepsis/hyperthermia  
• Metabolic acidosis 
 
Neuromuscular disorders  
• Diaphragmatic dysfunction 
• Prolonged neuromuscular 
blockade  
• Myotonic dystrophy 
• Cervical spinal injury 
 
Table 2 Causes of weaning and extubation failure  
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Weaning on mechanical ventilation involves tackling two issues:  
a. Identifying the right patients through appropriate objective 
assessment. 
b. In infant failing this assessment regular assessments to identify 
their readiness must be instituted.  
The ventilator management in patients needing mechanical ventilation 
include  
a. Normalising the loading conditions 
b. Optimising the patient comfort by increasing synchrony.  
 
Excessive loading predisposes to muscle fatigue and total unloading 
leads to muscle atrophy (MacIntyre, 2005). The goal is therefore to set 
the ventilator such that the patient generates some work of breathing 
to maintain and build muscle tone and at the same time prevent 
fatigue. This is well depicted in Figure 6 (MacIntyre, 2005). 
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Figure 6 Pressure volume curve depicting various patient ventilator interactions with 
constant tidal volume. 
  
In each curve, volume is on the vertical axis and pressure is on the horizontal axis. 
Airway pressure is depicted by solid lines, Oesophageal pressure is depicted by 
dashed lines. The bold angled line directed upward and to the right from the origin 
reflects passive inflation oesophageal pressure (chest wall compliance). The shaded 
area reflects patient work.  
A. A normally loaded spontaneous (unsupported) breath 
B. An abnormally loaded spontaneous breath 
C. A ventilator controlled breath in an abnormal patient 
D. A synchronous assisted breath designed to virtually unload an abnormal 
patient (only triggering is evident) 
E. A synchronous assisted breath designed to partially unload an abnormal 
patient 
F. A dyssynchronous assisted breath in an abnormal patient; high-pressure 
patient load exists through much of this breath from inappropriate ventilator 
flow delivery. 
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4.1 Misconceptions about the impact of endotracheal tubes on 
weaning mechanical ventilation 
The notion that breathing through the small ETT imposes a significant 
work of breathing is conflicting.  Data from observational study (Keidan 
et al., 2000) in children needing general anaesthesia, conclude that 
work of breathing through an endotracheal tube was half that of mask 
and oropharyngeal airway. They suggest this could be due to relatively 
larger proportion of subglottic area to the body size (20 times greater in 
proportion to adults)(Eckenhoff, 1951). Thus due to use of short 
endotracheal tube and flow rates less than that needed in adult 
intensive care, the infant is benefitted with endotracheal tube contrary 
to popular belief.  
In another observational study (Argent et al., 2008) the mid and peak 
inspiratory flow in humans is approximately 0.5L/kg/min. This finding is 
important when applied in the smallest infants ventilating through small 
endotracheal tubes for example flow limitation occurred with flow of 
24L/min or 8L/kg/min in a 3 kg infant.  
Another notion is an increase in flow rate changes the laminar flow to 
turbulent flow. Jarreau and colleagues (Jarreau et al., 1999) found that 
flows even in the smaller endotracheal tubes of 2.5 to 3.5 mm was 
laminar and therefore does not change increase the pressure drop. 
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These findings are helpful when planning weaning on mechanical 
ventilation. 
To assess pressure drop at fixed flow rates as used in volume controlled 
ventilation we performed an in-vitro experiment to investigate pressure 
drop to enhance our understanding at common flow rates used in 
volume controlled ventilation see Appendix 7. 
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4.2 Estimation of Neonatal Endotracheal Tube (ETT) Resistance 
by Water Manometer  
(Mallya et al., 2012). (See also Appendix 7) 
Aim of the study: to Assess in vitro the pressure drop using varying 
sizes of ETT commonly used in preterm infants at different lengths, flow 
rates with medical air and 100% oxygen.   
Methods: We used Portex tubes for this in vitro study. Portex tubes 
were chosen as similar make was used for intubation in our study. A 
water manometer (scale 0-300mm) was used to measure the pressure 
drop across the ETT. We used two different lengths (7 and 14 cms) and 
different sizes (2.5, 3.0, 3.5 and 4.0 mm). We assessed pressure drop 
across a range of flow rates from 4 L/min up to 11L/min. 
Flow (L/min) Pressure drop with medical air 
(cms H2O) 
Mean (SD) 
Pressure drop with 
100% Oxygen 
 (cms H2O) 
Mean (SD) 
4 4.34 (6.4) 5.5 (26.3) 
5 5.81 (8.3) 7.45 (20.3) 
6 7.99 (10.8) 9.77 (16) 
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7 10.16 (13.5) 12.9 (14.6) 
8 12.59 (16) 16.21 (18.9) 
9 15.67 (20) 19.8 (25.6) 
10 19.79 (25.7) 23.62 (33) 
11 22.77 (59.3) 18.24 (129) 
 
Table 3 Comparison of pressure drop with medical air and 100% oxygen 
 
Results: There was no difference in the pressure drop using medical air 
at 7 and 14cms ETT [(120.6 (66.12) vs. 127.3 (68.7) cm H2O; p=0.29] 
and there was statistically significant pressure drop with 100% oxygen 
at 14 cm compared to 7 cm ETT length [146.73 (72.94) vs. 130.48 
(72.94) cms H2O; p=0.015]. Difference in the ETT diameter did not 
seem to contribute to significant difference in the pressure drop across 
all the flow range. As expected there was a statistically significant 
increase in pressure drop at flow rates increasing from 4L/min to 
11L/min.  
Conclusion: Although, the results of this study could not be studied in 
vivo, the results of the study highlighted how the infant contributes to 
achieving the desired tidal volume with weaning the ventilator at a 
given flow rate in volume controlled ventilation.  
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4.3 Current evidence in weaning on mechanical ventilation 
With the advent of synchronised modes of mechanical ventilation, 
Intermittent Mechanical Ventilation (IMV) is now rarely practiced. 
Several studies (Chan and Greenough, 1993, Chan and Greenough, 
1994, Bernstein et al., 1996) even though were performed when 
surfactant uptake was about 50-60% confirmed some form of 
synchronisation was helpful than none. It was thought that patients 
‘fighting the ventilator’ had active expiration and the cause for air leak 
syndrome. Several studies conferred various advantages of 
synchronised ventilation which include improved oxygenation, improved 
CO2 elimination, increased minute ventilation, and decreased blood 
pressure fluctuations (Hummler et al., 1996).  
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4.4 Historic studies comparing various ventilation practices for 
weaning preterm infants. 
 In a large international randomised controlled trial (Baumer, 2000) 
compared patient triggered ventilation (A/C mode)with IMV. He 
concluded there was no benefit in view of higher than usual 
pneumothorax rate in the assisted group (<28 weeks gestation). In 
addition, there was no difference in other secondary outcomes of 
interest. The study methods were criticised due to a large number of 
infants deviating to the conventional IMV instead of using HFOV as a 
rescue mode. This study also highlighted how previous experience in 
using a particular ventilation strategy, particularly in triggered mode of 
ventilation is important to use a relatively new mode of ventilation. This 
could be the reason for the findings of the study. 
In another randomised controlled trial (Beresford et al., 2000) 
comparing SIMV with conventional fast rate ventilation in preterm 
infants (mean gestation 29 weeks) were randomised within two hours 
(range 0-24 hours) of decision to commence mechanical ventilation. 
SLE 2000 was used in this trial. No crossover was allowed. Respiratory 
rate of the infant was counted prior to intubation. Infants in the 
conventional fast rate started at the same rate or higher than resting 
rate and in the trigger group 20 breaths less than the resting rate. 
Weaning was performed reducing pressures until acceptable blood 
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gases were obtained and ventilator rate reduced down to 5-10 breaths 
per minute. The researchers concluded that there was no difference in 
the rate of chronic lung disease. The results of the trial could be 
influenced from the fact that infants in the conventional group got the 
benefit due to short time constants due to the nature of the disease 
(poor compliance and high resistance from surfactant deficiency). The 
back-up rate in the SIMV group was not clear. 13% infants in the 
trigger group ‘failed’ in assigned mode and were changed to 
conventional high rate mechanical ventilation. Interestingly 1/6th of the 
infants needed bagging and in up to 1/3rd of the infants there was no 
specific reason. The rest failed due to inadequate oxygenation, needing 
high peak pressures, poor respiratory effort, all indicating inadequate 
respiratory support rather than failed mode. Although this was not 
strictly a weaning trial, the results highlighted that SIMV was at least 
efficacious in managing preterm infants.  
In a two part randomised controlled trial, (Dimitriou et al., 1995) 
investigated PTV to SIMV. (N=40). They concluded PTV was a better 
mode of weaning on mechanical ventilation compared to SIMV. In 
addition, they also added concept of a minimum (critical number of 
breaths) 20 breaths/minute that is necessary to prevent failing on 
weaning. The major limitation of the study was obvious disadvantage in 
the SIMV group when the backup rate was reduced to 5 breaths per 
minute before commencing ET CPAP for 1 hour to demonstrate 
readiness to extubation. This phenomenon was not observed in the 
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second part of the study when the infants were extubated when SIMV 
back up rate was 20 breaths /minute. These results would be different 
in current practice with use of PSV (Reyes et al., 2006) favouring use of 
PSV with SIMV to reduce weaning duration.  
In a randomised controlled trial comparing duration of weaning and 
efficacy of weaning by patient triggered ventilation (A/C mode) and 
conventional ventilation, it was concluded, that PTV was more 
advantageous with mean duration of 39 hours (range 3-186) versus 65 
hours (range 15-262 hours) p<0.02. This study was performed after 
the authors acknowledged the studies previous to this were limited 
either due to triggering capabilities (Hird and Greenough, 1991b), or 
due to technological limitations. A purpose built neonatal ventilator 
(SLE 2000 HV) was used in this study. Infants were weaned either by 
PTV or conventional route once their back up rate was 40/min and had 
received a loading dose of aminophylline. Weaning on PTV was achieved 
by reducing the pressure and rate reduction in the conventional mode. 
Duration of weaning was defined as the time from entering the trial to 
extubation. The study reported A/C mode failed in three infants (25, 26 
and 27 weeks gestation and labelled them as the most immature 
infants in the intervention arm). However this study is limited in current 
context due to better antenatal care, antenatal steroids and liberal use 
of surfactant. In their study, less than 15% infants received 
surfactants. But despite these limitations the study showed PTV was 
superior to the conventional methods. 
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In another RCT comparing A/C mode of ventilation with SIMV in 1994 
(Chan and Greenough, 1994), mean gestation 29 weeks and only 50% 
recruited infants received surfactant, found no difference between the 
two groups. However, 15% of the infants in both the arms who failed 
weaning methods were <27 weeks gestation. The results of the study is 
limited in applying to current practice for the following reasons- the use 
of inadequate PEEP (limited to only 3cm H2O), use of airway pressure 
for trigger, and post extubation management (use of head box oxygen 
and or CPAP) which was not clearly described in this study. Despite no 
statistically significant results, there was a trend towards shorter 
duration of weaning in infants randomised to A/C mode [median 22 
(range 4-339) vs. median 36 (range 8-647)]. This suggests it is better 
to support spontaneous breaths in infants receiving mechanical 
ventilation with positive pressure inflations above PEEP. Whether PSV 
offers that advantage has been described before in section 4.3. 
In a randomised controlled trial comparing A/C mode to PSV (Patel et 
al., 2012) concluded that PSV has similar characteristics to weaning on 
A/C mode and was equally efficacious. The details of the study has 
been discussed in section 4.3 
Clinicians world over prefer SIMV for weaning from mechanical 
ventilation (Van Kaam et al., 2010). Thus study results from this 
research could be generalised in its application to wider population.  
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4.5 What is currently known? 
• The pressure-volume loop is altered by the infant effort and infant 
assumes greater role with weaning of ventilator support.  
• There is as yet lack of clear consensus as to superiority of one 
mode of ventilation to reduce the duration of mechanical 
ventilator days.  
• Pressure Support Ventilation seems to ‘mimic’ natural 
spontaneous breathing. 
These points are well illustrated in Figure 7 Schematic diagram 
depicting how patient effort alters pressure volume loop.(MacIntyre, 
1986) 
 
Figure 7 Schematic diagram depicting how patient effort alters pressure volume loop. 
 
Schematic diagram depicting how pressure assisting a patient’s spontaneous breath 
can alter the pressure volume change characteristics of that work. The horizontal axes 
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represent pressure (patient generated on the pleural space to the left, machine 
generated on the ventilator circuitry to the right) and the vertical axes represent lung 
volume change for a single breath. The left panel depicts an unassisted breath. The 
shaded area under this curve represents patient workload. The right panel depicts a 
pressure-supported breath in a lung. Note, for a similar level of patient total work, the 
pressure volume change work ratio for that breath are markedly reduced by pressure 
assisting the breath. 
 
The aim of weaning on mechanical ventilation is to gradually shift the 
pressure volume curve to the left and let infant assume greater work of 
breathing.  
 
4.6 What is the knowledge gap? 
• There is no clear consensus of defining weaning on mechanical 
ventilation  
• Pressure Support Ventilation seems to favour weaning on 
mechanical ventilation- however variable levels of support has not 
been investigated in a controlled study.  
• Whether reducing the weaning duration on mechanical ventilation 
improves rates of chronic lung disease is still unknown.  
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5 Extubation readiness  
Whilst most clinicians would agree with need for mechanical ventilation, 
there is no consensus on when to commence weaning to facilitate early 
extubation. The dangers of prolonged intubation would include bacterial 
colonisation, soft tissue injury such as subglottic stenosis and ventilator 
induced lung injury leading to poor long-term outcomes such as 
bronchopulmonary dysplasia and death. Up to 30% infants fail 
extubation and require further intubation and are re-commenced on 
mechanical ventilation. Re intubation is not innocuous with reported 
complications that include raised intracranial pressures, hypoxia and 
cardiovascular instability (Kelleher et al., 2009). It is therefore 
necessary to identify the infants who might fail extubation. However 
there is limited evidence that could guide clinicians in this decision-
making.  
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5.1 Causes of extubation failure  
Extubation failure is essentially an imbalance between respiratory load 
and respiratory capacity. This is explained in Table 2.  
 
5.2 Predicting successful extubation 
Multiple attempts have been made in the past to identify the babies for 
successful extubation. There are a few post extubation tests designed 
such as measure of functional residual capacity, post extubation x ray 
of the chest and measurement of the lung volumes (Dimitriou and 
Greenough, 2000). However these are of limited use as extubation has 
already happened. Researchers have also investigated use of occlusion 
tests to verify if this was useful and concluded low gestational age and 
older postnatal age (prolonged ventilation) were better predictors of 
extubation than measurement of respiratory muscle strength or 
respiratory load (Dimitriou et al., 2002).  
5.2.1 Clinical studies 
One of the earliest study to identify an objective test for extubation 
readiness is the minute ventilation test (Wilson et al., 1998). In this 
observational study 64 infants with a birth weight of <2500g, the 
authors reported 86% success in extubation (defined as extubation for 
at least 24 hours) if their spontaneous minute ventilation in the 10-
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minute trial on ET CPAP was ≥50% of mechanically generated minute 
ventilation.  
In another observational study involving 41 infants [median gestation 
27 weeks (range 25-29 weeks)], infants spent 2 hours on ETCPAP 
following specific weaning protocol (Vento et al., 2004). The 
researchers hypothesised from their previous study a spontaneous 
minute ventilation of at least 125ml/kg as minimum necessary to 
sustain spontaneous breathing upon extubation. They reported 
successful extubation (defined as 72 hours) in 73.2% infants and 
associated higher respiratory rate mean 53 (28-67) vs. 43 (37-56) in 
successful extubation. The findings of this study although helpful, do 
not satisfy in explaining the high respiratory rate and low oxygen 
consumption in the successful group. This is contrary to generally held 
belief that high respiratory rate is associated with higher work of 
breathing and therefore associated higher oxygen consumption. It may 
be that the rather long duration on ET CPAP could have tired a 
proportion of babies and thus been disadvantaged. The authors of the 
study also acknowledge this issue.  
Szymankiewicz (Szymankiewicz et al., 2005) investigated differences in 
pulmonary mechanics in ventilator dependent preterm infants (mean 
gestation 29.1 week±2 weeks) who were extubated following specific 
extubation criteria. 39% required reintubation within 72 hours. 
Pulmonary mechanics were studied in 51 infants before extubation. 
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They found significant differences between successful and unsuccessful 
infants in their pulmonary function. They concluded tidal volume of 
>6mls/kg, minute ventilation of >309ml/kg/min, work of breathing of 
<0.172J /lt and airway resistance of ≤ 176 cm H2O /L/sec predicted 
successful extubation.  
The predictive capability of successful extubation by minute ventilation 
test was further compared with clinical judgement in a randomised 
controlled trial (Gillespie et al., 2003). Infants randomised to minute 
ventilation test underwent 10 minute ET CPAP trial as described above 
in study by Wilson. They described, a significantly shorter duration of 
ventilation to extubation in the MVT group compared to infants 
extubated by clinical judgement (mean 8 hours versus 36 hours). They 
concluded the positive predictive value of the MVT for extubation to be 
76% (95% CI, 55-89%).  
More recently in an observational study (Kamlin et al., 2006) the 
investigators determined the accuracy of the three tests used to predict 
successful extubation in preterm infants (birth weight <1250g) 
considered ready for extubation. Tidal volumes, minute ventilation, 
heart rate, and oxygen saturations were recorded before and after the 
ET CPAP. The three tests were expired minute ventilation during ET 
CPAP, ratio of minute ventilation during ET CPAP to mechanical 
ventilation and the spontaneous breathing test (SBT). Extubation failure 
was defined as need for re intubation within 72 hours. The authors 
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concluded that only SBT was the most accurate with a sensitivity of 
97% and specificity of 73%. The positive predictive value was 93% and 
the negative predictive value was 89%.  
The same authors later compared the SBT to clinical decision making in 
a randomised controlled trial. They recruited 180 infants of birth weight 
less than 1250g. They reported there was no difference in the time to 
first extubation or in the duration of total respiratory support. However 
the study reflected infants’ extubated through SBT discontinued 
mechanical ventilation at higher mean airway pressure than through 
clinical judgement but there was no difference in the need for re 
intubation.  
In another prospective study (Currie et al., 2011), twenty ventilated 
infants median gestation 31 weeks (range 24-39 weeks) ventilated by 
either assist control mode of ventilation or pressure support ventilation 
underwent measurements of transdiaphragmatic pressure using dual 
pressure transducer tipped catheter. This yielded the diaphragm tension 
time index (TTdi). They also calculated the respiratory muscle tension 
time index (TTmus) from a non-invasive airway pressure measurement. 
The researchers concluded that the infants failing extubation had a 
significantly higher TTdi and TTmus. A TTdi >0.15 and TTmus >0.18 
was 100% sensitive and specific in predicting extubation failure. 
Although this seems to be promising in its application, the clinical 
application in routine practice is limited by the availability of the 
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technology at the bedside and ‘perceived’ invasive technique of placing 
the dual pressure transducer catheter.  
5.3 Present study 
In the present study, we chose to apply minute ventilation test as an 
objective measure for readiness to extubation (Gillespie et al., 2003). A 
modified approach of the same test was used in the another 
randomised controlled trial (Gupta et al., 2009b) where the research 
team used five minutes instead of 10 minutes to measure spontaneous 
minute ventilation via ET CPAP. They had 104 infants, mean gestation 
27.9 weeks (SD 1.8), and birth weight 1077g (SD 256). The study 
investigated two methods of CPAP support post extubation. They 
reported 77% infants maintained successful extubation at 72 hours in 
both the groups.  
As the clinical team at both the centres was well aware of the minute 
ventilation test we chose the modified minute ventilation test as 
objective measure of extubation readiness for our study. 
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6 Adjunctive therapies for weaning  
Although strict weaning protocol benefits patients towards faster 
weaning and extubation (MacIntyre, 2001), adjunctive therapies also 
help to facilitate extubation. The evidence and the strategies utilising 
adjunctive therapies to facilitate extubation are discussed in this 
chapter.  
6.1 Caffeine Citrate 
Methylxanthine alkaloids such as aminophylline, theophylline and 
caffeine citrate have been used to treat apnoea of prematurity. The 
predominant site of activity involves the central nervous system and 
the cardiovascular system. This is largely increasing excitatory pathway 
by translocation of intracellular calcium, and inhibit adenosine 
receptors. The pharmacological mechanism that alters the neonatal 
apnoea include: improved sensitivity of medullary respiratory centre to 
CO2, increased afferent nerve stimulation to brain stem, increased 
catecholamine response, stimulation of central inspiratory drive, 
improved skeletal muscle contraction. In a large multicentre trial 
(Schmidt B, 2006), infants weighing between 500 and 1250 grams 
(median gestation 28 weeks) were randomised in the first ten days of 
life to receive caffeine citrate or placebo. 2006 infants participated. The 
study concluded decrease in the incidence of bronchopulmonary.  
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Further analysis (Davis et al., 2010) suggested early administration was 
associated with faster weaning on mechanical ventilation. Hence in the 
current study, caffeine citrate 20 mg/kg loading dose at the earliest 
opportunity was given and further maintenance dose was continued 
until 34 weeks gestation. This approach is also supported by the 
Cochrane meta analysis(Henderson-Smart, 2010) The review included 
seven studies and concluded caffeine citrate reduced failure of 
extubation within one week (RR 0.48, 95% CI 0.32 to 0.71). 
6.2 Use of diuretics 
Use of diuretics in infants with bronchopulmonary dysplasia is widely 
practiced. However there is a lack of good quality current evidence to 
support this(Stewart A, 2011). The perceived advantage comes from a 
study in preterm infants who received furosemide or chlorthiazide 
within the first five days (Green TP, 1983). Although the study 
investigated early water management with severity of respiratory 
distress syndrome the study results have been extrapolated for later 
management. In the current practice, use of diuretics is at the 
discretion of the attending physician. 
6.3 Use of CPAP 
CPAP has been utilised as an adjunct to maintain extubation. In a meta 
analysis comparing CPAP with head box oxygen supplementation, the 
authors concluded CPAP is superior to prevent re intubation rates 
(Davis, 2003). Multiple physiologic reasons support its use in particular 
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this is related to increase in functional residual capacity, decreased 
work of breathing and respiratory stimulus in preventing apnoea of 
prematurity. 
In a randomised controlled trial, comparing Infant Flow Driver with 
Bubble CPAP, researchers established Bubble CPAP was superior in 
infants ventilated for ≤ 14 days to maintain successful extubation 
(Gupta et al., 2009b). In view of familiarity with the technique, identical 
patient base to that reported in the above trial and ease of application 
we chose to support extubated infants with Bubble CPAP. 
6.4  Heated Humdified High Flow Nasal Cannula oxygen 
(HHHFNC) 
There have been several clinical studies comparing HHHFNC to nasal 
CPAP in non inferiority study designs and has been shown to have 
similar efficacy and safety to nasal CPAP when applied as a post 
extubation strategy (Yoder et al., 2013), (Collins et al.), (Manley  et al., 
2013). Meta analysis (six studies, 934 infants) in Cochrane review in 
2016 (Wilkinson et al., 2016) showed HHFNC when used as respiratory 
support after receiving mechanical ventilation – there was no difference 
in the rates of re-intubation. Long-term outcomes such as chronic lung 
disease and death were also not different when compared to CPAP. 
There is also a decrease in soft tissue injury with use of HHFNC (Collins 
et al.). 
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6.5 Postnatal Corticosteroids 
Corticosteroid use could be divided into two categories.  
Use of prophylactic dexamethasone for extubation in view of laryngeal 
oedema has been reported with some success (Khemani et al., 2009). 
Although this Cochrane review has 11 trials, only two were neonatal. 
The study by Couser, (Couser et al., 1992) included the ‘high risk’ 
infants who had multiple intubation and traumatic intubation or 
received mechanical ventilation for at least 14 days (n=50). First dose 
of Dexamethasone was given at least four hours before extubation and 
then further two doses were administered. The results of this study 
suggested a decrease in the incidence of stridor and rate of re 
intubation in the Dexamethasone treated group. In view of inconclusive 
strong evidence for treatment or otherwise the decision was left at the 
discretion of the attending physician. 
Use of corticosteroids for facilitating extubation after prolonged 
intubation-Use of low dose Dexamethasone therapy in select infants 
who received mechanical ventilation for more than two weeks and who 
had failed extubation on at least two occasions is well recognised (Doyle 
et al., 2006). Although the Cochrane review (Halliday et al., 2009) 
suggests benefits in the immediate short term outcomes (incidence of 
BPD and IVH), they advice, caution in the post natal steroid use in view 
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of lack of evidence in the long term neuro sensory outcomes. However, 
in a meta- regression of 20 studies (1721 randomised infants), 
postnatal use of systemic corticosteroids and the risks of cerebral palsy 
and mortality was further reviewed as per the risk for chronic lung 
disease (Doyle et al., 2005). They concluded there was a significant 
negative relationship between the treatment effect on death or cerebral 
palsy and the risk for chronic lung disease in control groups. With the 
risks for chronic lung disease below 35%, corticosteroid treatment 
significantly increased the chance of death or cerebral palsy, whereas 
with risks for chronic lung disease exceeding 65%, it reduced this 
chance. The decision to commence steroid treatment was based after 
discussion with the parents. The dose and duration of the treatment 
used in this study is followed as per the DART trial protocol (Doyle et 
al., 2006).  
6.6 Use of Cyclo oxygenase inhibitors for PDA treatment 
Use of cyclo oxygenase inhibitor has been in practice since 1975 when 
Ment et al reported it reduced IVH apart from closing PDA. Since then 
indomethacin and ibuprofen have been used in a number of clinical 
trails to reduce the co-morbidity of PDA associated with RDS and 
preterm babies. For few years only IV Ibuprofen is commercially 
available in UK.  
The use of NSAID for closure of PDA has mainly two-fold approach in 
UK- 
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a. Use of Ibuprofen as early prophylaxis –defined as attempt to 
close the PDA within 72 hours  
b. Late symptomatic closure.  
Early prophylactic closure was based on routine echocardiographic 
assessment. This was based on echo finding of large PDA (i.e. PDA 
diameter of ≥ 1.5mm, and a Pulsatile or growing flow pattern in PDA). 
Late symptomatic treatment was based on clinical findings and difficult 
ventilation management attributed to presence of significant PDA in 
absence of other obvious cause. In view of lack of clear evidence on the 
treatment approach, the decision to treat is left to the discretion of the 
attending physician.  
6.7 Vitamin A for preventing chronic lung disease 
In a meta analyses of Vitamin A for prevention of bronchopulmonary 
dysplasia (Darlow and Graham, 2011) compared nine studies (1291 
infants). They report intramuscular vitamin A seems to be beneficial in 
reducing death or oxygen requirement at one month of age (RR 0.93, 
95% CI 0.88 to 0.99; RD -0.05, 95% CI -0.10 to -0.01; NNTB 20, 95% 
CI 10 to 100; 1165 infants) and oxygen requirement at 36 weeks 
postmenstrual age (RR 0.87, 95% CI 0.77 to 0.98; RD -0.08, 95% CI -
0.14 to -0.01; NNTB 13, 95% CI 7 to 100; 824 infants). However the 
uptake for this evidence has been poor perhaps from the need for 
multiple intramuscular doses. 
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6.8 Use of inhaled Nitric Oxide therapy 
There is no clear evidence in the use of inhaled Nitric Oxide (iNO) 
therapy in preterm infant. The lack of evidence is from wide variation in 
the gestation of the infants, dosage regimes, timing of the treatment 
intervention and duration of treatment.  
Based on various trial entry criteria, one of the classifications as a 
treatment strategy (Subhedar and Dewhurst, 2007) is : 
• Early prophylactic- when treatment is instituted < 72 hours,  
• Early rescue treatment -when treatment is given in the first week 
of life and  
• Late treatment -when treatment is commenced more than 72 
hours of life  
Early prophylactic treatment confers marginal benefits for the combined 
outcome of death and chronic lung disease. However, this effect was 
only seen in a sub group (infants weighing at least 1000 grams) of the 
study population (Kinsella  et al., 2006). Similar effect was seen in 
study involving preterm infants with mean gestation 27 weeks and 
mean birth weight of 1000 grams stratified in five groups (Schreiber  et 
al., 2003). 
All other strategies have shown no benefits in the group receiving nitric 
oxide therapy. Therefore, current treatment approach in both the units 
use inhaled Nitric oxide therapy on a case-by-case basis.   
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7 Methods 
7.1 Introduction  
Mechanical ventilation is an art in as much it is a science. Current 
treatment strategy to ventilate newborn babies has evolved over the 
years. There are a number of modalities and modes of ventilation but 
the underlying principle is to choose the mode as per the underlying 
lung disease.  
Once the infant is stabilised the process of weaning commences and the 
work of breathing is gradually transferred from the ventilator to the 
infant. There is limited evidence on the best mode of weaning and the 
strategies to wean preterm babies on ventilator. It is often experience 
based rather than evidence based. 
Synchronised Intermittent Mandatory Ventilation (SIMV) is the most 
popular form of assisted mechanical ventilation(Van Kaam et al., 2010) 
in Europe and UK (Mallya et al., 2010). A general perception is infants 
weaned on SIMV mode of ventilation could be disadvantaged from 
fatigue prior to extubation. Pressure support ventilation could help by 
providing the ‘inspiratory boost’ to overcome resistance of the ventilator 
system. This could be advantageous for gradual shift of work of 
breathing to infant.  
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In a randomised controlled trial comparing SIMV alone to SIMV+PS (up 
to 50% of the Peak inspiratory pressure), addition of PSV facilitated 
shorter duration of ventilation (Reyes et al., 2006). 
Though there is no consensus on the best approach to wean the infant 
off mechanical ventilation, clinicians agree that prolonged mechanical 
ventilation should be avoided to prevent Ventilator Induced Lung Injury 
(VILI).  
The following questions remain largely unanswered. 
a. How to define weaning on mechanical ventilation?  
b. When to commence weaning?  
c. Mode of respiratory support during weaning 
d. Predicting successful extubation  
 SIMV is time cycled pressure or volume controlled ventilation with fixed 
inspiratory and expiratory time which could cause patient ventilator 
asynchrony and thereby VILI needing prolonged ventilation. PSV is a 
flow cycled pressure limited mode of ventilation. PSV has the advantage 
of letting the infant take control of the frequency and the duration of 
breathing with the benefit of better patient ventilator synchrony and 
less VILI perhaps needing shorter duration of ventilation. In addition, 
variable flow feature to satisfy patient demand provides comfort. In 
pure PSV mode there is no back up rate. Hence to tackle apnoea of 
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prematurity, in neonatal medicine, PSV is always provided along with 
SIMV.  
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7.2 Objectives 
To study if weaning on Pressure support ventilation (PSV) as compared 
to Synchronised intermittent mandatory ventilation (SIMV) affects 
duration of weaning from mechanical ventilation in preterm infants born 
between 23+0 and 31+6 weeks gestation.   
7.2.1 Primary outcome 
The primary outcome of interest for this study was duration of weaning 
on mechanical ventilation. The duration of weaning was defined as the 
time interval from commencing the randomised mode to passing the 
minute ventilation test.  
7.2.2 Secondary outcomes 
The secondary outcomes for this study include: 
a. Total duration of mechanical ventilation 
b. Incidence of extubation failure  
c. Duration of non invasive respiratory support post-extubation 
d. Total duration of respiratory support until discharge or death 
e. Discharged on home oxygen 
f. Bronchopulmonary dysplasia at 36 weeks post menstrual age 
g. Air leak post randomisation needing treatment  
h. Pulmonary Haemorrhage 
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i. Definitive or complicated Necrotising enterocolitis (NEC) – stage 
II or III 
j. Weight gain until discharge or death 
k. Retinopathy of prematurity (ROP) Stage 2 or more 
l. Patent Ductus Arteriosus (PDA) 
a. PDA Requiring medical treatment 
b. PDA requiring surgical closure 
m. Severe IVH (Grade 3/4)- Intra-ventricular haemorrhage with 
ventricular enlargement or parenchymal extension 
n. Cystic Periventricular leukomalacia (PVL) 
o. Number of Sepsis episodes  
p. Death before discharge 
 
7.3 Definition of secondary outcomes 
7.3.1 Total duration of mechanical ventilation  
Time when mechanical ventilation via endotracheal tube was first 
commenced to the time when the infant was successfully extubated.  
7.3.2 Incidence of extubation failure  
This was defined as need for re intubation and mechanical ventilation 
through endotracheal tube within 72 hours of extubation.  
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Re-intubation criteria: pH<7.25 with pCO2  >8 kPa and or FiO2 more 
than 50%. 
If such a situation occurred, the infant would be weaned as per study 
protocol in the previously assigned mode. 
Data on extubation failure was prospectively collected. 
7.3.3 Duration of non invasive respiratory support post 
extubation 
Non-invasive respiratory support was defined as providing respiratory 
support through an interface that does not cross the vocal cords. This 
could be a nasal interface using any pressure generation device. 
Common nasal interface during the study period included nasal mask or 
prongs, or nasal cannulae to deliver positive airway pressure. The unit 
policy was to use ‘bubble CPAP’ post extubation initially but on a case-
by-case basis clinical decision for using variable flow CPAP was also 
considered e.g. in presence of moderate to severe nasal injury. As a 
step down approach, High Flow Nasal Cannula oxygen was also 
provided in some babies. The use of bi-level CPAP was left at the 
discretion of the clinician but this was not routinely practiced. Thus 
duration of non-invasive respiratory support was calculated as the total 
duration of all these methods of delivering respiratory support during 
the infant’s stay in the neonatal unit after extubation.  
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7.3.4 Total duration of respiratory support  
This was calculated by accounting respiratory support type recorded 
contemporaneously by the nurses on an hourly basis in their 
observation charts. This includes total duration of mechanical 
ventilation and non-invasive respiratory support until discharge or 
death.  
7.3.5 Discharge on home oxygen 
If the infant was discharged on home oxygen therapy to maintain 
oxygen saturation above 94%, a pre-discharge overnight saturation 
study was performed to confirm the proportion of time spent below the 
threshold to justify home oxygen supplementation. 
7.3.6 Bronchopulmonary dysplasia  
Data was collected to define severity of BPD. Babies who required 
oxygen supplementation or any respiratory support for more than 28 
days were assessed at 36 weeks post-menstrual age. Severity of BPD 
was classified as mild, moderate and severe (Sahni R, 2005, 
Ehrenkranz et al., 2005). It was aimed to perform Jones test (Walsh et 
al., 2003) to define percentage of oxygen requirement in babies 
requiring <30% oxygen but no respiratory support. Supplemental 
oxygen was provided just enough to maintain saturations as per unit 
policy and recorded for classification.  
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7.3.7 Air leak post randomisation 
Only large collections of extra-pulmonary air reported after initiating 
the allocated mode of study, confirmed by chest x-ray and needing 
intervention such as needle thoracocentesis and or chest drain insertion 
as part of clinical management were recorded for analysis. 
7.3.8 Pulmonary Haemorrhage 
Pulmonary haemorrhage was defined as either frank blood or ‘pink 
stained’ endotracheal tube secretions with clinical signs of deterioration 
such as increase in ventilator requirements, escalation of respiratory 
support including increase in oxygen or change in biochemical profile, 
and or clinical condition sufficient to instigate blood products for 
treatment was considered as significant pulmonary haemorrhage and 
recorded for data collection. 
7.3.9 Necrotising enterocolitis 
Necrotising enterocolitis (NEC) was defined using Bell’s staging criteria. 
Only definitive or complicated NEC (stage 2 or worse) was considered 
significant. We considered NEC definitive, if the infant was kept nil 
orally and commenced on at least 5 days antibiotics regime to cover 
anaerobic microorganisms. 
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7.3.10 Weight gain 
The difference between infant’s discharge weight and birth weight was 
divided by the length of stay in the hospital to work out average weight 
gain per day.  
7.3.11 Retinopathy of prematurity 
Babies were routinely screened as per the unit protocol (beginning 6 
weeks postnatal age). Only stage 3 and above was considered as 
significant and included in data analysis (Association of Perinatal, 
1996). 
7.3.12 Patent Ductus Arteriosus  
Babies were managed for PDA either conservatively, medically or those 
who required surgical closure of PDA. Data was collected for babies who 
received medical treatment for PDA or surgical closure. Medical 
treatment was offered either as targeted early treatment in first 72 
hours using echocardiography or late symptomatic treatment at 
clinician discretion. The drug used for medical closure was ibuprofen.  
7.3.13 Intraventricular Haemorrhage 
As per unit policy cranial ultrasonography was performed either by 
Consultant Radiologist and or trained ultra sonographer in the first 
week of life and again at six weeks postnatal age. However if there 
were clinical concerns additional scans were performed. Standard views 
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were obtained to establish normality or for classifying the extent of the 
bleed as proposed by Papile (Papile et al., 1978). 
7.3.14 Hydrocephalus needing shunt 
Following any intracranial bleed the neonate was monitored at weekly 
intervals and their head circumference plotted on the age specific 
growth charts. If there were any clinical concerns with regards to 
increase in head circumference or ultrasound findings on head scan, a 
neurosurgical consultation was requested. If hydrocephalus was 
diagnosed, further management was continued as per the advice of 
neurosurgical team. Data on babies requiring shunt insertion for 
management of hydrocephalus was recorded for comparison. 
7.3.15 Cystic Periventricular leukomalacia  
PVL was defined as cystic changes in the periventricular white matter 
region. This was defined as either present or not present (Khwaja and 
Volpe, 2008). 
7.3.16 Sepsis  
Definitive sepsis episodes were defined as either a positive growth of a 
virulent micro organism in either blood, CSF or urine specimen which 
was obtained due to clinical concerns in the infant necessitating 
antibiotic treatment. In addition, if the infant received at least five days 
treatment of antibiotics without any positive growth then this was also 
considered as sepsis episode  
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7.4 Study site  
This was a multicentre randomised controlled trial. The two 
participating centres recruiting infants were University Hospital of North 
Tees (SITE 1), Stockton-on-Tees and James Cook University Hospital 
(SITE 2), Middlesbrough. Both the units are level three neonatal units 
as per British Association of Perinatal Medicine Criteria. SITE 1 has 5 
intensive care cots and SITE 2 has 10 intensive care cots. There were a 
total of 203 admissions of infants less than 32 weeks gestation in the 
two years preceding the study period in the two centres. The units are 
part of the Northern Neonatal Network and represent neonatal care for 
the south of the region. There is a well-established 24-hour neonatal 
transport service for ex-utero transfer of babies from other hospitals in 
the region requiring intensive care treatment. 
7.5 Inclusion criteria  
Infants born between 23+0 weeks and 31+6 weeks’ gestation 
ventilated for respiratory distress from surfactant deficiency were 
eligible for participating in this study. RDS was diagnosed as respiratory 
insufficiency manifested by either rising oxygen requirement or 
inadequate CO2 clearance along with clinical signs of respiratory 
distress. The diagnosis of surfactant deficiency was confirmed by age at 
presentation, chest X-ray findings and clinical presentation of the infant 
adjudged by the clinician on call.  
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The other mandatory criteria before considering randomisation were: 
1. Need for mechanical ventilation for at least 6 hours – this 
criterion excluded infants who could have been managed by 
non-invasive respiratory support and therefore not reflecting 
the true cohort of infants with surfactant deficiency needing 
mechanical ventilation. This criteria helped to eliminate 
selection bias  
2. Signed parental consent  
7.6 Exclusion criteria  
Infants were excluded from participating in the study if they had  
o Antenatally diagnosed severe congenital anomalies affecting 
survival and in particular known airway anomalies 
o Known neuromuscular abnormalities  
o No parental consent. 
7.7 Ethics  
The national research ethics committee via the Integrated Research 
Application System (IRAS) and the Hospital Research and Development 
Department reviewed the study protocol and provided approval. The 
trial was registered at the International Standard Randomised 
Controlled trial registry and a unique identifier issued 
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(ISRCTN74272142). University hospital of North Tees was the sponsor 
for this study. The study protocol was also reviewed by an external 
expert who was well researched in the field of neonatal ventilation to 
assess the robustness of the study. 
7.8 Consent  
Parent information leaflet (see appendix 1) was given antenatally to 
expectant mothers admitted to the delivery suite whenever possible or 
at the earliest opportunity postnatally. A baseline eligibility form was 
used to screen all the admissions that helped in identifying the eligible 
babies for participation in the trial. Parental consent was obtained after 
they were given every opportunity to ask questions and seek 
clarification. At all stages it was highlighted that they could withdraw 
this consent without affecting their infants’ care. 
The baseline eligibility form also helped to record the reason for non-
enrolment at both the sites. In addition we also had access to Neonatal 
Audit Programme for both the sites that recorded all admissions to the 
respective units to ensure eligible infants were not missed. 
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7.9 Randomisation 
The cohort of eligible infants was stratified into three groups based on 
their gestation at birth. This was done to allow both study groups 
balanced for gestation. 
Gestation at birth Acronym  
23 +0 to 25 +6 Very Very Prem group (VVPrem) 
26 +0 to 28 +6 Very Prem group (V Prem) 
29 +0 to 31 +6 Prem  
 
A Consultant in Tropical medicine with an interest in clinical research 
based at SITE 2 helped to generate the concealed randomisation 
sequence. He was not involved with the trial in any other way. Block 
randomisation with a variable block size of two to six blocks using 
random number tables was used. The sequence was emailed to the 
ward matron. She was also not involved with the study at any stage. 
The sequence was sealed in an opaque sealed envelope which were 
serially numbered and marked and placed in three separate boxes 
clearly showing the stratified group as listed above. The infant was 
randomised only if he/she met all of the inclusion criteria and exclusion 
criteria. 
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At the time of randomisation, a log was maintained with the patient 
details with the assigned mode with date and time recorded. The 
opaque envelope was kept with the eligibility form for later verification.  
As this was an open labelled trial, allocated mode was highlighted at the 
bed side and on their ventilator to remind health care professionals to 
follow weaning as per the assigned mode to prevent cross over and 
contamination from trial protocol violation.  
7.10 Ventilation strategies 
Intubated infants received porcine exogenous surfactant at a 
recommended first dose of 200 mg/kg (Sweet DG, 2010) Infant 
received further 100 mg/kg dose of surfactant treatment if despite the 
first dose they needed more than 30% oxygen and mean airway 
pressure on ventilator of >8 cm H2O  at 12 hours of life. Volume 
controlled ventilation modality was the preferred method to commence 
mechanical ventilation in both the units. All babies needing mechanical 
ventilation were commenced on volume controlled Assist Control mode 
(A/C mode). In the occasional circumstance, when A/C mode failed to 
provide adequate support then High Frequency Oscillatory Ventilation 
(HFOV) was commenced. Use of HFOV did not exclude the eligible 
infants from participation and further weaning in the assigned mode. 
Avea ventilator (Care Fusion corporation, San Diego, USA; previously 
Viasys Healthcare) was used in both the units. 
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Both nursing and medical staff received regular training and updates 
and was comfortable in troubleshooting routine problems with use of 
ventilator. 
The ventilator trigger systems use variable orifice differential pressure 
flow transducer or pneumotachograph near the proximal end of the 
endotracheal tube to detect small variation of flow in the ventilator 
circuit. Routinely the flow trigger is usually set at 0.2 L/minute. Whilst 
in the assist control (A/C) mode, the initial back up rate was set 
between 40 and 60 breaths per minute. Oxygen supplementation was 
titrated to maintain saturations as per unit policies. This was changed 
after the BOOST II trial interim report (Stenson et al., 2011). After the 
recommendations, at SITE 1 policy was changed from targeting 88-
92% (lower alarm limit at 85% and upper limit at 95%) to targeting 
oxygen saturations between 91-94% (lower alarm limit at 90% and 
upper at 95%). Whilst at SITE 2, target oxygen saturation was changed 
to 91-94% with alarm limits of 85-95%. A check X-ray was performed 
routinely in all infants post intubation to verify tube position and to 
assess the severity of surfactant deficiency (Slama et al., 1999). 
Infants were monitored hourly with ventilator observations documented 
in the intensive care charts as usual practice. Ventilator adjustments in 
the initial stages aimed at maintaining tidal volumes between 4 and 
6mls/kg/breath. PEEP was initially commenced at 5 cms H2O but this 
was adjusted and increased to 6 cms H2O or higher if the Pressure 
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Volume loops reflected need of higher PEEP for lung opening. Blood gas 
analysis to manage ventilation was decided by the clinician on a case-
by-case basis.  
The trial protocol was rigorously implemented for ventilation 
management after entry into the trial and therefore all acute care 
aspects of the infant were managed as per standard unit policies. 
A loading dose of caffeine citrate (20mg/kg) was administered to the 
infant followed by 5mg/kg maintenance dose (Schmidt B, 2006). It was 
a standard practice in both the units and caffeine administration was 
commenced early during the course of ventilation. 
There was variable use of low dose Morphine infusion for pain relief and 
for comfort whilst receiving mechanical ventilation (Anand et al., 2004). 
Although some physicians chose to use it during the acute phase of the 
illness, it was stopped before the infant was commencing the 
randomised mode. In the occasional situation when a more mature 
infant with BPD was unsettled and ‘fighting’ the ventilator, other 
measures such as Chloral Hydrate was provided for sedation to achieve 
better patient ventilator synchrony. 
7.11 Trial entry criteria 
Randomised infants were commenced in the assigned mode if the infant 
maintained all of the following parameters for at least two consecutive 
hours. This was recorded on trial enrolment form (Appendix 3): 
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• Mean airway pressure less than 10 cm H2O   
• FiO2 less than 40%  
• Good respiratory drive demonstrated by spontaneous breaths 
more than or equal to 50% of the total respiratory rate. 
As an aide memoir, nursing staff caring for the infant was also required 
to maintain a ‘tick box’ chart (see Appendix 3) indicating the infant 
meeting the trial entry criteria. This served as prompt and as a trigger 
to the clinician on-call suggesting the infant is ready to commence the 
randomised mode. 
This was a slight deviation from the normal practice in both the units. 
Infants were traditionally weaned significantly on the volumes or 
pressures whilst in the A/C mode before switching to the partial support 
modes such as SIMV with PSV. In the present study, infants were 
commenced on the weaning modes when they met the aforesaid 
weaning criteria.  
Hence, weaning in the assigned mode commenced earlier than routine 
practice perhaps. Weaning in the control arm (SIMV +PSmin group) 
was primarily reducing high back up rate to a rate of 10 (section 7.13) 
and weaning in the intervention arm (PSmax +10 breaths of SIMV) was 
primarily reducing pressure support level to PSmin before performing 
the minute ventilation test (section 7.14). 
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7.12 Overview of Ventilation management 
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7.13 Weaning on Synchronised Intermittent Mandatory 
Ventilation 
 
 103 
 
7.14 Weaning on Pressure Support Ventilation 
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7.15 Minute ventilation Test  
Minute ventilation test (MVT) was used as an objective assessment for 
readiness to extubation. MVT test was originally used in SITE 2 in 
different clinical studies (Singh et al., 2006, Gillespie et al., 2003, 
Gupta et al., 2009b).  
The Minute ventilation test consisted recording heart rate, respiratory 
rate, oxygen saturation, oxygen requirement, minute ventilation and 
tidal volumes for five consecutive minutes whilst on minimal mechanical 
ventilation (MVM) followed by five further consecutive minutes whilst 
spontaneously breathing (MVS) on endotracheal CPAP (no pressure 
support and no mandatory back). The average minute ventilation 
during the two epochs was used for calculating the ratio.  
7.15.1 MVT success criteria 
If MVS /MVM was more than 50% the infant was deemed ready for 
extubation or ‘PASS’.  
7.15.2 MVT failure 
The infant was considered to be failing the MVT test if it developed: 
o Severe bradycardia following hypoxia needing IPPV and or  
o If the oxygen requirement was more than 15% above the 
baseline to maintain oxygen saturation  
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The test was repeated again in eight hours if there was no further 
changes in the clinical condition.  
 
7.16 Post extubation management 
After passing the MVT, all possible steps were taken to minimise the 
delay in extubation and further management on non-invasive 
respiratory support. ‘Bubble CPAP’ was the default method of non-
invasive respiratory support due to putative advantage of shorter 
duration of CPAP support. Such an approach has been shown to be 
helpful in infants ventilated for less than 14 days (Gupta et al., 2009b). 
If bubble CPAP was not available then variable flow CPAP device was 
commenced. In either case CPAP was commenced at 6 cms H2O and 
reduced every six to twelve hours to a minimum of 4 cms H2O before 
discontinuing. If CPAP needed recommencing then it was recommenced 
at 6 cms H2O pressure. 
Bi-level CPAP was not a routine mode of respiratory support and this 
was left to the discretion of the senior clinician on a case-by-case basis 
to limit re-intubation when clinically considered to be beneficial. When 
Synchronised Bi-level CPAP was commenced, a back up rate of 30 
breaths per minute was provided. Bi-level CPAP commenced with an 
inspiratory peak pressure of 9 cms H2O and positive end expiratory 
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pressure of 6 cms H2O. This was assessed every 6 hours and weaned by 
one cm H2O pressure whenever possible before discontinuation of CPAP. 
Humidified High flow nasal cannula oxygen was used as step down 
approach in infants who developed respiratory distress after weaning 
off CPAP therapy. The flow was never prescribed more than 8 L/min. 
As per unit policy whenever possible while receiving non-invasive 
support, nasal interface was alternated between nasal prongs and nasal 
mask to minimise nasal injury. 
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7.17 Re intubation criteria  
The trial protocol suggested to consider re-intubation if there were any 
or all of the following features: 
• Respiratory compromise was evident along with increasing 
oxygen requirement (FiO2 >60%)  
• Uncompensated respiratory acidosis developed (pH<7.20, and 
pCO2 >8 kPa 
• Major apnoea needing intermittent mandatory ventilation or a 
major cardio vascular compromise requiring resuscitation. 
If the infant was re-intubated within 72 hours of extubation then 
weaning on mechanical ventilation was commenced in the previously 
assigned mode. If re intubation occurred any time later than 72 hours 
post-extubation, then weaning on mechanical ventilation was left at the 
discretion of the attending clinician. 
7.18 Serious Adverse Events reporting  
Considering the gestation of the infants included in this study, the 
following were considered as expected serious adverse events that did 
not merit reporting for further investigation:  
• Necrotising enterocolitis 
• Chronic lung disease  
• Air leak syndrome 
• Pulmonary haemorrhage 
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• Intracranial haemorrhage 
• Retinopathy of prematurity 
• Death- Local policy of child death review was followed. 
These outcomes were investigated as secondary outcomes of interest. 
Any other adverse events was planned for further follow up by the 
research team until complete resolution of the issue was identified. 
During such a time it was at the discretion of the clinical team to decide 
whether to continue the infant in the study and follow the trial protocol.  
7.19 Co-intervention and contamination 
There were two other studies conducted at the same time as this study 
with concomitant recruitment of the eligible infants into these research 
trials. 
1. Multicentre randomised controlled trial investigating Iodine 
Supplementation in preterm infants born less than 31 weeks 
gestation (I2S2 Trial Clinical trial number NCT 00638092). This 
was a double blind placebo controlled trial investigating the effect 
of Iodine supplementation on long term neurodevelopmental 
outcome at two years corrected age. However this was not a 
competing study. Participating in this study did not exclude 
infants from participating in other studies.  
2. A multicentre randomised controlled trial investigating CPAP or 
SiPAP (CoSi trial Controlled trial registry number 15997073) in 
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preterm infants born between 28+0 and 31+6 weeks gestation as 
primary mode of respiratory support. The trial included only those 
infants who did not receive any positive pressure ventilation via 
endotracheal tube immediately after birth. Hence infants who 
progressed to receive an endotracheal tube were eligible to 
recruit in POST trial. Non-invasive respiratory support prior to 
intubation is not considered to have any effect on duration of 
ventilation including weaning on mechanical ventilation. As there 
was an emphasis on both studies, non-invasive respiratory 
support at birth perhaps helped to recruit infants who truly 
required endotracheal intubation for respiratory distress. 
7.20 Duration of the study 
After obtaining ethics and research approvals the study at SITE 1 
commenced in January 2011 with first infant recruited on 26/01/2011. 
The study started recruitment at SITE 2 in August 2011 with first 
patient recruited on 20/09/2011.  
However, due to slower than expected recruitment at one of the two 
centres it was decided by the data monitoring committee to stop the 
study with 93 infants instead of 110 infants as planned initially and to 
analyse the results for primary outcome analysis to write this 
dissertation in order to fulfil the student requirement to obtain the 
Doctorate in Medicine pending submission. 
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7.21 Data collection 
Data collection was recorded on standard case report forms (see 
Appendix 5). The data was collected prospectively and completed at the 
time of discharge or death of the infant. Patient confidentiality was 
maintained at all stages and only necessary information relevant to the 
study was extracted from the case notes. The data collection and 
storage followed the guidance as per Caldecott guardian. This was later 
transcribed onto excel spread sheet for further analysis using SPSS® 
statistical software. At all stages data protection guidelines was 
followed. At the time of final analysis, accuracy of the transcription was 
confirmed by manually validating the data. 
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8 Statistical analysis 
8.1 Sample size and Power estimation 
Sample size calculation was based on the results from a previous 
randomised controlled trial comparing volume controlled ventilation to 
time cycled pressure limited ventilation (Singh et al., 2006). The 
weaning protocol followed in that trial is currently the standard practice 
in both the units and served as the control arm in this trial. They 
reported duration of weaning (achieving mean airway pressure ≤ 8cm 
H2O for 12 consecutive hours) using SIMV in volume-controlled mode 
with minimal pressure support as 80 hours. To show a difference of 
25% between the two arms at 80% power and two sided alpha of 0.05 
we would need a total of 162 infants and at similar alpha level with 
80% power to show a 40% difference we would need a total of 66 
infants (SAS 9.4 TS Level 1M0). Based on this we chose to demonstrate 
a 33% difference (80 vs. 53 hours) a therefore a total of 90 babies 
were required (45 in both groups) with a two sided alpha of 0.05 and 
80% power.  
8.2 Statistical tests  
All data were analysed on an intention to treat basis with all 
randomised infants included. To determine the statistical test for the 
analysis the data was checked for normality using Kolmogorov-Smirnov 
test. Parametric or non-parametric statistical methods were used 
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accordingly if the data was normally distributed or not. Unpaired 
Students t test or Wilcoxon rank- sum test or Mann Whitney U test was 
used comparing the control and the study arms. Chi square test was 
used to compare the categorical outcome measures.  
Spearman’s correlation coefficient of variables on primary outcome was. 
run to predict the variables thought to have significant impact on 
Primary Outcome.  
Time based analyses of duration to achieve the primary outcome 
measure and duration of ventilation was done using Kaplan-Meier 
curves. A log rank test was run to determine if there were differences in 
the survival distribution between the two groups.   
All statistical analyses were performed using SPSS for windows version 
22 (SPSS Inc., Chicago, Illinois). 
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9 Results  
9.1 Enrolment  
After obtaining approvals from the National Ethics Committee and the Hospital 
Research and Development department the study commenced recruiting at 
SITE 1 in January 2011 and in August 2011 at SITE 2 site. A total of 247 
babies were identified eligible for enrolment of which 93 were enrolled (Figure 
8: Flow diagram showing recruitment and randomisation of babies). 
 
Figure 8: Flow diagram showing recruitment and randomisation of babies 
 
The historic data for 2 years previous to commencing the study 
suggested an average of 10 infants in the eligible gestation group were 
Total	no	of	preterm	
infants	needing	
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1		
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Infants	randomised	to	
SIMV	mode		
N=	39		
Infants	analysed		
N=		39	
Infants	randomised	to	
PSV	mode		
N=40	
Infants	analysed		
N=	40	
Infants	not		recruited		
N=	59		
Eligible	infants	in	site	
2	
109	infants	
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N=	14	
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Infants	analysed		
N=	7	
Infants	randomised	to	
PSV	mode		
N=7	
Infants	analysed		
N=	7	
Infants	not	recruited		
N=95	
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admitted per month i.e. 4 babies per month at University Hospital of 
North Tees (SITE 1), and, 6 babies per month at James Cook University 
Hospital (SITE 2).  
Taking into consideration approximately 75% recruitment, the study 
was anticipated to complete in 16 months time.  
However, REC approval for study extension was requested on two 
occasions due to slower than anticipated recruitment in one of the two 
centres. The study was stopped in SITE 1 in Sept 2013 with last 
recruitment in May 2013. Recruitment was stopped in SITE 2 earlier 
than SITE 1 due to poor recruitment rate in March 2013, 18 months 
from commencing the study, with last recruitment in October 2012.  
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9.1.1 Recruitment activity at SITE 1  
57% of eligible infants available for recruitment were consented and 
randomised see Figure 9.  
 
Figure 9: Flow diagram showing reason for non-recruitment of eligible infants at SITE 1 
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9.1.2 Recruitment activity at SITE 2  
13% of the eligible infants were consented and randomised see Figure 
10. 
 
Figure 10: Flow diagram showing reasons for non-recruitment of eligible infants at 
SITE 2 
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9.2 Maternal characteristics  
Characteristic  SIMV group 
N= 46 
PSV group 
N= 47 
p value 
Antenatal steroids 
Incomplete course 
At least 1 completed 
course 
No steroids 
43 (93.5%) 
1(2.3%) 
42 (97.7%) 
 
3 (6.5%) 
45 (95.7%) 
15(33.3%) 
30 (66.7%) 
 
2 (4.3%) 
0.490 
0.000 
0.000 
 
0.490 
Prolonged rupture of 
membranes 
12 (26.1%) 
 
11 (23.4%) 0.476 
Prelabour rupture of 
membranes 
0 0 N/A 
Chorioamnionitis*  12 (35.3%) 10 (34.5%) 0.579 
Ante partum 
haemorrhage 
7 (15.2%) 3 (6.4%) 0.149 
Pregnancy induced 
hypertension^ 
4 (8.7%) 5 (10.6%) 0.514 
Maternal diabetes  0 0 N/A 
Mode of delivery  
Vaginal delivery 
Caesarean section  
1. In Labour  
2. Not in labour 
 
24 (52.2%) 
 
8 (17.4%) 
14 (30.4%) 
 
24 (51.1%) 
 
10 (21.3%) 
13 (27.7%) 
 
 
 
 
0.473 
Table 4: Baseline maternal characteristics 
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*Chorioamnionitis – defined as fever with raised inflammatory markers and/or 
histopathologic features  
^Pregnancy induced hypertension-needing treatment 
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9.3 Baseline characteristics of the study population 
Baseline characteristics of the babies randomised into the two groups is 
highlighted in Table 5  
Characteristic SIMV group 
N= 46 
PSV group 
N=47 
p value  
Gestational age in 
weeks Median 
(IQR) 
27.2 (3.83) 27.5 (3.90) 0.612 
Birth weight 
(grams)  
Median (IQR) 
950 (373) 980 (560) 0.439 
Male infants 25 (54.3%) 28 (59.6%) 0.382 
Multiple birth 
Twins 
23 (50%) 17 (36.2%) 0.128 
In born 
Postnatal transfer 
35 (76.1%) 
11 (23.9%) 
36 (76.1%) 
11 (23.4%) 
0.574 
Intubated at birth  33 (73.3%) 31 (67.4%) 0.348 
Mechanical 
ventilation from 
birth 
33 (71.7%) 31 (66.0%) 0.353 
Modality of 
ventilation 
• Pressure 
limited  
 
 
9 (20.5%) 
 
 
 
4 (8.5%) 
 
 
 
0.092 
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• Volume 
controlled 
35 (79.5%) 43 (91.5%) 
CRIB 2* score  
Median (IQR) 
9.0 (5) 
 
8.0(5) 0.666 
Table 5: Baseline characteristics of the infants 
*Clinical risk index for babies II 
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9.4 Comparison of baseline characteristics between inborn and 
out born infants 
Inborn infants constituted 76% of the total recruited. Table 6 shows 
characteristics of babies. First dose of surfactant administered was 
significantly different (177 mg/kg vs. 139 mg/kg). There was no other 
significant difference between the two groups. 
 
Characteristics  Born in the 
participating 
centre  
N= 71 
 
Postnatal 
transfers  
N=22 
p value 
Gestational age 
(weeks) 
Median (IQR) 
27.40 28.06 0.278 
Birth weight 
(grams) 
910 (551) 1130 (344) 0.121 
CRIB –II score  9 (5) 6.50 (5) 0.316 
Birth order 
• Singleton  
• Higher 
 
42 
 
11 
 
0.470 
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order 29 11 
Intubated at birth 51 13 0.193 
1st dose of 
Surfactant 
(milligrams/kg) 
177 139 0.008 
Antenatal steroids  
• No 
dose/partial 
course 
• Full course 
 
10 
 
58 
 
6 
 
14 
 
0.183 
Table 6: Baseline characteristics of babies born at the study centre and those 
admitted following postnatal transfer 
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9.5 Comparison of the two study groups- stratification based on 
the gestational age at birth 
The infants were recruited in three groups, based on the gestation at 
birth. Table 7 shows the numbers of babies recruited on each of the 
gestational groups.  
Gestation at 
birth  
SIMV group 
N (%) 
PSV group 
N (%)  
p value 
23+0 to 25+6 12 (26.1%) 10 (21.7%) 1.00 
26+0 to 28+6 19 (41.3%) 21 (45.7%) 1.00 
29+0 to 31+6 15 (32.6%) 15 (32.6%) 1.00 
Table 7: Proportion of babies in the randomised mode based on gestation at birth 
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9.6 Time duration to enrol babies into the study 
The trial protocol recommended that parents of pre term infants 
needing mechanical ventilation be approached for consenting when the 
infant was stabilised. Since the trial was designed to investigate the 
weaning modes of ventilation it was deemed, not necessary to approach 
parents in the early phase to minimise parental anxiety. This also 
served to obtain an informed consent. 
Consenting procedure was followed as per section 8.8. When consent 
was available antenatally or soon after birth, and the preterm infant 
was ventilated for more than six hours they were considered eligible for 
randomisation. 
Figure 11 shows the bar chart of time to randomisation once eligible 
infants consented to participate in the trial. The median time for 
randomisation for both groups was less than 48 hours with IQR =1, 
(Mann-Whitney U test p 0.692). 
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Figure 11: Box plot for time to randomisation after consent of eligible infants 
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9.7 Comparison of two study groups based on the length of 
primary mode of ventilation prior to commencing 
randomised mode.  
Table 8 shows the proportion of time infants received the primary mode 
of ventilation prior to commencing randomised mode.  
Duration of 
ventilation 
SIMV  
N= 46 (%) 
PSV 
N=47 (%) 
p value 
Up to 72 hours  35 (76%) 35 (74%) 1.00 
Over 72 hours  8 (17%) 10 (21%) 1.00 
Table 8 Proportion of time infants received primary mode of ventilation prior to 
randomisation 
 
Note: There were 5 infants (3 from the SIMV group and 2 from the PSV 
group) randomised but did not commence the randomised mode due to 
clinical deterioration. Their data is not included in the above analysis. 
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Figure 12 Box plot of the duration of primary mode of ventilation prior to commencing 
the randomised mode   
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9.8 Comparison of the severity of the lung disease prior to 
commencing the randomised mode  
The following parameters in Table 9 were collected to reflect the 
severity of the lung disease from surfactant deficiency. The data was 
collected from the intensive care charts prospectively as documented by 
the nursing staff. The highest value for a particular parameter recorded 
for at least two consecutive hours in the ITU chart were deemed 
significant and used for comparison in this analysis. 
Variable  SIMV mode PSV mode p value 
Peak inspiratory 
pressure (cm/H2O 
) 
23 24 1.00 
Mean Airway 
pressure (cm/H2O 
) 
9 9 1.00 
FiO2 (median) 35 30.5 0.994 
Oxygenation 
index 
10.2 8.2 0.994 
Table 9: Highest ventilator settings prior to commencing the randomised mode 
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9.9 Comparison of disease severity based on need for multiple 
surfactant therapy  
Table 10 shows proportion of infants needing multiple surfactant 
therapy. There was no significant difference between the two groups.  
Surfactant 
therapy 
SIMV 
N=46(%) 
PSV 
N=47 (%) 
p value 
1 dose 45 (49.5%) 46 (50.5%) 1.00 
2 doses  12 (26%) 13 (27.6%) 1.00 
3 doses  1 (2%) 0 1.00 
 
Table 10 Proportion of infants needing multiple surfactant therapy 
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9.10 Comparison of problems of primary ventilation prior to 
randomisation  
Table 11 shows problems associated with primary mode of ventilation 
prior to commencing randomised mode. There was no significant 
difference between the two groups.  
Problems of 
ventilation  
SIMV PSV p value 
Air leaks 
needing 
treatment  
5 (11.9%) 4 (8.9%) 0.733 
PIE 3 (7.1%) 3 (6.7%) 1.00 
Pneumonia 0 3 (6.7%) 0.134 
Pulmonary 
haemorrhage 
before 
randomisation 
7 (17.9%) 2 (5.4%) 0.154 
Table 11 Problems associated with ventilation 
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9.11 Time delay to commence randomised mode from when trial 
entry criteria achieved 
A ten-hour delay in commencing the randomised mode was observed in 
both the groups (Table 12). Although Mann Whitney U test showed this 
delay was significant in both the groups with infants in SIMV arm 
commencing randomised mode two hours earlier than infants in PSV 
arm, this difference was not statistically significant (Mann Whitney U 
test p=0.47).   
 Trial entry 
criteria 
achieved 
Randomised 
mode 
commenced 
p value 
SIMV 
Median (IQR) 
22.0 (27) 32.0 (34) 0.000 
PSV 
Median (IQR) 
23.50 (46)  34.5 (48) 0.000 
Table 12 Time delay to commence the randomised mode after achieving the trial entry 
criteria 
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9.12 Respiratory parameters at commencing weaning of 
mechanical ventilation in the assigned mode 
Table 13 shows the respiratory parameters at the time of commencing 
randomised mode. A Mann- Whitney U test confirmed there were no 
significant differences between the two groups. 
Respiratory 
parameter 
SIMV PSV p value 
Mean airway 
pressure at 
weaning  
Median (IQR) 
7 (1) 8.0 (1) 0.390 
FiO2   at weaning 
Median (IQR) 
21% (4) 21% (2) 0.545 
Inspired tidal 
volume  
Median (IQR) 
5.6 (1.7) 5.6 (1.8) 0.875 
Minute volume 
Median (IQR) 
323 (125) 329 (147) 0.986 
PaCO2  (kPa) 5.21 (1.52) 5.14 (1.67) 0.391 
Table 13 Respiratory parameters at the time of commencing randomised mode  
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9.13 Respiratory parameters prior to performing minute 
ventilation test whilst receiving minimal mechanical 
ventilation 
The respiratory parameters were compared between the group prior to 
commencing the minute ventilation test see Table 14. The mechanical 
ventilation aimed to provide an inspired tidal volume of 2-
3mls/kg/breath. There was no significant difference between the 
groups.  
Respiratory 
Parameter 
SIMV PSV p value 
Minute 
ventilation 
(ml/kg/min) 
Median (IQR) 
367.2 (150.2)  321.1 (118) 0.76 
Respiratory Rate 61 (16.2) 62 (15) 0.88 
Inspired Tidal 
volume  
5.69 (2.49) 5.61 (2.17) 0.77 
FiO2   21%(6.5) 21% (7) 0.72 
 
Table 14 Respiratory parameters prior to performing minute ventilation test 
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9.14 Comparison of respiratory parameters at the time of 
minute ventilation test whilst receiving ET CPAP 
Respiratory parameters whilst receiving ET CPAP (Table 15) were 
compared at the time of performing minute ventilation test. There was 
no significant difference between the groups.  
Respiratory 
parameters 
SIMV PSV p value 
Spontaneous 
Minute 
ventilation 
Median (IQR) 
306 (190) 258.8 (106.8) 0.101 
Spontaneous 
Respiratory Rate 
Median (IQR) 
66.8 (14.6) 65.6 (14.05) 0.913 
Spontaneous 
Inspired Tidal 
volume  
Median (IQR) 
4.55 (2.57) 4.89 (2.34) 0.928 
FiO2  
supplementation 
21 (7) 21 (7) 0.874 
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for spontaneous 
breaths  
Median (IQR) 
RSBI MVM 11.2 (6.3) 11.2 (8.01) 0.933 
RSBI MVS 15.0 (8.0) 13.8 (10.4) 0.915 
Table 15 Respiratory parameters at the time of minute ventilation test  
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9.15 Minute ventilation not performed  
Passing the Minute ventilation was an objective assessment for 
readiness to extubate. Table 16 details the reasons for not performing 
the MVT.  
Case number Alive  Reason for non 
performing MVT 
Reintubated in 
72 hours 
(Yes/No) 
1 Yes Transferred to 
another hospital 
before MVT 
N/A 
2 Yes Consultant 
decision, failed 
low rate SIMV 
No 
3 Yes No clear reason No 
5 Yes Failed multiple 
extubation and 
therefore 
withdrawn to 
follow protocol  
No 
6 No Died before 
getting 
randomised mode  
N/A 
7 Yes Consultant 
decision, did not 
No 
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tolerate weaning 
18 No Died before 
getting  
randomised mode  
N/A 
21 Yes Did not 
commence 
randomised 
mode, transfer for 
tertiary care  
 
26 Yes Self extubated  No 
38 No Died before MVT N/A 
50 Yes  Transfer for 
tertiary care 
N/A 
52 No Died before MVT  N/A 
55 Yes  Transferred for 
tertiary care 
No 
92 Yes Transferred for 
tertiary care  
No 
93 Yes No clear reason  No 
Table 16 Reasons for not performing Minute ventilation test.  
 
In only two infants there was no clear reason for not performing the 
minute ventilation test. This was a major trial protocol violation. This 
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issue was discussed in the directorate meetings and appropriate 
measures such as further training and staff awareness was increased.   
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9.16 Proportion of infants failing Minute Ventilation Test 
A total of 23 episodes (in 8 infants) needed repeat minute ventilation 
test. 12 episodes (52%) in SIMV group and 11 (47%) episodes 
occurred in the PSV group.  
Table 17 shows the proportion of infants failing their first MVT and 
subsequent tests prior to the final MVT test.  
Randomised 
Mode 
Failing first 
MVT 
Failing second 
MVT 
Failing third 
MVT 
SIMV (N) 5  1 1 
PSV (N) 3 3 2 
Table 17 Proportion of infants failing the minute ventilation test prior to final minute 
ventilation test 
  
 140 
 
9.17 Comparison of re-intubation rate in infants when MVT 
performed versus when not performed  
 Reintubation in 
< 72 hours 
No reintubation 
in <72 hours 
Total  
MVT not 
performed  
0 (0%) 6 (100%) 6 (7.1%) 
MVT performed  10 (12.8%) 68 (87.2%) 78 (92.9%) 
Total  10 (11.9%) 74 (88.1%) 84 (100%) 
Table 18: Comparison of infants needing reintubation when MVT not performed  
 
A chi- square test was conducted for reintubation episodes when MVT 
was not performed. Fisher’s exact test (2 sided) was used in view of cell 
frequencies less than 5. There was no statistically significant association 
between reintubation and MVT (p=1.00). 
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9.18 Minute ventilation journey prior to extubation 
Randomised 
mode 
MVT1 
MVS:MVM 
No. of 
MVT 
Tests 
Episodes of 
reintubation in 
<72 hours 
Final MVT 
PSV 86% 2 1 10 DAYS 
SIMV 97% 1 1 TRANSFERRED 
OUT FOR NEC 
SIMV 104% 2  24 HOURS 
SIMV 78% 2 1 5 DAYS  
SIMV FAILED IN 
LESS THAN 
5 MINUTES 
2  48 HOURS 
SIMV 52% 3 1 TRACHY 
PSV 63.5% 5 1 48 HOURS 
PSV 80% 3  72 HOURS 
SIMV 81% 2  8 HOURS 
SIMV 95% 2 1 27 DAYS 
PSV 92% 1 1 TRANSFERRED 
OUT 
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PSV 73% 3 2 40 DAYS  
SIMV 90% 4 2 5 DAYS 
PSV FAILED IN 
LESS THAN 
5 MINUTES 
4  48 HOURS 
PSV 90.6% 1 1 12 HOURS 
Table 19: Table showing the details of the minute ventilation test in infants after the 
first minute ventilation test. 
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9.19 Need for re-intubation within 72 hours of extubation  
There were a total of 10 episodes of re ventilation in less than 72 hours 
of extubation with 5 each in PSV arm and SIMV arm respectively (Table 
20). Chi squared analysis for success of passing minute ventilation test 
and reintubation rates between the two groups showed no difference 
(p= 1.00).  
Reintubation in 
<72 hours  
N (%) 
SIMV PSV Total 
No 41 (89.1) 42 (89.4) 83 (89.2) 
Yes 5(10.9) 5 (10.6) 10 (10.8) 
Total  41 (100) 42(100) 93 (100) 
Table 20 Need for re-intubation within 72 hours of extubation 
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9.20 Primary Outcome measure  
Kaplan Meier survival analysis was used to compare the time taken 
from commencing the randomised mode to passing the minute 
ventilation test. If there was self-extubation or tube dislodgement and 
the infant did not require re-intubation in 72 hours then this was also 
considered as achieving the primary outcome. A similar percentage of 
censored cases were present in the SIMV and the PSV group. The 
median time to extubation in the SIMV arm was 42 (95% CI, 28.23 to 
55.76) hours. The median time to achieving the primary outcome in the 
PSV arm was 31 (95% CI, 12.59 to 49.40) hours.  A log rank test was 
run to determine if there were differences in the survival distribution 
between the two groups. The survival distribution between the 
interventions was statistically not significant, Chi-square 0.768, p 
0.381.  
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Figure 13: Kaplan Meier survival curves showing time taken to passing the minute 
ventilation test.  
The vertical axis shows cumulative survival and horizontal axis time in 
hours 
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9.21 Spearman’s Correlation coefficient of variables on primary 
outcome 
Variable  Spearman’s Rho P value  
Partial Antenatal 
steroids 
0.213 0.052 
Gestational age at 
birth  
-0.638 0.000 
Birth weight  -0.637 0.000 
Inborn 0.228 0.034 
Intubated at birth  0.329 0.002 
CRIB 2 score  0.607 0.000 
Ventilated from birth 0.369 0.000 
Mode of ventilation -0.256 0.018 
Maximum Oxygenation 
index prior to 
commencing 
randomised mode 
0.210 0.013 
First dose of surfactant 
(mg/kg) 
0.211 0.052 
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Air leak needing 
treatment  
0.221 0.048 
PIE changes  0.426 0.000 
Ventilator associated 
Pneumonia 
0.225 0.044 
Use of inotropes 0.438 0.000 
Length of primary 
mode of ventilation 
prior to commencing 
randomised mode 
0.351 0.001 
Use of diuretics to 
wean ventilation  
0.447 0.000 
Use of post natal 
steroids 
0.530 0.000 
Table 21 Univariate analysis of variables affecting primary outcome 
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9.22 Multiple regression analysis of Primary outcome measures  
A multiple regression (Table 22) was run to predict the primary 
outcome from the variables listed thought to have significant impact. 
The variables statistically significantly predicted the duration of the 
primary outcome F (13, 33)= 12.86, p<0.000, adjusted R2 =0.77. Of all 
of the variables, only gestation at birth, need for intubation at birth, 
length of primary mode of ventilation prior to randomisation and need 
for post-natal steroids contributed significantly to the prediction model.   
Below is the summary of the multiple regression analysis. 
Variable Unstandar
dised 
regression 
coefficient  
Standard 
error of the 
coefficient  
Standardised 
coefficient  
P value 
Partial Antenatal 
steroids 
99.61 51.80 0.186 0.063 
Gestational age at 
birth  
-46.75 21.25 -0.466 0.035 
Inborn 32.87 43.26 0.061 0.453 
Intubated at birth  -126.13 37.29 -0.322 0.002 
CRIB 2 score  4.41 11.41 0.079 0.701 
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Maximum 
Oxygenation index 
prior to 
commencing 
randomised mode 
1.270 1.978 0.056 0.525 
First dose of 
surfactant (mg/kg) 
-.018 0.270 -0.006 0.947 
Air leak needing 
treatment  
42.60 71.45 0.055 0.555 
Use of inotropes 1.04 0.729 0.122 0.162 
Length of primary 
mode of ventilation 
prior to 
commencing 
randomised mode 
-2.201 0.765 -0.293 0.007 
Use of diuretics to 
wean ventilation  
87.82 137.96 0.093 0.529 
Use of post natal 
steroids 
467.56 84.09 0.600 0.000* 
Table 22 Multiple regression analysis of variables affecting primary outcome 
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9.23 Effect of gestational age on primary outcome  
The study was primarily performed to identify the effect of gestational 
age on the primary outcome (passing the minute ventilation test) Table 
23. The initial sample size calculation required a total of 110 infants for 
subgroup analysis. However, due to slower than anticipated recruitment 
rate, and upon advice of the data monitoring committee along with 
statistician’s input the study was stopped with 93 infants randomised. A 
Mann-Whitney U test confirmed there was no difference between the 
groups. 
 
Primary outcome  
(Passing minute 
ventilation test)  
Median (standard error) 
Randomisation arm p value 
SIMV  PSV 
23+o to 25+6 
 
252 (264.8) 550 (570.9) 0.25 
26+0 to 28+6  49 (14.4) 45 (35) 0.98 
29+0 to 31+6  25 (3.1) 17 (1.9) 0.28 
Table 23: Gestation distribution between the two randomised modes. 
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9.24 Impact of gestation at birth on primary outcome 
Kaplan Meier survival analysis was used to compare the time taken 
from commencing the randomised mode to passing the minute 
ventilation test. If there was self-extubation or tube dislodgement and 
the infant did not require re-intubation in 72 hours then this was also 
considered as achieving the primary outcome. A similar percentage of 
censored cases were present in the SIMV and the PSV group.  
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In the group stratified to the 23+0 to 25+6 birth gestation (Figure 14), 
the median time to extubation in the SIMV arm was 252 (95% CI, 0 to 
771) hours. The median time to achieving the primary outcome in the 
PSV arm was 550 (95% CI, 0 to 1669) hours.  A log rank test was run 
to determine if there were differences in the survival distribution 
between the two groups. The survival distribution between the 
interventions was statistically not significant, Chi square 1.274, p =0.25  
 
Figure 14 Kaplan Meier survival curves showing time taken to achieve the primary 
outcome in the infants stratified in 23+0 to 25+6 gestation group.  
The vertical axis shows cumulative survival and the horizontal axis time 
in hours  
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In the group stratified to the 26+0 to 28+6 weeks (Figure 15), the 
median time to achieve the primary outcome in the SIMV arm was 49 
(95% CI, 20.76 to 77.23) hours. The median time to achieve the 
primary outcome in the PSV arm was 45 (95% CI, 0 to 113.78) hours. 
A log rank test confirmed the observed difference was not statistically 
significant, Chi-square 0.00, p =0.98. 
 
Figure 15 Kaplan Meier survival curves showing time taken to achieve the primary 
outcome in the infants stratified in 26+0 to 28+6 gestation group.  
The vertical axis shows cumulative survival and the horizontal axis time 
in hours 
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In the group stratified in the 29+0 to 31+6 weeks (Figure 16), the 
median time to achieve the primary outcome in the SIMV arm was 25 
(95% CI, 18.10 to 31.19) hours. The median time to achieve the 
primary outcome in the PSV arm was 17 (95% CI, 13.21 to 20.78) 
hours. A log rank test confirmed the observed difference was not 
statistically significant, Chi-square 1.05, p =0.30. 
 
Figure 16 Kaplan Meier survival curves showing time taken to achieve the primary 
outcome in the infants stratified in 29+0 to 31+6 gestation group.  
The vertical axis shows cumulative survival and the horizontal axis time 
in hours 
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9.25 Impact of birth weight on the primary outcome measure 
The infants were divided into three groups, see Table 24: Effect of birth 
weight on primary outcome. Mann-Whitney U test showed no difference 
between the groups.  
Primary outcome  
(Passing minute 
ventilation test) 
Randomisation arm p value 
SIMV  
Median (IQR) 
PSV 
Median (IQR) 
500-1000 grams 
Median wt. (IQR) 
802 (210) vs. 777.5 (223) 
144 (500) hrs 
 
166 (542) hrs 
 
1.00 
1001-1500 grams  
Median weight 
1240 (150) vs. 1150 (285) 
20 (25) 22 (20) 0.525 
Above 1501 grams  32.50 (41) 14 (3) 0.154 
Table 24: Effect of birth weight on primary outcome 
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9.26 Impact of birth weight on Primary Outcome 
Post hoc analysis, was also carried out for the different weight groups 
to verify its impact on the primary outcome Figure 17, Figure 18 & 
Figure 19. In infants with birth weight <1000 grams, the median time 
to achieve the primary outcome in the SIMV arm was 112 (95% CI, 0 
to 238.02) hours. The median time to achieve the primary outcome in 
the PSV arm was 165(95% CI, 69 to 260.38) hours. A log rank test 
confirmed the observed difference was not statistically significant, Chi 
square 0.174, p =0.67  
 
Figure 17 Kaplan Meier survival curves showing time taken to achieve the primary 
outcome in the infants with birth weight <1000 grams.  
The vertical axis shows cumulative survival and the horizontal axis time 
in hours 
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In infants with birth weight 1001 to 1500 grams, the median time to 
achieve the primary outcome in the SIMV arm was 20 (95% CI, 13.69 
to 26.30) hours. The median time to achieve the primary outcome in 
the PSV arm was 22 (95% CI, 13.47 to 30.52) hours. A log rank test 
confirmed the observed difference was not statistically significant, Chi 
square 0.100, p =0.75 
 
Figure 18 Kaplan Meier survival curves showing time taken to achieve the primary 
outcome in the infants with birth weight between 1001-1500 grams.  
The vertical axis shows cumulative survival and the horizontal axis time 
in hours 
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In infants with birth weight >1500 grams, the median time to achieve 
the primary outcome in the SIMV arm was 24 (95% CI, 0.00 to 53.4) 
hours. The median time to achieve the primary outcome in the PSV arm 
was 14 (95% CI, 13.40 to 14.60) hours. A log rank test confirmed the 
observed difference was statistically significant, Chi square 4.36; p 
=0.03 
 
Figure 19 Kaplan Meier survival curves showing time taken to achieve the primary 
outcome in the infants with birth weight >1500 grams.  
The vertical axis shows cumulative survival and the horizontal axis time 
in hours 
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9.27 Duration of initial mode of mechanical ventilation on 
primary outcome measure 
The effect of duration of initial ventilation was studied by post hoc 
analysis. Babies were stratified into two groups based on the duration 
of preceding ventilation; ≤ 1 week and those requiring > 1 weeks 
(Table 25). A Mann- Whitney U test was performed to assess the 
significance. 
Primary outcome  
(Passing minute 
ventilation test) 
Median (Hour)(IQR) 
Randomisation arm p value 
SIMV  
N=34 
PSV 
N=35 
≤1 week ventilation 38 (67) 26 (133) 0.49 
 
Primary outcome  
(Passing minute 
ventilation test) 
Median (Hour)(IQR) 
Randomisation arm p value 
SIMV 
N=8 
PSV 
N=10 
≥1 week ventilation 408 (1244) 125.5 (564) 0.51 
Table 25: Effect of duration of initial ventilation on primary outcome 
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9.28 Total duration of respiratory support 
Figure 20 shows Kaplan Meier survival analysis for the median time for 
total duration of respiratory support in the SIMV arm was 312 (95% CI, 
185.15 to 438.84) hours. The median time for total duration of 
respiratory support in the PSV arm was 512 (95% CI, 184.09 to 
839.90) hours. A log rank test confirmed the observed difference was 
not statistically significant, Chi square 0.140, p=0.709 
 
Figure 20 Kaplan Meier survival curves showing time for total duration of respiratory 
support between the two groups.  
The vertical axis shows cumulative survival and the horizontal axis time 
in hours  
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9.29 Duration of respiratory support according to the 
gestational age at birth  
In infants with birth gestation 23+0 to 25+6 weeks, the median time 
for duration of respiratory support in the SIMV arm was 1283 (95% CI, 
1057.4 to 1508.5) hours. The median time in the PSV arm was 829 
(95% CI, 627.3 to 1030.6) hours. A log rank test confirmed the 
observed difference was not statistically significant, Chi square 2.39, p 
=0.1 
 
Figure 21 Kaplan Meier survival curves showing time for total duration of respiratory 
support in infants stratified to 23+0 to 25+6 weeks.  
The vertical axis shows cumulative survival and the horizontal axis time 
in hours 
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In infants with birth gestation 26+0 to 28+6 weeks, the median time 
for respiratory support in the SIMV arm was 467 (95% CI, 213.1 to 
720.8) hours. The median time in the PSV arm was 670 (95% CI, 
556.35 to 783.6) hours. A log rank test confirmed the observed 
difference was not statistically significant, Chi square 1.12, p =0.289 
 
Figure 22 Kaplan Meier survival curves showing time for total duration of respiratory 
support in infants stratified to 26+0 to 28+6 birth gestation.  
The vertical axis shows cumulative survival and the horizontal axis time 
in hours.   
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In infants with birth gestation 29+0 to 31+6 weeks, the median time 
for respiratory support in the SIMV arm was 91 (95% CI, 35.45 to 
146.54) hours. The median time in the PSV arm was 83 (95% CI, 40.08 
to 125.92) hours. A log rank test confirmed the observed difference was 
not statistically significant, Chi square 0.001, p =0.973 
 
Figure 23 Kaplan Meier survival curves showing time for total duration of respiratory 
support in infants stratified to 29+0 to 31+6 birth gestation.  
The vertical axis shows cumulative survival and the horizontal axis time 
in hours 
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9.30 Adjuvant therapy to assist extubation 
Chi squared test for the effect of diuretic therapy and need for postnatal 
steroid use did not differ from each other significantly.  
Treatment  SIMV group  
N=44 
PSV group  
N=43 
p value  
 
Diuretics 5 (11.4%) 2 (4.7%) 0.434 
Post natal 
corticosteroid use 
7 (16.3%) 6 (13.7%) 0.503 
Table 26 Adjuvant therapy to aid extubation 
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9.31 Difference in the weight gain between the two groups 
Variable 
Median (IQR) 
SIMV  
N= 29 
PSV 
N= 34 
p value 
Enteral Feed 
commenced on  
3 (2) 3(2) 0.51 
Full enteral 
feeding 
established on 
9 (4) 11 (9) 0.30 
Birth weight 
reached on  
16 (8) 14 (5) 0.10 
Weight gain per 
day  
18.4 (7.59) 18.1 (8.21) 0.56 
 Table 27: Weight gain per day between the two groups 
 
Mann Whitney U test confirmed the observed difference between the 
two groups was not statistically significant.   
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9.32 Duration of hospital stay 
KM analysis of the duration of the hospital stay between the 
randomised groups showed the median duration in the SIMV arm was 
69 (95% CI, 52.7 to 81.2) days. The median time for discharge home 
in the PSV arm was 70 (95% CI, 61.9 to 78) days. A log rank test 
confirmed the observed difference was not statistically significant, Chi 
square 0.039, p =0.52 
 
Figure 24 Kaplan Meier survival curves showing duration of hospital stay between the 
two randomised groups.  
The vertical axis shows cumulative survival and the horizontal axis time 
in days 
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9.33 Survival to discharge  
There were a total of 7 deaths. 5 in the SIMV group and 2 deaths in the 
PSV group. Note however, 2 infants died before commencing the 
randomised mode. Chi square analysis of this outcome was not 
significant (p=0.20). Odds of death (PSV: SIMV) for death= 2.7 (95% 
CI -0.50 to 14.5). This changed to odds ratio of 1.6 (95% CI 0.26 to 
10.3).   
 
Variable  
N (%) 
SIMV PSV Total 
Alive 41 (93.2%) 45 (95.7%) 86 (94.5%) 
Dead 5 (10.8%) 2 (4.3%) 7 (7.5%) 
Total  46 (100%) 47 (100%) 93 (100%) 
 
Table 28: Chi square analysis for death as variable between the two groups 
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9.34 Time of death of infants in the study  
Case no  Randomi
sed ARM 
Gender Birth 
Gestation 
Age  
at death 
Cause of death 
9 SIMV FEMAL
E 
28.4 30.5 NEC 
19 PSV MALE 24.1 32 NEC 
38 PSV MALE 24.3 8 NEC 
52 SIMV MALE 24.2 26 NEC 
66 SIMV MALE 28.4 32.4 SEPSIS 
Table 29 Time of death of infants in the study 
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9.35 Incidence of Bronchopulmonary Dysplasia  
Chi squared analysis did not show any statistical significance in the 
incidence of BPD between the two groups.   
BPD  SIMV group 
N=42 
PSV group 
N=43 
p value 
 
BPD at 28 days 29 (69%) 30 (69%) 0.309 
BPD at 36 weeks 
PMA 
22 (52%) 24 (55%) 0.815 
Home oxygen 18 (42%) 21 (48%) 1.00 
Table 30: Comparison of BPD incidence in the two-study group 
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9.36 Other complications of prematurity  
Outcome SIMV 
(N) 
PSV 
(N) 
ODDS ratio 
(95% CI) 
p value 
Any IVH 13  15 0.840  
(0.344-2.048) 
0.438 
Grade 3 IVH 
or more  
7 9 0.737  
(0.248-2.18) 
0.784 
Hydrocephalus 
needing 
shunting 
0 3 0.933 
(0.86-1.00) 
0.242 
PVL 1 1 1.04 
(0.063-17.29) 
1.00 
Air leak 
needing chest 
drain in the 
randomised 
mode 
1 1 1.00 
(0.06-16.48) 
1.00 
Pulmonary 
Haemorrhage 
after 
commencing 
randomised 
mode 
 
4 3 1.41 
(0.29-6.75) 
0.712 
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PDA treated in 
<72 hours  
2 5 0.37 
(0.06-2.02) 
0.434 
PDA treated 
after 72 hours  
6 7 0.85 
(0.26-2.78) 
1.00 
PDA needing 
surgical 
ligation 
3 3 0.976 
(0.18-5.11) 
1.00 
NEC (Bell 
stage 2 or 
more) 
17 16 1.14 
(0.48-2.69) 
0.828 
NEC needing 
surgery  
3 4 0.75 
(0.15-3.56) 
1.00 
Sepsis 32 30 1.46 
(0.51-4.14) 
0.601 
ROP stage 2 
or more 
12 18 0.56 
(0.22-1.42) 
0.255 
ROP needing 
surgery 
6 5 1.27 
(0.35-4.55) 
0.756 
Table 31: Incidence of other common complications of prematurity in the two groups 
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9.37 Comparison of ventilation control in the two randomised 
mode  
Hypocarbia was defined as PaCO2 value less than 4KPa (Ambalavanan 
and Carlo, 2001). An unpaired student t test was performed to assess 
the variability in the two groups. The CO2 values recorded in the 
observation chart in the assigned mode were averaged during the 
period and the average value of each infant was compared against the 
other using unpaired t test as the values were normally distributed (KS 
test for normality, p=0.380 for PSV and 0.490 for SIMV).  
 SIMV PSV p value 
Mean CO2  
Mean, 95%CI 
5.61 (5.27-
5.95) 
5.72 (5.41-
6.03) 
0.622 
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Figure 25 Box plot of CO2 recorded whilst in the randomised mode 
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10 Discussion 
Improved antenatal care, fetal surveillance, use of antenatal steroid 
therapy coupled with use of surfactant therapy has had a positive 
impact on the intact survival of the preterm infants. Use of volume 
controlled ventilation (Wheeler et al., 2010), and improved 
understanding of the patient ventilator interaction has helped to 
minimise the incidence of ventilator induced lung injury and other 
morbidities including chronic lung disease and death.  
Microprocessor based technology has facilitated development of newer 
ventilation modes each with perceived advantages. Pressure support 
ventilation is relatively newer mode of ventilation that allows improved 
patient ventilator interaction. PSV is reported to be better tolerated and 
more comfortable when compared to volume controlled continuous 
mandatory ventilation in intubated awake adults (Betensley et al., 
2008).  
There is wide practice variation when it comes to ‘weaning’ on 
mechanical ventilation. In current practice, there is an urgent need to 
define what is ‘weaning’ on mechanical ventilation. The general 
perception is, supporting only fixed number of breaths instead of all the 
breaths i.e. changing from A/C mode to SIMV is viewed as ‘weaning’ on 
mechanical ventilation. It is perceived, in doing so, there is a transfer of 
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work of breathing from ventilator to the infant. On the same corollary, 
therefore reducing any ventilation on a given mode should be 
considered as weaning on mechanical ventilation. 
Weaning on mechanical ventilation and subsequent extubation in 
majority of the UK neonatal units is directed by clinician’s subjective 
decision and their assessment. This assessment is usually based on 
combination of clinical examination along with the clinician’s ‘hunch’, 
biochemical monitoring in form of blood gases and in some cases 
radiographic guidance to monitor ‘optimum’ lung volumes. These are 
inadequate as none of the above assessments include objective criteria 
to include preterm infants’ contribution to the work of breathing in 
achieving the desired tidal volume.  
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10.1 Rationale for the present study 
The feasibility and safety of Pressure support ventilation (PSV) has been 
tested in previous physiological studies and in randomised controlled 
trial (Reyes et al., 2006), (Patel et al., 2012), (Farhadi Roya, 2016).  In 
most of the studies, the level of PSV applied is generally less than 50% 
of the difference between peak inspiratory (PIP) and peak end 
expiratory pressure (PEEP), or arbitrarily set between 10 and 12 cms of 
H2O. This is generally in conjunction with SIMV as the parent mode.  
Choosing an arbitrary ‘fixed’ level of PSV might not suffice all infants 
because of varied severity of disease process. Therefore existing clinical 
studies precludes the generalisability of applying a ‘fixed level’ of PSV 
for weaning infants on mechanical ventilation. This estimation is further 
compounded by lack of easy cot side assessment of work of breathing.  
Generally weaning is initiated by the change in ventilation strategy from 
A/C mode to SIMV once the mean airway Pressure (MAP) is below 10 
cm H2O and supplemental oxygen less than 40%.  
In the United Kingdom, majority of the tertiary neonatal units use SIMV 
alone (73% in 2007 and 64% in 2010) for respiratory support during 
acute stages and for weaning on mechanical ventilation. However, there 
is a practice change with an increasing recognition that SIMV alone with 
fixed number of back up rate is not sufficient to support spontaneous 
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respiration for weaning on mechanical ventilation.  Currently up to 19% 
units use varying levels of PSV support (Mallya et al., 2010), compared 
to no units in 2007 (Sharma and Greenough, 2007).  
Hence a randomised study to define weaning objectively and utilising 
variable PSV support for weaning infants is required to assess if this 
approach facilitates earlier and successful extubation. 
 
10.2 Aim of this study 
The aim of the study was to compare the duration of weaning on 
mechanical ventilation using variable PSV level with the standard 
approach of weaning on SIMV. 
 
10.3 Regulatory approvals 
National Research Ethics Committee (Newcastle and North Tyneside 
Research Ethics Committee) approval (approved 10/01/2011) and 
Hospital Research and Development Review Board approval was sought 
before commencing the study. The study was also registered with 
International Standard Randomised Controlled Trials Number (Ref no. 
74272142) at the start of the study. Parents’ comments were sought 
prior to finalising the parent information leaflet (see Appendix 1) and it 
was encouraging to see their enthusiasm with this study.  
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10.4 Study objectives 
This study targeted expired tidal volume using variable PSV support 
delivered to the infant instead of a set pressure as elucidated in the 
previous studies.  
This was an open label randomised controlled study, designed to 
compare duration of weaning of mechanical ventilation in preterm 
infants with RDS using study mode of variable PSV with standard 
weaning mode of SIMV.  
Infants born between 23+0 weeks but less than 31 completed weeks 
(31+6 weeks) were included in the study. Based on gestation at birth, 
infants were stratified in three groups: 
a. 23+0 to 25+6 weeks  
b. 26+0 to 28+6 weeks  
c. 29+0 to 31+6 weeks  
Gestation was chosen over birth weight for stratification because of its 
correlation in predicting the neonatal mortality and morbidity (Wariyar 
et al., 1989), (Verloove-Vanhorick et al.).  
The primary objective of duration of weaning was objectively defined as 
time from commencing the randomised mode to passing the minute 
ventilation test (MVT).  
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10.5 Methodology 
This is a two unit randomised controlled study comparing weaning on 
PSV with weaning on SIMV. The two participating study centres 
primarily use volume-controlled ventilation at birth and both the 
medical and the nursing staffs are well versed with the study modes. 
The limitations of testing PSV as a study mode in an open label RCT 
such as ours was mitigated by the existing practice of using advanced 
ventilation modes on both the units. This is an important variable when 
testing any ventilation modality to minimise bias in an unmasked study 
and for staff acceptance. Familiarity with the ventilation mode helped to 
site set up and conduct the study with relative ease.  
Eligible infants were stratified into three gestation groups as mentioned 
above. The stratification for recruitment was important to achieve a 
balance between the two study modes of ventilation and to minimise 
the associated risks of prematurity in any one group. We included 
infants born less than 24 weeks (but over 23 weeks gestation) because 
of paradigm shift in their management in the last few years with 
increased survival rates (Costeloe et al., 2012). 
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Infants were deemed ready to commence the randomised mode when 
they achieved  
a. Mean Airway Pressure (MAP) of <10 cm H2O   for at least 6 hours, 
and,  
b. Oxygen supplementation of less than 0.4 along with   
c. Good respiratory drive- defined as at least 50% of the back up rate.   
The combination of ventilator settings and infants’ clinical condition are 
intricately linked. The entry criteria facilitated transfer of work of 
breathing from the ventilator to the infant. The objective criteria of 
when to commence randomised mode ensured the traditional subjective 
‘clinician hunch’ approach eliminated bias in the study.  
Once weaning in the assigned mode was commenced the study protocol 
directed further weaning on mechanical ventilation. If the clinical 
condition warranted, the study mode was stopped until resolution of the 
clinical issue and weaning was recommenced in the assigned mode. The 
senior clinician on duty always assessed such a situation. The study 
protocol had clear pathways when such changes could be made. Once 
the infant was randomised and allocated to a study mode no cross over 
was allowed.  
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Before commencing randomised mode, all sedatives and morphine 
infusion was stopped to prevent apnoea. All infants received caffeine 
citrate loading dose of 20 mg/kg followed by the maintenance dose of 5 
mg/kg once a day. This was increased to 10 mg/kg depending upon 
clinical requirement (Schmidt B, 2006). Use of Caffeine is a standard 
practice to facilitate extubation and to prevent apnoea of prematurity 
(Davis et al., 2010).  
Prior to commencing the study, multiple training for all of the staff was 
used to explain the study protocol in the two participating centres. In 
addition new starters were also explained the study protocol at their 
department teaching programme. Despite these measures, there was 
slower than expected recruitment in one of the two centres. Hesitation 
of deploying low back up rate in the PSV study mode compared to the 
conventional arm was perhaps the reason for that. 
For both groups of infants the study protocol aimed to maintain a tidal 
volume of 4-6mls/kg/breath. In volume controlled SIMV ventilation 
mode this was achieved by dialling the desired volume of gas. The 
initial back up rate on commencing weaning was 40 breaths/minute. In 
the PSV mode, the peak pressure achieved in Assist Control (A/C) mode 
for achieving the desired tidal volume was targeted. This ensured 
appropriate tidal volume was targeted at the start of the study. In true 
PSV mode there is no back up rate. Thus to prevent labelling as ‘failure’ 
of weaning from fleeting apnoeas in the PSV mode - ten low volume (2-
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3mls/kg) SIMV breaths were added to the PSV arm. It is unlikely that 
the low rate and low volume SIMV breaths in the PSV arm would have 
significantly contributed to the minute ventilation. Thus weaning was 
purely based on variable PSV level. Expired tidal volume was targeted 
for ventilator changes to compensate for volume leak in the circuit. 
SIMV with some pressure support (delivering 2-3mls/kg/breath) is the 
standard weaning method in both the units. From a previous study 
(Dimitriou et al., 1995) low rate SIMV (less than 20 breaths/minute) 
has been shown to be disadvantageous to the infants from fatigue 
leading to extubation failure. In that study, they report rate below 20 
was associated with increased duration of weaning. In order to avoid 
imbalance and to compare study groups, Pressure Support aiming 2-3 
ml/kg/breath was provided to support spontaneous breathing in the 
SIMV arm. This was deliberate and ensured the infants were not 
disadvantaged with fatigue from low rate SIMV prior to extubation.  
Passing the minute ventilation test was necessary to demonstrate 
readiness of extubation and be able to cope with the work of breathing 
upon extubation. The objective test has shown to reduce the duration of 
mechanical ventilation than clinicians’ perception of readiness to 
extubate (Gillespie et al., 2003). There are other extubation 
assessment tools (Kamlin et al., 2006), (Kamlin et al., 2008) arguably 
with greater sensitivity and positive predictive value. The study by 
Kamlin et al., suggests that infants can be safely extubated at higher 
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mean airway pressure than clinician perception with no differences in 
the rates of re-intubation and other clinical outcomes thereby reducing 
the duration of mechanical ventilation. Minute ventilation test has been 
previously used in ventilation studies conducted in the participating 
units previously and this was well integrated and accepted by the 
clinical and research staff.  We therefore chose minute ventilation test 
as an objective measure for extubation readiness.  
The progression of recruitment was projected on the historical clinical 
activity based on the admission rates in the two units. A short-term 
clinical outcome such as duration of weaning as primary outcome was 
considered more achievable and meaningful given the time constraints 
for study completion. Sample size calculation was based on the 
clinically considered significant reduction (33% reduction) on primary 
outcome and the logistics of completing the study in timely manner. As 
the weaning protocol in our study closely matched the weaning protocol 
used in the volume ventilation study (Singh et al., 2006) the sample 
size calculations used the published data. A statistician’s input was 
sought to confirm that at least 85 infants were sufficient to provide 
80% power with two-sided alpha of 0.05 to detect any statistical 
differences between the two groups. 
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10.6 Results 
The delays in obtaining centre specific approval to commence study in 
one of the two sites led to commencing the study at different times with 
a seven-month difference between the two participating centres. Slower 
than anticipated recruitment activity in one of the two centres further 
lead to prolongation of study (see Figure 26 and Figure 27 for 
recruitment activity). 
 
Figure 26: Projected recruitment at the two centre 
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Figure 27: Actual recruitment activity at the two centres 
 
Consent for participation was to be considered during the resolving 
phase of the RDS. This was deliberate as it was assumed explaining 
weaning on mechanical ventilation would be easier at that stage. 
However it soon became apparent that infants made fast progress and 
some infants were commenced on standard weaning mode prior to 
gaining consent. To boost infant recruitment, following trial steering 
committee meeting it was suggested that parents be approached for 
consent as soon as possible after admission to the neonatal unit.  
Another issue for poor uptake was a lack of consensus amongst the 
clinical team on previously agreed weaning protocol. It was perhaps 
earlier than usual commencement of the SIMV mode in the control arm, 
which was a deviation from the usual practice at this site.  
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A request to capture patient data from the eligible but not recruited 
infants to compare primary outcome measure with the recruited infants 
was turned down by the national ethics committee with a suggestion 
that a new application for the same be put forth for consideration. Due 
to time constraints this was not pursued.  
The two study groups matched for all the maternal and the infant 
baseline characteristics. Although the uptake of steroids was high in 
both the groups, there were a higher proportion of infants who received 
incomplete course of steroids in the PSV group, and higher proportion 
of infants who received more than one completed course of steroid in 
the SIMV group. As this could significantly affect the severity of 
Respiratory Distress and other associated outcomes this variable was 
used in the multiple regression analyses for the primary outcome and 
this was found to be not significant (p=0.063).  
Although the standard practice is to administer 200 mg/kg of 
exogenous surfactant [Poractant Alpha (Curosurf®) is the standard 
exogenous surfactant therapy], infants born in the participating centres 
received significantly higher surfactant therapy (177 mg/kg vs. 139 
mg/kg; p=0.008). However, there was no difference in the duration of 
primary mode of ventilation before randomisation between the two 
groups (Mann Whitney U Test p=0.62). There were no other 
demographic differences between the two study groups. 
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The median time to enrol in both the groups was similar at less than 48 
hours (IQR=1, Mann Whitney U test p=0.69). This ensured that the two 
groups were similar at the time of randomisation. There was no other 
significant difference between the groups. The randomised mode was 
commenced within 72 hours in 77% in both the groups.  
Lung disease severity between the groups was compared using 
maximum peak inspiratory pressure, maximum mean airway pressure, 
oxygen supplementation and Oxygenation Index prior to commencing 
the randomised mode and there was no difference between the groups. 
In addition, CRIB2 score between the two groups was not statistically 
different (Mann Whitney U test p=0.66). This was further supported by 
the fact that both groups received equal number of multiple surfactant 
therapy.  
Some of the commonly occurring problems of ventilation that further 
compound the course of respiratory distress syndrome such as air 
leaks, ventilator associated pneumonia and pulmonary haemorrhage 
were also compared. There were no significant differences between the 
two groups.  
Although an hourly check list of variables to assess readiness to 
commence randomised mode was available to prevent delay in 
commencing the randomised mode, there was a significant delay in 
both the groups (10-hour delay in SIMV group vs. 11-hour delay in the 
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PSV group). The delay reflects the pragmatic issues such as shift 
changes, lack of staff and staff bias in an open label RCT study.  
There was no difference in the respiratory parameters - respiratory 
rate, minute ventilation, inspired tidal volume or oxygen 
supplementation between the two groups prior to minute ventilation 
test. This is not surprising and supports the trial design of adding low 
PSV (aiming 2-3mls/kg/breath) to support spontaneous breaths in the 
low rate SIMV mode to prevent fatigue prior to extubation. Contrary to 
the popular belief of inability to use ‘true PSV’ with no back up rate due 
to apnoea of prematurity, our study suggests very immature infants 
can be safely weaned in this mode without significant issues. This is an 
important finding. CO2 clearance was also equal in the two arms. This is 
possible from effective transfer of work of breathing from the ventilator 
to the infant and most likely from respiratory muscle preconditioning by 
use of pressure support. There were a lower proportion of infants failing 
the MVT in the SIMV group compared to the PSV group (4 vs. 10 
respectively). However, there was no difference in the rate of re-
intubation within first 72 hours. Whether this is due to ventilator 
induced diaphragm dysfunction (Jaber et al., 2011) from prolonged 
ventilation needs further investigation.  
The median time to extubation in the SIMV group was 42 hours. Infants 
randomised to the PSV group achieved the primary outcome sooner 
with median time to extubation at 31 hours. (95%CI 12.59-49.4hours), 
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but this was not significant. The survival distribution between the 
interventions was statistically not significant, Chi-square 0.768, 
p=0.381. Specifically, this difference favouring PSV group was seen in 
> 26 weeks gestation infants, however the differences were not 
statistically significant. A plausible explanation for this could be the 
availability of ‘demand flow’ in the PSV mode to satisfy air hunger and 
more stable respiratory drive from Hering-Breuer reflex. The other 
reason could be synchrony at inspiration and expiration, with least 
disruption to the spontaneous breathing cycle. Preconditioning of the 
respiratory muscles and preventing atrophy from prolonged ventilatory 
support could also be another important contributing factor for this 
observed effect (Knisely et al., 1988) (Jaber et al., 2011). However the 
insignificant difference favouring the PSV could be due to small sample 
size and larger studies could are needed to investigate this further. 
The total duration of respiratory support showed a median time of 312 
hours in the SIMV group as compared to 512 hours in the PSV group. 
This difference was not statistically significant. The total duration of 
respiratory support included all forms of respiratory support provided. A 
possible explanation for this difference is the use of High flow device as 
a non-invasive respiratory mode instead of CPAP device. The use of 
humidified high flow nasal cannulae (HHFNC) support came into 
practice after the study was commenced. Infants were supported with 
CPAP at initial extubation as per trial protocol. In a proportion of infants 
needing some form of respiratory support after weaning on CPAP 
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humidified high airflow was used as a subsequent ‘step down’ therapy. 
The uncontrolled use of HHFNC could be the reason for the observed 
difference. Prolonged duration of respiratory support has been seen in 
randomised controlled studies comparing HHFNC with CPAP (Abdel-
Hady et al., 2011)  Another factor for the observed difference could be 
the role of partial course of antenatal steroid (higher in the PSV group), 
although statistically there was no difference between the two groups, 
based on our knowledge from historic studies this cannot be ignored.  
There was no significant difference in the use of adjuvant therapy (i.e. 
use of diuretics and post natal steroids) to assist extubation. Although 
the study was not designed to investigate other secondary outcomes, 
death and chronic lung disease are important outcome measure of 
interest. There were a total of 5 deaths after randomisation: 3 in the 
SIMV group and 2 in the PSV group. This difference was not statistically 
significant.  
There was no difference in: days to reach the birth weight, days to 
establish full enteral feeding or average weight gain per day prior to 
discharge between the two groups. The results were identical (Table 
27). This is an important finding and adds more information to our 
understanding of interaction of mode of ventilation and energy 
expenditure. In a randomised controlled study comparing PSV with flow 
cycled A/C mode (Patel et al., 2012) the authors conclude there was no 
difference in the energy expenditure and work of breathing. But there 
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was no information on weight gain between the two groups. Thus it 
appears flow cycling extends its benefits to both the groups by 
providing greater synchronicity to prevent ‘fighting the ventilator’ 
scenario and asynchronous breathing leading to higher energy 
expenditure. When PSV was compared with SIMV (Gupta et al., 2009a), 
authors observed, addition of PSV stabilised breathing and increased 
minute ventilation. This was proportional to the level of PSV. The 
observation suggested improved respiratory efficiency. However, our 
data suggests the end point of such benefits is not translated in definite 
clinical outcomes such as effective weight gain per day. The observed 
effect highlights the obvious – there are many other factors not 
considered in this study rather than mode of ventilation that contributes 
to infant growth. 
There was no difference in incidence of bronchopulmonary dysplasia 
between SIMV and PSV at 28 days (69% in both groups) and at 36 
weeks (52% vs. 55%). There was no significant difference in the infants 
going home with oxygen supplementation between the two groups. 
Although the two weaning modes differ from one another in their breath 
delivery, we targeted tidal volume for adjusting ventilator setting to 
prevent ventilator induced lung injury.  This could be the reason for 
equal incidence of chronic lung disease and home oxygen 
supplementation in both the groups. 
 192 
 
There was no difference in any of the secondary outcomes of interest 
between the two groups.  Infants weaned in the PSV arm had a longer 
duration of stay. Median duration of hospital stay [SIMV-69 (95% CI, 
52.7 to 81.2) days, vs. median duration of weaning in PSV arm 70 
(95% CI, 61.9 to 78) days] p=0.52. Our results are different from the 
previous randomised controlled study comparing PSV to SIMV weaning 
(Reyes et al., 2006). The likely reason could be inclusion of more 
immature infants (inclusion criteria of 23+6 gestation) and use of HHFNC 
leading to need for longer duration of respiratory support. 
Since this study commenced, data on newer mode of ventilation – 
Neurally Adjusted Ventilatory Assist (NAVA) has been published 
suggesting greater synchronicity and decreased work of breathing 
(Beck et al., 2009). This benefit was observed despite presence of large 
ET leak (Stein and Howard). The ability to deliver assisted breaths and 
to maintain synchronicity by monitoring diaphragmatic activity in 
presence of large leak holds advantage over conventional ventilation 
and particularly useful as a non invasive respiratory modality. The 
improved patient ventilator interaction was studied in another 
observational study (Piastra et al., 2014) suggesting lower heart rate, 
lower arterial blood pressure and improved comfort score in a group of 
infants with ARDS needing HFOV and weaned on NAVA as compared to 
weaning on PSV. Weaning on NAVA was considered to be superior to 
PSV. However a major limitation is that infants were compared in two 
different epochs retrospectively. As the data was published in an 
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abstract form complete details on methodology is unavailable. A 
limitation of NAVA to current date is non-availability of transducers for 
infants below 26 weeks gestation. Any use in infants below this 
gestation is purely experimental and lacks robust scientific evidence.  
From adult experience, an important aspect of PSV mode of ventilation 
is patient comfort from greater synchrony at both inspiration and 
expiration. In that respect, the reported findings of greater comfort 
score in NAVA is not surprising.  
Assessing pain scores/comfort scores could be challenging and practice 
variation makes it difficult to generalise the findings. Although there are 
validated tools in practice (mostly from paediatric intensive care 
practice), personal communication with the nurses at the cot side in 
both the units suggests subjective variation in recording comfort scores. 
Thus, although pain scores on 11 infants recruited in SITE 2 was 
collected for comparison, there were several issues surrounding training 
and subjective bias. Therefore, in an open labelled study such as ours, 
reporting pain/comfort scores was inappropriate. This could be 
considered in future studies. 
Our study like most other open labelled studies would be affected by 
health care professionals’ bias especially in commencing the assigned 
weaning mode. In both the groups there was at least ten-hour lag to 
commence the randomised mode. Whilst this could affect the primary 
outcome of the study, it did not favour any of the two arms. Other 
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important bias was the clinician perception and report of ‘inability’ to 
wean on any particular assigned mode as seen in three infants reported 
to fail weaning as per the study protocol. Two infants were assigned to 
PSV weaning protocol and one in SIMV arm. This has not been 
discussed in the previous randomised studies (Farhadi Roya, 2016), 
(Reyes et al., 2006). Farhadi et al used 15 SIMV breaths and Reyes et 
al used variable rate SIMV to maintain adequate gas exchange. Hence 
weaning was not on pure PSV.  
PSV is designed to provide variable flow (demand flow) to meet patient 
demand. It is thought this could particularly favour infants with chronic 
lung disease. In our study, PSV took longer time to wean in the very 
immature infant group. This is also the group of infants with higher 
incidence of chronic lung disease. It is puzzling to see the results 
different from the current opinion. A likely explanation for this finding is 
that risk factors such as prematurity, antenatal events such as sepsis, 
maternal factors such as chorioamnionitis, mechanical ventilation, 
oxygen supplementation and other post natal stress could have 
contributed to chronic lung disease rather than the mode of respiratory 
support. It may also be our strategy of using PSV with only ten SIMV 
breaths was inadequate and iatrogenic in contributing to the longer 
duration of mechanical ventilation.  
Although it was envisaged that whole body plethysmography would be 
used to study the work of breathing at variable PSV levels, cost 
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implications and time constraints to conduct this study meant it was not 
possible during the study period.  
Comparing average total duration of mechanical ventilation in our study 
[PSV arm - 281.8 (95% CI 155.17- 408.61) hours and 306.4 (95% CI 
152.3- 460.4) hours in the volume SIMV arm] with volume controlled 
ventilation study in 2006 (Singh et al., 2006) [Volume controlled 
ventilation arm 255 (95% CI 160-249) hours and 327 (95% CI 214-
441) hours in the pressure controlled arm] suggests volume controlled 
ventilation with added pressure support is the way forward to reduce 
mechanical ventilation days. We recruited infants from 23 weeks’ 
gestation compared to above 24 weeks in their study and infants in our 
study also had the worst OI prior to randomisation (11.56 for the PSV 
arm, 11.81 for the volume controlled arm compared to 6.6 for the 
volume controlled arm and 5.5 for the PSV group). These differences 
could be the reason for the slightly longer duration of mechanical 
ventilation in our study. The findings are however comparable and 
therefore suggest the results are generalisable to neonates of all 
gestation with surfactant deficient lung disease. The above finding is 
also the strength of the study in utilising the staff knowledge and their 
previous research experience in ventilation study. This made site set up 
and training the staff with the new study protocol relatively easy. 
A few eligible infants were lost to randomisation early in the study 
period. Following advice from the trial steering committee it was 
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decided to gain consent and randomise the infants once ‘early stability’ 
was achieved. Hence future studies could be designed to stratify the 
infants based on gestation and on the duration of initial ventilation 
period to identify benefits in infants with chronic lung disease. 
Our study limited data capture prior to discharge from our hospital or to 
home. This was intentional with limited resources and in the available 
limited time. A major limitation was poor uptake of the study in one of 
the two centres. This was most likely from deploying SIMV earlier than 
traditional approach and use of PSV with only ten SIMV back up 
breaths. This suggests a degree of anxiety for the clinical team 
deviating from the traditional set up of reducing the ventilator support 
significantly on the A/C mode prior to deploying (SIMV with some PSV) 
just prior to extubation. 
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11 Summary, Conclusions and Future 
Directions 
There is good evidence favouring antenatal intervention of 
corticosteroid administration to labouring preterm mothers. This has led 
to increased incidence of preterm infants survivability (Costeloe et al., 
2012). Postnatally, surfactant administration and targeting tidal 
volumes has further significantly reduced incidence of chronic lung 
disease and death (Wheeler et al., 2010) this is most likely by reducing 
ventilator induced lung injury. However an area of uncertainty is 
defining weaning on mechanical ventilation. Reducing mechanical 
ventilation days could lead to reduction in incidence of chronic lung 
disease. 
A randomised controlled study was undertaken to wean infants early 
during the course of their respiratory distress from surfactant 
deficiency. Infants were stratified into three groups based in their 
gestation at birth. In the intervention arm, variable PSV commencing 
from PSVmax targeting 4-6mls/kg was weaned to PSmin targeting 2-
3ml/kg. In addition, ten SIMV breaths targeting low tidal volumes (2-
3ml/kg/breath) was added to the PSV breaths to compare it with the 
standard arm. In the standard arm, weaning on mechanical ventilation 
was as per standard practice with weaning on backup rate and dialled 
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volumes. 50% PSV (50% of the peak inspiratory pressure at the start of 
weaning, targeting 2-3ml/kg) was added to support spontaneous 
breaths over the SIMV back up rate. All other care was provided as per 
standard unit practice.  
Duration of weaning was defined as the time taken from commencing 
the randomised mode to passing the minute ventilation test.  
We conclude, there was no significant difference in the duration of 
weaning in the two weaning modes and there were no significant 
differences in the secondary outcomes of interest. However, an overall 
trend of faster weaning in the PSV mode was observed. The observed 
trend is likely from greater autonomy provided to the premature infant 
i.e. determining its own respiratory rate by managing when to breathe 
and how long to breath. The added feature of demand flow in PSV mode 
also could have satisfied their demand to generate a sigh breath, that 
could have helped to stabilise their breathing.  
Our randomised controlled study adds more insight into variable level of 
PSV for weaning on mechanical ventilation with only a few (ten) SIMV 
breaths in the background. The results are comparable with the 
traditional SIMV weaning without any apparent disadvantages.  
Weaning infants on mechanical ventilation involves interplay of many 
processes and in particular also optimising cardiac status. It is difficult 
to conceive that by optimising respiratory care alone would reduce 
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duration of weaning. Inability to wean and extubation failure has been 
related to cardiac compromise (Boles et al., 2007). This deserves a 
special mention here, as PDA is a common confounding clinical problem 
in our infants. This often contributes to difficult ventilation. Whilst all of 
the weaning studies including ours, PDA management was as per 
routine standard practice. Haemodynamic assessment and strategies to 
optimise it was not routinely assessed for extubation readiness. In 
future studies, it would be useful to include haemodynamic and cardiac 
monitoring in weaning and extubation assessment.  
In addition, acquiring physiologic variables of work of breathing and 
ascertaining the actual transfer of work of breathing at variable PSV 
levels could provide us the insight into the ‘critical’ PSV level for 
preventing failure or prolonged duration of mechanical ventilation in the 
PSV mode.  
Adult studies suggest patients experience greater comfort compared to 
other intermittent mandatory ventilation. Newer generation ventilators 
are able to provide pure PSV with back up built in when unreliable 
respiratory drive is detected. However this mode has not been tested to 
ascertain patient comfort.  
Whether greater infant autonomy and greater comfort of breathing 
from better synchrony could lead to a reduction in chronic lung disease 
should also be investigated in future larger studies.  
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Appendix 1 Parent Information Leaflet 
 
 
Information Leaflets for Parents  
Pressure support Ventilation or Synchronised Intermittent Mandatory 
Ventilation for weaning premature babies on Mechanical Ventilation. A 
multi centre randomised controlled trial. [POST trial] 
Information for Parents 
Currently we are undertaking a study to compare two different methods 
of providing breathing support to babies during weaning (reducing 
support) on the ventilator. We are writing to invite you to let your baby 
take part in this research study. Before you decide it is important for 
you to understand why this research is being done and what it will 
involve for your baby. Please take the time to read the following 
information and feel free to discuss it with your family and friends. This 
leaflet is not meant to frighten or cause alarm, but to give you enough 
information to help you to decide whether your baby should take part in 
this study or not. If there is anything that is not clear to you, or you 
need more information, please feel free to ask us. This decision does 
not have to be rushed. 
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What is the purpose of the study? 
Premature infants born more than 8 weeks before the due date often 
suffer from breathing difficulties due to reduced amount of a chemical 
called “surfactant”. This is called as “acute respiratory distress 
syndrome (RDS)”. Most commonly they require breathing support 
through a tube placed in the wind pipe (endotracheal tube) and assisted 
by the breathing machine (ventilator). The severity of RDS varies 
between babies and will gradually get better with time and support. As 
the lungs mature the level of breathing support is gradually reduced. 
This process is called “weaning” off the ventilator. The length of time of 
weaning differs between babies and depends on their degree of 
prematurity and severity of underlying lung problem.  
Currently different special care baby units have different ways to wean 
babies on ventilator. Synchronised intermittent mandatory ventilation 
(SIMV) and Pressure support ventilation (PSV) are two recognised 
modes of ventilation for weaning on the ventilator. Both these modes 
are routinely used in premature babies. SIMV is widely used as the 
standard way for weaning and supports only fixed number of 
spontaneous breaths set on the ventilator, any additional breaths of 
baby remain unsupported. In the PSV mode, every breath of the baby 
is supported. Currently there is however lack of evidence in premature 
babies on any proven advantages of PSV over SIMV. This study is 
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designed to compare these two modes of ventilation (SIMV and PSV) 
for weaning premature babies on ventilator. 
Why has my baby been chosen? 
Your baby is chosen to take part in this study as he/she is born more 
than 8 weeks before the due date and has needed breathing support on 
a ventilator (breathing machine). As your baby improves, we would like 
to put your baby to one of the two modes (SIMV or PSV) and start 
weaning on the breathing machine.  This will allow us to compare the 
two breathing modes in a scientific way. Before we enrol your baby into 
this trial, we would like you to read this information and decide if you 
would grant permission for your baby to participate in this study.   
Does my baby have to take part? 
You do not have to agree to your baby taking part in this study. Your 
decision whether or not to take part will NOT affect the care provided to 
your baby.  
What will happen to my baby if I agree to take part in the trial? 
If you agree, your baby will have an equal chance of being put into 
either of these two ventilation modes. It is not possible to know 
beforehand which one your baby will be allocated. The allocation will be 
done by computer generated allocation to have an equal number of 
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babies in the two study groups. This study design will allow comparing 
the two study modes scientifically.   
No extra blood tests or injections are necessary over and above the 
routine care. The level of care your baby receives on the neonatal unit 
will be the same whether you decide to take part in the study or not. 
What will happen to my baby if I do not agree to take part in the trial?  
If you are not able to decide then your baby will receive what is 
currently practiced in the unit i.e. SIMV mode of ventilation, this is the 
unit’s standard approach to reducing (weaning) breathing support. Your 
decision whether or not to take part will not affect the care provided to 
your baby.  
What are the possible side effects or complications of the treatment?  
There are no perceived additional side effects of participating in this 
study. The known complications and the risks associated with being 
premature would be the same in both the study groups, whether or not 
your baby participates in this study. 
Both ways of the ventilation are safe. Both ventilation modes within the 
study conform to the manufacturers’ recommendations and safety for 
use in newborn infants within the range of values that are routinely 
used in babies. We are only studying if one mode is better than the 
other in reducing the duration of weaning on mechanical ventilation.   
 204 
 
Whichever group your baby is in, your baby will be monitored very 
closely by the hospital staff in the neonatal intensive care unit and 
conform to all the standard practices on the neonatal unit. 
What are the possible advantages and disadvantages of taking part in 
this trial?  
There are no direct advantages of participating in this study. The results 
of the study would however help in better understanding of these 
modes which might further assist in improving the care of these very 
preterm babies. There are no known or perceived disadvantages of 
participating in this trial. 
What if new information becomes available?  
The staff conducting this study will inform you of any new information 
that becomes available during the course of the study. 
What if something goes wrong?  
It is unlikely to have any major adverse effects of participating in this 
trial. You however remain covered by the trust indemnity scheme and 
participating in the trial does not affect your legal rights. 
Will my taking part in this study be kept confidential?  
Strict policies and procedures will be followed as per best practice 
guidance, issued by the Department of Health; November 2003 for 
confidentiality. If you choose so, your GP will also be informed that your 
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baby has taken part in this study. These details will be kept securely 
and will only be seen by the study team and people from the regulatory 
authorities. They may also look at your baby’s notes to check that the 
study is being carried out correctly. Information about your baby will 
not be used for any purpose other than to answer the research 
question.  
What will happen to the results of the research study?  
At the end of the study, the anonymised results will be analysed and 
published in peer reviewed medical journal and will be presented in 
medical seminars and conferences. We could send you a summary of 
the final results of the study. A copy of the full journal article can be 
requested from the Chief Investigator. You and your baby will not be 
identified in any report or publication about the study.  
Who is organising and funding this study?  
The study is sponsored by University Hospital of North Tees. This study 
is a topic for a higher degree with the university pursued by the co-
investigator.  
Who has reviewed the study? 
The study been assessed and approved by the NHS Research Ethics 
Committee, the Hospital Research and Development Committee, 
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independent parent of a baby and by a panel of external experts in the 
field of newborn ventilation.  
Approval means the Committees are satisfied that your rights will be 
respected, that any risks have been reduced to a minimum and 
balanced against possible benefits, and that you have been given 
sufficient information on which to make an informed decision to take 
part or not.  
What if I have concerns?  
If you have any concerns or questions about this study or the way it 
has been carried out, you should contact the Principal Investigator 
[their name and contact details are on this page]. If you have any 
questions about this study you may also choose to get information from 
the hospital Research and Development department or you could 
alternatively contact INVOLVE (www.invo.org.uk/Resources.asp or 
contact 02380 651088) for more advice and support.  
Thank you for reading this information leaflet. The doctor or nurse who 
gave you this leaflet will be pleased to discuss the study in more detail 
and provide further information if this would be helpful. Alternatively, 
the contact details of the study’s Principal Investigator for the site is 
provided on this page. 
Local contact for your Hospital is  
NAME: Dr Prashant Mallya 
DESIGNATION: Neonatal Research Registrar 
CONTACT NO: 01642 624248 Bleep 6103 
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Appendix 2 Baseline eligibility form 
Name: _______________________________________ 
Hospital No: ________________________________ 
Date of Birth: _______________________________ 
 
Baseline Eligibility Screening Assessment  
Please use the screening questions below to assess eligibility for 
participation in the POST UK trial 
 
1 Gestational Age: _______/40 
Scan EDD: 
______________/40 
Agreed EDD: 
____________/40 
GA between 23+0 and 31+6 
are eligible  
Yes No 
2 Ventilated for at least 6 hours  Yes No 
3 No severe congenital or 
neuromuscular disorder 
Yes No 
 208 
 
diagnosed antenatally or at the 
time of birth which could affect 
respiratory function  
4 Signed written parental consent 
for participation 
Yes No 
 
Infant transferred from other units if have reached trial entry criteria at 
the time of randomisation will not be eligible 
If answer is NO to any of the above then the baby is not eligible for 
participation. 
 
Eligibility assessment outcome:   Eligible / Non-eligible 
 
If eligible for randomisation 
 
Envelope Number  
Allocated to   
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Please select the most appropriate answer if baby is eligible and not 
randomised: 
 
1 Parents were not contacted /aware of the 
POST UK trial 
Yes No 
2 Parents contacted but declined Yes No 
3 Unable to obtain an informed consent Yes No 
4 Infant self extubated in the 6 hours period and 
did not require further mechanical support  
Yes No 
5 Infant too unwell for recruitment* 
* must be discussed with the senior clinician 
and documented in the clinical notes 
Yes No 
 
Signature_____________________________ 
Designation__________________________ 
Date____________________________________ 
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Appendix 3 Trial enrolment form 
	Time		 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	MAP	<10cm	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	FiO2	<40%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Spontan
eous	
breaths
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	Time		 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	MAP	<10cm	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	FiO2	<40%	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Spontan
eou
s	breath
s	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
TICK	BOXES	AS	AND	WHEN	ACHIEVED	
Name	 			DOB	 	Gestation	at	birth	 	
When	intubated		 Date	and	time	Trial	entry	criteria	reached	on		 Date	and	time		Weaning	mode	commenced	on		 Date	and	time	
POST	TRIAL		
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Appendix 4 Minute Ventilation Test 
 
POST	TRIAL		Minute	ventilation	Test		Whilst	on	mechanical	ventilation		Time	(in	minutes)	 Heart	Rate	 Respiratory	Rate		 FiO2	 Saturations	 Tidal	Volume	 Minute	ventilation	(MVM-	mls/kg/min)	End	of	1st	minute	 	 	 	 	 	 	End	of	2nd	minute	 	 	 	 	 	 	End	of	3rd	minute	 	 	 	 	 	 	End	of	4th	minute	 	 	 	 	 	 	End	of	5th	minute	 	 	 	 	 	 		 Average	MVM=			Whilst	on	ET	CPAP		Time	(in	minutes)	 Heart	Rate	 Respiratory	Rate		 FiO2	 Saturations	 Tidal	Volume	 Minute	ventilation	(MVS-	mls/kg/min)	End	of	1st	minute	 	 	 	 	 	 	End	of	2nd	minute	 	 	 	 	 	 	End	of	3rd	minute	 	 	 	 	 	 	End	of	4th	minute	 	 	 	 	 	 	End	of	5th	minute	 	 	 	 	 	 		 Average	MVS=		
Name	 	Hospital	No	 	Randomised	to		 	
 212 
 
	Baby	is	ready	for	extubation	only	when		
• MVS/MVM	is	more	than	50%	and		
• No	bradycardia	needing	IPPV	and		
• Rise	in	FiO2	of	no	more	than	10%						Test	done	by		Name		 	Designation		 	Signature	 	 Date:		
MVS/MVM	 ___________%	Minute	ventilation	test	 Pass/failed			Date	and	time	when	extubated		 	
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Appendix 5 Data collection form  
 
 
Data	collection	form			 	 	 	 	 POST	TRIAL			Hospital	Identifier	NHS	No			Time	of	Birth	
	
Date	and	time	of	admission	to	the	NNU	 		Maternal	Contact	Details			 	Parity	 		Contact	telephone	no			 	Antenatal	steroids	given		 Yes/No	Antenatal	steroids	 Date	 Full	course		Partial		course	Date	 Full	course		Partial	course	Antenatal	events	 1. Prelabour	ROM		2. PROM	3. Chorioamnionitis		4. Pregnancy	induced	Hypertension	5. Diabetes	in	pregnancy	needing	treatment		6. Antepartum	haemorrhage		7. Maternal	Pyrexia		8. Intrapartum	antibiotics	Birth	Order	 Singleton		 Twins	 Higher	Antenatal	scan	abnormalities	 Yes/NO	If	Yes	 Known	upper	airway	anomaly		 	Complex	congenital	heart		problem			 	Neuromuscular	disorder			 	Syndromic	diagnosis			 	Comments		 	Cord	blood	gas		 Arterial	pH																							BE		Venous	pH																								BE		
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Mode	of	delivery		 NVD	 	Breech	Delivery		 	Emergency	LSCS	in	labour		 	Emergency	LSCS	not	in	labour	 	Elective	LSCS		Instrumental	delivery			 	LMP	 	EDD	by	dates		 	EDD	by	scan		 	Agrees	gestation		 	Birth	weight		 	Gender	 Male/	Female		Place	of	delivery	 Inborn/	Outborn	If	outborn,	referring	hospital	details	 	Transferred	at		 ____________Hours	of	life	Date	and	time	of	admission	to	the	NNU	 	Condition	at	birth	 No	support	needed	 	Oxygen	via	face	mask	 	CPAP	 	Ventilation	via	ETT	 	External	cardiac	compression		 	Drugs		 		Time	heart	rate	more	than	100	 	Time	to	first	gasp	 	Time	to	establish	spontaneous	respiration		 				
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APGAR	score	 At	1	minute		 		At	5	minutes	 	At	10	minutes	 	Temperature	on	admission	to	the	NNU	 	Worst	base	deficit	in	the	first	12	hours		 	CRIB2	score		 	Mechanical	ventilation	from	birth		 Yes/No	If	No	 Non	invasive	respiratory	support	for	_________Hours		Age	mechanical	ventilation	commenced		 __________Hours	from	birth		Endotracheal	tube	size	on	commencing	mechanical	ventilation	 	2.0mm		 	2.5	mm	3.0mm		 3.5mm			Primary	mode	of	ventilation	 Volume	modality/	Pressure	modality/	HFOV		Date	and	time	of	commencing	mechanical	ventilation	 		Maximum	OI	 	
First	blood	gas	upon	mechanical	ventilation		 pH								pCO2									BE							Other	adjuncts	of	ventilation	 Nitric	Oxide	Duration								Maximum	dose		Surfactant		 1st	dose	________mg/kg	2nd	dose	________mg/kg	3rd	dose_________mg/kg	Problems	of	ventilation		 Air	leaks	needing	treatment	 	PIE	 	Pneumonia		 		Inotropic	support		 _______________hours		
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Mean	airway	pressure	on	commencing	mechanical	ventilation		 	Maximum	peak	inspiratory	pressure		 	Maximum	FiO2	at	admission	to	the	NNU/	commencing	mechanical	ventilation		 	Respiratory	rate	at	admission	to	the	NNU	 	Date	and	time	when	randomised		 	Date	and	time	to	achieve	the	trial	entry	criteria		 	Time	to	achieve	the	trial	entry	criteria		 _____________Hours		Duration	of	primary	mode	of	ventilation	before	randomisation		 _____________Hours		Date	and	time	of	commencing	randomised	mode	 	Randomised	to		 PSV/SIMV	Stratified	to		 Very	very	prem		 	Very	prem		 	Prem		 	Caffeine	citrate	loading	dose	administered	before	/	at	commencing	randomisation		 Yes/No	Maintenance	dose		 a.	5mg/kg	b.	10mg/kg	Adjuncts	to	maintain	weaning	–	diuretics	administered		 Yes/No	ETT	at	commencing	weaning	 2.0	mm	 2.5mm	3.0mm	 3.5mm	Length	of	the	ETT	tube		 	Mean	airway	pressure	at	the	time	of	commencing	weaning	 	FiO2	at	the	time	of	commencing	weaning		 	pCO2	at	commencing	weaning		 	Vti/kg	at	commencing	weaning		 	MVT	(Ve)	at	commencing	weaning		 	Blood	gas	at	commencing	weaning		 pH								pCO2									BE	Postnatal	steroid		 Yes/No	If	yes	 No	of	courses		MVT	performed		 Yes/No	If	yes	 First	MVT		 	Second	MVT	 	Third	MVT	 	
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Fourth	MVT	 	Fifth	MVT	 	Average	MVM	Vti	 	Average	MVS	VTi	 	Respiratory	rate	at	MVM	 	Respiratory	rate	MVS	 	pCO2	at	MVT	 	Average	of	the	PCO2	in	the	assigned	mode	during	the	weaning	period	 	FiO2	at	MVT	 MVM	 MVS		 	RSBI	 MVM	 MVS		 	PEFR/Tube	Resistance		 	Haemoglobin	at	MVT	 	No.	of	times	MVT	failed	 	Date	and	time	of	passing	MVT	 	Date	and	time	of	extubation	 	If	MVT	not	performed		 Comments:			Need	of	re	intubation	in	72	hours		 Yes/No	Date	and	time	of	maintaining	extubation	for	72	hours		 	Date	and	time	of	re	intubation	 	Date	and	maintaining	extubation	for	7	days		 	Date	of	transfer	to	other	hospital		 	Primary	outcome:	Duration	of	weaning	in	the	assigned	mode/passing	MVT	 ___________Hours		(Includes	time	from	commencing	randomised	mode	to	passing	the	final	MVT	before	extubation)	Total	duration	of	mechanical	ventilation	through	ET	tube		 	Non	invasive	respiratory	support	upon	extubation		 1. CPAP______________hours			2. SiPAP______________hours			 3. High	Airflow________hours		Need	for	oxygen	at	28	days	of	life		 Yes/No	Need	for	oxygen	at	36	weeks	of	life	 Yes/No	Modified	Jones	Test	performed	 Yes/No	If	yes	 Need	for	oxygen	to	maintain	saturations	91-93%	confirmed?		Yes/No		
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Total	duration	of	respiratory	support	including	non	invasive	respiratory	support		 	Discharge	on	home	oxygen		 Yes/No	Date	of	discharge	home		 	Enteral	feeding	commenced	on		 _____Days	of	life		Time	to	full	enteral	feeding		 _____days	of	life		Time	to	gain	birth	weight		 _______days	of	life		Weight	gain	from	admission	to	discharge	 	Average	weight	gain	per	day		 	Total	duration	of	hospital	stay		 	
Complications	of	prematurity	Any	IVH	 	Intraventricular	haemorrhage	grade	3	or	more	 	Periventricular	Leukomalacia	 	Hydrocephalus	needing	intervention	 	Retinopathy	of	prematurity	requiring	surgery	 	ROP	stage	2	or	more	 	Prophylactic	PDA	treatment	 	Patent	Ductus	Arteriosus	(PDA)	medically	treated	after	72	hours	of	birth	as	per	unit	protocol	 	PDA	surgically	ligated		 	Necrotising	Enterocolitis	(NEC)	stage	2	or	above	 	NEC	requiring	surgery		 	Pneumothorax	during	weaning	phase		 	Chronic	lung	disease	(need	for	supplemental	oxygen	at	36	weeks	after	failing	room	air	challenge)	 	Severity	of	CLD	 Mild		 	Moderate		 	Severe	 	Sepsis	episodes	(defined	as	need	for	antibiotics	for	>5	days/	positive	blood	culture)	or	other	fluid	culture	 	Death	before	discharge	 		BPD	is	classified	as	
• Mild	BPD	defined	as	need	for	supplemental	oxygen	at	≥	28	days	but	not	at	36	weeks	postmenstrual	age	(PMA)	or	discharge	
• Moderate	BPD	is	oxygen	supplementation	for	≥28	days	plus	treatment	with	<30%	oxygen	at	36	weeks	PMA	
• Severe	BPD	as	oxygen	supplementation	at	≥	28	days	plus	≥30%	oxygen	supplementation	or	positive	pressure	support	at	36	weeks	PMA	
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Appendix 6 Ventilation Practice survey  
Poster presentation- Paediatric Academic Society, Denever 2011. 
 
 
Type of non invasive
respiratory support  Number of Units (%)
BiPAP 37 (69%)
Infant flow driver 42 (79%)
Ventilator derived CPAP 3 (5.6%)
Bubble CPAP 7 (13%)
Weaning CPAP
By pressure 15 units (28.8%)
By cycling 33 units (63.4%)
High flow nasal cannula oxygen 25 (47.1%)
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Background: The respiratory management
of very low birth weight (VLBW) infants has
changed over the last decade. This includes
volume targeted and pressure support
ventilation, use of non-invasive respiratory
support at birth, oxygen saturation
targeting and use of caffeine.
Objective: To study current trends in
respiratory management of VLBW infants
in level 3 neonatal units.
Methods: A structured questionnaire was
designed and a senior staff at all level 3
units in England were contacted
telephonically in November 2010. The data
was collected by a single interviewer and all
questions were validated.
Results: A total of 54 units were identified
from British Association of Perinatal
Medicine database. Of these 53 units (98%)
responded.
Pressure limited ventilation was used as
initial mode of mechanical ventilation in
69.8% units, volume targeted ventilation in
24.5% and High Frequency Ventilation in
5.7% units. Pressure support (PS)
ventilation was used in 50.9% units, with
18.8% using PS of up to 50% and only 7.5%
units used more than 50% PS. 69.8% units
targeted tidal volume and 54.7% units
aimed a tidal volume of 4-7mls/kg.
Synchronised intermittent mandatory
ventilation (SIMV) was most widely used for
weaning on ventilator (64.2%), followed by
SIMV with PS (18.9%) and Assist control
(AC) mode (11.3%). Only 7.6% units used
any objective criterion to assess readiness
for  extubation.
Most units (77.4%) used target oxygen
saturation between  82 to 95%. Caffeine
was used by 28.3% units in the acute phase
of the respiratory distress syndrome, and
67.9% units preferred to give caffeine only
when infant deemed  ready for extubation.
81.1% units try CPAP at birth in babies less
than 28 weeks gestation. Infant flow driver
CPAP is used by 79.2% units, Bubble CPAP
by 13.2% units and Bi-level CPAP by 69%
units. Weaning CPAP by reducing pressure
was practiced in 28.3% units, but 62.3%
used cycling method by increasing time off
on CPAP. High flow nasal cannula oxygen
was also used in 47.2% units.
Conclusions: This survey highlights wide
variation among England neonatal units
for respiratory support of VLBW infants.
This precludes generalisability of current
research findings in clinical practice and
there is an urgent need to drive for a
consensus amongst neonatologists
regarding their respiratory care protocols
which can be used both for clinical
practices and future research.
Abstract
North Tees and Hartlepool
NHS Foundation Trust
NHS
! Advances in microprocessor technology and the perceived advantages of synchronised mechanical ventilation
have led to availability of newer modes of patient triggered ventilation.
! Cochrane meta analysis on volume controlled ventilation has highlighted reduced death and chronic lung
disease compared with pressure limited ventilation.
! Three large trials comparing CPAP and mechanical ventilation reported no difference in chronic lung disease at
36 weeks post menstrual age.
! Neonatologists worldwide continue practicing newer modes of respiratory support with no agreed consensus
on ventilation practices.  There is lack of evidence on superiority of one mode of ventilation over the other in
neurodevelopmental outcome.
! To ascertain if the current practice of respiratory management of the preterm infants in level 3 neonatal units
in England is guided by current evidence base.
! A structured telephone questionnaire was formulated and senior clinical team member in all level three
neonatal units in England identified from British Association of Perinatal Medicine (BAPM) register were
contacted by a single interviewer in September 2010.
! The questionnaire included aspects of invasive and non invasive modes of respiratory support.
! All questions were validated.
Conclusions
! Fifty four level 3 neonatal units were identified and 53 units responded (98%).
! 70% units provide initial ventilation using Pressure controlled ventilation (Fig.1)
! 83% of the units chose SIMV (64%) or SIMV with pressure support (18.8%) for weaning (Fig. 2)
! Only 4 units (7.5%) used an objective evaluation in form of spontaneous breath test or Minute ventilation test
for extubation.
! 69.8% units targeted tidal volume delivery for mechanical ventilation (Fig. 3)
! Most units aimed to deliver a tidal volume between 4- 6mls/kg (Fig. 4).
! Caffeine was widely used for extubation (96%), however only 28.3% units administered caffeine in early phase
of RDS.
Invasive ventilation
Background
Aims
Methods
! Most units continue to use pressure controlled ventilation to provide the initial respiratory support despite convincing evidence in
favour of volume controlled ventilation.
! Non invasive modes of respiratory support are increasingly used in infants less than 28 weeks gestation.
! The current survey highlights wide variation among UK neonatologists and precludes generalisability of current research findings in
clinical practice.
! This requires consensus amongst neonatologists regarding their ventilatory management of the very low birth weight infants.
Results
! 83% units have used non invasive mode of respiratory support at birth using CPAP or high flow nasal
cannula oxygen.
! 47% units used high flow nasal cannula oxygen for respiratory support of the preterm infant.
Figure 1
Figure 2
Other
SIMV+PSV
Assist Control/ SIPPV
SIMV
Figure 3
High Frequency
Volume Controlled
Pressure Controlled
No
Yes
Initial mode of ventilation
Weaning on mechanical ventilation
Tidal volume targeted?
Non invasive respiratory management (Table 1)
Current trends in Respiratory Care of Very Low Birth Weight (VLBW) Infants : Based on Evidence or Habit?
Table 1
3, 6%
13, 24%
37,70%
6,11%
10,19%
34,64%3,6%
16,30%
37,70%
Prashant Mallya, MRCPCH
1
, Samir Gupta, MD
1
, C Harikumar, MD
1
 and Sunil K Sinha, MD, PhD
2
.
1
Neonatal Medicine, University Hospital of North Tees, Stockton, United Kingdom;
2
Neonatal Medicine, James Cook University Hospital, Middlesbrough, United Kingdom
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Appendix 7 In-vitro Endotracheal tube resistance experiment  
Poster presentation- European Society of Pediatric Research Istanbul, 2012. (ADC 2012;97:A483) 
Background: 
Endotracheal tube diameter, tube length, gas type and gas
flow rates have an effect on mechanical ventilation and
patient ventilator interaction. Understanding the physics and
their interaction could help us in better understanding the
effect of this on patient-ventilator interaction.
Estimation of Neonatal Endotracheal Tube Resistance by Water Manometer
Prashant Mallya1, Paul Webb2 , and Samir Gupta1
1Neonatal Unit, University Hospital of North Tees 
2Regional Medical Physics, James Cook University Hospital 
Aim/Objective: 
1.To ascertain the resistance offered by the endotracheal
tube commonly used in neonatal practice (2.5mm, 3.0mm,
3.5mm and 4.0mm) across different flow rates commonly
used in volume controlled ventilation (4lt/min to 11lt/min).
2.To ascertain the effect of tube length (7 cm and 14 cm) and
the effect of medical air and 100% oxygen on the observed
pressure drop.
Methods: 
An in-vitro laboratory based observational study was
performed to ascertain endotracheal tube resistance using
100% hospital oxygen and medical air. We used a paediatric
flow regulator to study the pressure drop across flow rates of
4 to 11lt/min. The flow meter had an accuracy of +/-
0.5lt/min. Water used as reference fluid was contained in a
‘U’ plastic tube. The proximal end of the plastic tube was
used to connect the proximal end of the Portex endotracheal
tube through the standard 1 mm side port using a connector
and air flow directed as per usual practice to maintain
laminar flow pattern. Menisci difference measured against
the standard scale (range 0 - 300mm) from 8 observations for
each flow rate was used to determine the pressure drop.
Results: 
1. ANOVA was used to compare variation at different flow rates & tube diameters, and  paired t 
test to compare variation at different type of gases and tube length. 
2. Multiple regression of the various factors showed the p-values for the estimated coefficients of 
tube length, gas type and flow rate are all 0.000.  The p-value for tube diameter is 0.161, at an α of 
0.05.  The R-sq value indicates that the predictors explain 66.4% of the variance in pressure drop. 
Conclusion:
•The regression model confirms endo tracheal tube diameter commonly used in 
neonatal respiratory support does not significantly impact the pressure drop.
•The results from this study could be utilised in setting the ventilator to achieve the 
desired pressure delivery at different flow rates using air / oxygen at varying ET tube 
sizes.
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